Library › Toxicology, therapeutic drug monitoring, toxic metals, porphyrias, vitamins and newborn screening
Toxicology, therapeutic drug monitoring, toxic metals, porphyrias, vitamins and newborn screening
Last reviewed 2026-11-17 by a board-certified pathologist. 348 references.
Therapeutic Drug Monitoring: Pharmacokinetics, Sampling and Assays for Antiepileptic, Antimicrobial, Immunosuppressant, Cardioactive, Psychiatric and Antineoplastic Drugs
Definition. Therapeutic drug monitoring (TDM) is the measurement of drug concentrations at designated times to individualize dosing. It is used mainly for drugs with a narrow therapeutic range, marked pharmacokinetic variability, therapeutic effects that are difficult to monitor clinically, and a definable relationship between concentration and effect (Kang 2009). Interpretation requires the sampling time in relation to the dose, the dosage history, the clinical response and the target concentration (Kang 2009). Errors in sampling time cause the largest number of errors in interpretation (Kang 2009).
Related page: Analytical Methods and Immunoassays in Clinical Chemistry (competitive immunoassays, cross-reactivity, LC-MS/MS principles and lithium by dry slide) Related page: Preanalytic Variables, Specimen Integrity and Point-of-Care Testing in Clinical Chemistry (collection tubes, additives and lithium heparin contamination) Related page: Method Validation, Statistical Quality Control and Proficiency Testing in Clinical Chemistry (CLIA proficiency testing limits for therapeutic drugs) Related page: Liver, Kidney and Gastrointestinal Function Tests (estimated GFR for drug dosing) Related page: Antimicrobial Susceptibility Testing, Breakpoints and Resistance Mechanisms (vancomycin MIC and susceptibility testing) Related page: Anticoagulant Monitoring, DOAC Measurement and Heparin-Induced Thrombocytopenia Testing (warfarin pharmacogenetics) Related page: HLA Typing, HLA Antibody Testing, Crossmatch and Platelet and Neutrophil Antibody Testing (HLA-B57:01, HLA-B15:02 and HLA-B*58:01) Related page: Toxic Alcohols, Acetaminophen, Salicylate and Other Poisonings: Laboratory Evaluation and Monitoring (acute and chronic lithium and digoxin poisoning, extracorporeal removal and Fab dosing in overdose)
Pharmacokinetic principles for drug monitoring
- Bioavailability. Absolute bioavailability is the fraction of a dose that reaches the systemic circulation (Lea-Henry 2018). Saturable presystemic metabolism, as in verapamil, propranolol and hydralazine, makes systemic availability dependent on dose size and absorption rate (Ludden 1991).
- Volume of distribution (Vd). Vd is the amount of drug in the body divided by the plasma concentration. Molecular size, protein binding and lipophilicity determine Vd. Capillary leak and fluid resuscitation in sepsis increase Vd and lower plasma concentrations (Fleuren 2019).
- Clearance (CL). Clearance determines the maintenance dose rate needed for a target concentration. Kidney disease decreases drug clearance, and Vd is unchanged or increased (Lea-Henry 2018). Uremic toxins inhibit enzymes and transporters and reduce nonrenal clearance (Lea-Henry 2018). Augmented renal clearance occurs early in critical illness. Young age, multitrauma and few comorbidities are risk factors (Fleuren 2019).
- Half-life and steady state. Half-life is t½ = 0.693 × Vd ÷ CL, so a larger Vd or a lower clearance prolongs it. Steady state is reached after 4 to 5 half-lives (Fleuren 2019; Lea-Henry 2018).
- Loading dose. The loading dose depends on Vd only. The full loading dose is given when clearance is reduced, including renal failure (Fleuren 2019).
- Peak and trough. A trough (Cmin) sample is drawn at the end of the dosing interval, immediately before the next dose, and reflects clearance. Estimating Vd requires an additional sample earlier in the interval. AUC estimation uses limited sampling strategies of 1 to 3 informative time points (Abdul-Aziz 2020).
- First-order and saturable (zero-order) elimination. Partial saturation of elimination produces Michaelis-Menten kinetics. Small changes in dosing rate then cause disproportionately large changes in steady-state concentration, and the time to reach steady state lengthens as the dosing rate approaches the maximum elimination rate. Phenytoin and ethanol behave this way. Theophylline and salicylate have saturable pathways plus parallel first-order pathways (Ludden 1991). Phenytoin follows Michaelis-Menten elimination at therapeutic concentrations (Salhi 2026).
- Autoinduction. Autoinduction increases clearance during long-term administration. Carbamazepine is the main example (Ludden 1991). Carbamazepine and carbamazepine-10,11-epoxide induce CYP3A4 and CYP1A2, with estimated enzyme half-lives of 70 h and 105 h (Magnusson 2008).
- Concentration-dependent protein binding. Saturable binding makes parameters based on total concentration vary with concentration, while parameters based on free concentration remain linear. Valproic acid shows this pattern, and free concentration is measured (Ludden 1991).
Pharmacokinetic quantities for dose setting.
| Quantity | Formula or rule | Terms | Source |
|---|---|---|---|
| Half-life | t½ = 0.693 × Vd ÷ CL | Vd in L; CL in L/h; t½ in h | Fleuren 2019 |
| Worked example | Vd 100 L and CL 10 L/h give t½ of about 7 h | t½ = 0.693 × 100 ÷ 10 | Fleuren 2019 |
| Time to steady state | 4 to 5 × t½ | A t½ of 3 h gives steady state at 13–17 h | Fleuren 2019 |
| Loading dose | Determined by Vd; independent of CL | Given in full in renal failure | Fleuren 2019 |
| Maintenance dose rate | CL × target average steady-state concentration (Css,avg = AUC over the dosing interval ÷ interval); for vancomycin, an AUC24 of 400 mg·h/L equals a Css,avg of 16.67 mg/L | Reduced when kidney clearance falls, to prevent accumulation | Holford 2022; Lea-Henry 2018 |
Indications, specimens and sampling times for drug monitoring
Indications. For antiepileptic drugs, the ILAE position paper lists six situations in which measurement helps: establishing an individual therapeutic concentration after the desired response, diagnosing toxicity, assessing adherence, guiding dosing when pharmacokinetic variability is high (children, the elderly, comorbid disease, formulation changes), anticipated pharmacokinetic change (pregnancy, an added or withdrawn interacting drug), and dose-dependent kinetics, particularly with phenytoin (Patsalos 2008). Laboratories obtain the dosage regimen and the time of sampling with each request (Kang 2009).
Specimens and sampling times by drug.
| Drug or class | Specimen | Sampling time | Source |
|---|---|---|---|
| Tacrolimus and cyclosporine | Whole blood with EDTA (the drugs are distributed mainly in red cells) | Trough (C0); cyclosporine C0 or 2-h post-dose level (C2); every 2–3 days after transplant until the target is reached | Udomkarnjananun 2026 |
| Sirolimus and everolimus | Whole blood with EDTA | C0, no earlier than 4–6 days (everolimus) or 5–7 days (sirolimus) after starting or a dose change | Udomkarnjananun 2026 |
| Mycophenolic acid | EDTA plasma, heparinized plasma or serum | Full-interval AUC(0–12) estimated by limited sampling; C0 not recommended | Udomkarnjananun 2026 |
| Lithium | Serum; lithium heparin tubes excluded | 12 h after the last dose | Köhler-Forsberg 2025; Wills 2006 |
| Digoxin | Serum | At least 6 h, ideally 8–12 h, after the last dose | Andrews 2023 |
| Gentamicin, tobramycin and amikacin | Plasma or serum (usual antimicrobial matrices); dried blood spots and volumetric microsampling are alternatives | Peak 30 min after the end of infusion; second sample 6–22 h after infusion for AUC; trough just before the next dose | Abdul-Aziz 2020 |
| Vancomycin | Plasma or serum | Two samples preferred, with Bayesian estimation of AUC (first-order equations as the alternative); target reached within the first 24–48 h | Rybak 2020; Abdul-Aziz 2020 |
| Beta-lactams | Plasma or serum | Trough 24–48 h after starting; any time during continuous infusion | Abdul-Aziz 2020 |
| Voriconazole; itraconazole; posaconazole | Plasma or serum | Trough at 2–5 days; within 5–7 days; after 7 days | Abdul-Aziz 2020 |
| High-dose methotrexate | Plasma | End of infusion, then 36, 42 and 48 h after the start of infusion | Ramsey 2018 |
- Lithium heparin tubes. Lithium heparin tubes from volunteers who had never taken lithium gave serum lithium of 1.05–1.07 mmol/L at full draw and 3.31–4.04 mmol/L when filled with 1 mL, compared with 0.16 mmol/L in a serum separator tube (Wills 2006).
- Separator gels. Amiodarone and desethylamiodarone stored in gel tubes at 4 °C decreased after 24 h and 6 h. Acrylic-based gel tubes are not used for amiodarone, flecainide or the direct oral anticoagulants (Hegstad 2022).
- Lithium sampling time. Most lithium tests in practice do not meet the required 12-h timing. An equation estimating the 12-h level (eLi12) from a level drawn 3–24 h after the dose was closer to the true 12-h level in 97% of tests (Köhler-Forsberg 2025).
Free and total drug concentrations
- Relation of free to total concentration. Free fraction is free concentration divided by total concentration. Free concentration is independent of total concentration, so a rise in free fraction lowers the total concentration at an unchanged free concentration (Levy 1985). Free concentration is monitored for drugs with extensive and variable protein binding, including phenytoin and valproic acid (Levy 1985).
- Causes of a higher free fraction. Hypoalbuminemia in hepatic and renal disease, burns and pregnancy; saturable binding (valproic acid); and competitive displacement (valproic acid displacing phenytoin) (Levy 1985). Chronic kidney disease decreases protein concentration or binding and increases the free fraction (Lea-Henry 2018). Phenytoin-albumin binding is altered in end-stage renal disease (Soriano 2017).
- Effect of a raised free fraction on the total concentration. A total concentration within or below the reference range coexists with a high free concentration. In hypoalbuminemia, high unbound valproic acid occurred with normal or low total concentrations. Unbound valproic acid predicted neurologic adverse symptoms (ROC area 0.776), and total valproic acid did not (0.642, p = 0.167) (Doré 2017).
- Phenytoin free fraction. In 140 neurointensive care patients, mean unbound phenytoin was 1.4 µg/mL, a free fraction of 10% (Kane 2013). Free phenytoin is not measured routinely because the analysis is complex and costly. Free concentrations are estimated mainly in renal dysfunction or reduced albumin (Jun 2020).
Albumin correction of total phenytoin. The Sheiner-Tozer (Winter-Tozer) equation is used when free phenytoin is unavailable (Kiang 2016). The equation is biased and imprecise in critical care, head trauma and general neurology patients. Albumin concentration, the temperature of the free phenytoin assay, sampling conditions, renal function, age and comedications contribute to the error (Kiang 2016). The equation overpredicted normalized concentrations in elderly nursing home and trauma patients, and a revised equation reflecting room-temperature free phenytoin assays reduced bias (Anderson 1997). The traditional equation underpredicted unbound phenytoin in neurointensive care patients, with prediction error above 50% in 32.1% of the validation cohort (Kane 2013). The end-stage renal disease version had a percentage error of 75% in hemodialysis patients, and a revised version had error above 50% in 5% of samples (Soriano 2017). In 133 adults, the Winter-Tozer and Anderson equations overpredicted free phenytoin, the two Kane equations underpredicted it, and all equations performed poorly in critical care; a population-specific equation had an albumin coefficient of 0.275 (Cheng 2016). Unbound phenytoin, the pharmacologically active fraction, is the ideal marker for monitoring (Jun 2020).
Sheiner-Tozer albumin correction of total phenytoin. Each equation divides the observed total phenytoin by [(coefficient × albumin) + 0.1]. The result is the total concentration expected at a normal free fraction of 10%, and multiplying it by 0.1 gives the predicted free phenytoin (Cheng 2016; Jun 2020). Phenytoin is in µg/mL (mg/L) and albumin in g/dL (Kiang 2016; Jun 2020).
| Equation | Albumin coefficient | Corrected total phenytoin (µg/mL) | Population in which it was derived | Source |
|---|---|---|---|---|
| Sheiner-Tozer (Winter-Tozer), original | 0.2 | Observed total ÷ [(0.2 × albumin) + 0.1] | Original equation; assumes a free fraction of 10% and a normal albumin of 4.4 g/dL | Kiang 2016; Cheng 2016; Jun 2020 |
| Anderson revised equation | 0.25 | Observed total ÷ [(0.25 × albumin) + 0.1] | Elderly nursing home patients and critically ill head trauma patients with hypoalbuminemia; free phenytoin measured at room temperature | Anderson 1997; Cheng 2016; Jun 2020 |
| Kane revised equation | 0.29 | Observed total ÷ [(0.29 × albumin) + 0.1] | Adults in a neurointensive care unit | Kane 2013; Cheng 2016; Jun 2020 |
| Cheng population-specific equation | 0.275 | Observed total ÷ [(0.275 × albumin) + 0.1] | Adults in critical care, general medicine and neurology at one hospital; hemodialysis excluded | Cheng 2016 |
| Worked example (original equation) | 0.2 | Total 9 µg/mL with albumin 1.9 g/dL: 9 ÷ 0.48 = 18.8 µg/mL; predicted free 1.9 µg/mL | Reference range for total phenytoin 10–20 µg/mL | Kiang 2016; Salhi 2026 |
Immunoassay and chromatographic methods for drug monitoring
LC-MS/MS is the reference method for immunosuppressants. It is costly, requires skilled staff and has limited automation. Immunoassays are simpler to implement, and cross-reactivity with drug metabolites limits them (Strydom 2024). General immunoassay and LC-MS/MS principles are covered in Analytical Methods and Immunoassays in Clinical Chemistry.
Reported metabolite and drug interferences in therapeutic drug assays.
| Drug measured | Interfering compound | Effect | Setting | Source |
|---|---|---|---|---|
| Phenytoin | Unidentified fosphenytoin metabolites or adducts | Falsely high total and unbound phenytoin, up to 20 times HPLC results, on several immunoassays | Critically ill patients with renal insufficiency receiving fosphenytoin | Roberts 1999 |
| Carbamazepine | Carbamazepine-10,11-epoxide | Positive bias on a PETINIA assay; CMIA and CEDIA agreed with LC-MS/MS | Patients taking carbamazepine | Dasgupta 2016 |
| Tacrolimus | Inactive metabolites | MEIA-II results 3.67 µg/L above LC-MS/MS in 25 of 104 specimens | Liver and kidney transplant recipients | Armstrong 1998 |
| Everolimus and sirolimus | 24- and 25-hydroxy everolimus; 12-hydroxy, 27-O-desmethyl and 39-O-desmethyl sirolimus | Median positive bias of 41.2% (everolimus) and 34.9% (sirolimus) by ECLIA; cyclosporine bias 2.1% | Transplant recipients | Strydom 2024 |
| Methotrexate | DAMPA after glucarpidase; 7-hydroxymethotrexate to a variable extent | Overestimated methotrexate for about 48 h after glucarpidase | High-dose methotrexate with acute kidney injury | Ramsey 2018 |
| Digoxin | Digoxin-like immunoreactive substances | False-positive digoxin in 60% with severe liver disease, 89% of newborn venous and 100% of cord samples, and 6 of 25 hemodialysis patients | Patients not taking digoxin | Avendaño 1991 |
| Digoxin | Spironolactone and canrenone | Modest false increase at high concentrations; potassium canrenoate did not interfere | Dimension Vista assay | Dasgupta 2010 |
| Digoxin | Digoxin bound to Fab | Total digoxin misleading until Fab is cleared, up to 3 weeks | After digoxin immune Fab | Andrews 2023 |
| Itraconazole | Hydroxyitraconazole | Bioassay results exceed chromatography; the metabolite circulates at about twice the parent concentration and is equipotent | Patients taking itraconazole | Hostetler 1993 |
Antiepileptic drug monitoring
Antiepileptic drug reference ranges. Ranges are method- and laboratory-specific. The ranges below are those applied in a 25-year laboratory cohort of 9,232 measurements (Salhi 2026), which cites the ILAE position paper (Patsalos 2008) and a later review.
| Drug | Reference range (µg/mL = mg/L) | Main monitoring issue | Source |
|---|---|---|---|
| Phenytoin | 10–20 | Michaelis-Menten kinetics; high albumin binding; free fraction about 10% | Salhi 2026; Kane 2013 |
| Valproic acid | 50–100 | Saturable protein binding; unbound concentration predicts adverse effects in hypoalbuminemia | Salhi 2026; Doré 2017 |
| Carbamazepine | 4–12 | Autoinduction; epoxide cross-reactivity on some immunoassays | Salhi 2026; Ludden 1991; Dasgupta 2016 |
| Phenobarbital | 10–40 | Long half-life; accumulation 2–3 weeks after a dose change | Salhi 2026 |
| Lamotrigine | 3–14 | Valproic acid inhibits glucuronidation; clearance rises in pregnancy | Salhi 2026; Goo 2024 |
| Levetiracetam | 12–46 | Linear kinetics; clearance rises in pregnancy | Salhi 2026; Fallik 2024 |
- Phenytoin. A small dose increment causes a disproportionately large increase in concentration (Salhi 2026). Phenytoin adverse effects correlate more closely with free than with total concentration (Levy 1985). Fosphenytoin is a phosphate ester prodrug of phenytoin. No fosphenytoin itself was detected in the falsely high uremic specimens, which indicates accumulation of metabolites or adducts (Roberts 1999).
- Valproic acid. Free fraction rises with saturable binding, and valproic acid displaces phenytoin (Levy 1985). In 41 adults tested for unbound valproic acid, total valproic acid and albumin predicted unbound concentration (Doré 2017).
- Carbamazepine. Autoinduction increases clearance during long-term therapy (Ludden 1991).
- Phenobarbital. In the 9,232-measurement cohort, 15.7% of phenobarbital results exceeded 40 µg/mL. The long elimination half-life causes accumulation, and toxicity appears 2–3 weeks after a dose change, as the new steady state is reached (Salhi 2026).
- Lamotrigine. Valproic acid inhibits lamotrigine glucuronidation and can double or triple lamotrigine concentrations; 25.9% of lamotrigine results exceeded 14 µg/mL in the cohort (Salhi 2026).
- Monitoring in pregnancy. Lamotrigine clearance increased across trimesters, most in the second and third, and studies measured concentrations every 1–3 months to maintain the prepregnancy baseline concentration (Goo 2024). Levetiracetam concentration-to-dose ratio fell during pregnancy and rose abruptly postpartum. The dose was increased by 75% during pregnancy and reduced by 24% postpartum (Fallik 2024).
- Levetiracetam outside pregnancy. Routine monitoring is not indicated, because levetiracetam has linear kinetics, minimal protein binding and few CYP interactions (Salhi 2026).
Aminoglycoside and vancomycin monitoring
Extended-interval aminoglycoside dosing (Hartford program). An aminoglycoside (gentamicin in 94% of patients) was given at a fixed 7 mg/kg intravenous dose with the interval set by estimated creatinine clearance: every 24 h at ≥60 mL/min, every 36 h at 40–59 mL/min and every 48 h at 20–39 mL/min. Later interval changes used a single serum concentration and a nomogram. Among 2,184 patients, nephrotoxicity occurred in 1.2%, compared with a historical rate of about 3%–5% (Nicolau 1995). Extended-interval dosing raises the peak-to-MIC ratio, which is the pharmacodynamic index for concentration-dependent killing (Nicolau 1995; Abdul-Aziz 2020).
Aminoglycoside targets in critically ill adults.
| Drug | Efficacy target | Trough limit associated with toxicity | Sampling | Source |
|---|---|---|---|---|
| Gentamicin and tobramycin | Cmax/MIC ≥8–10; AUC 80–120 mg·h/L | Cmin <0.5 mg/L as target; toxicity threshold Cmin >1 mg/L | Peak 30 min after infusion; AUC from a second sample at 6–22 h | Abdul-Aziz 2020 |
| Amikacin | Cmax/MIC ≥8–10; AUC 80–120 mg·h/L | Cmin <2.5 mg/L as target; toxicity threshold Cmin >5 mg/L | Same as gentamicin | Abdul-Aziz 2020 |
AUC-based monitoring from at least two time points with Bayesian dose adaptation best predicts aminoglycoside dosing requirements, and Bayesian-guided gentamicin dosing shortened hospital stay and reduced nephrotoxicity (Abdul-Aziz 2020).
Vancomycin monitoring: 2020 consensus and the 2009 rule it replaced.
| Element | 2020 ASHP/IDSA/PIDS/SIDP consensus (current) | 2009 consensus (previous) | Source |
|---|---|---|---|
| Exposure target for serious MRSA infection | AUC24/MIC 400–600, assuming a broth microdilution MIC of 1 mg/L | Trough 15–20 mg/L for complicated Staphylococcus aureus infection, as a surrogate for AUC | Rybak 2020; Lim 2023 |
| Monitoring method | Bayesian software preferred, ideally with 2 samples; first-order equations from 2 levels as the alternative | Trough-only monitoring | Rybak 2020 |
| Status of trough-only monitoring | No longer recommended | Recommended as "accurate and practical" | Rybak 2020; Lim 2023 (2009 quotation) |
- AUC calculation by the equation method. A near-steady-state postdistributional peak (1–2 h after the end of infusion) and a trough are fitted with first-order equations. A change in total daily dose changes AUC24 proportionally. The older linear-trapezoid method needed multiple samples in one dosing interval and was impractical outside research (Rybak 2020).
- 2020 consensus dosing recommendations. The AUC target is reached early, preferably within the first 24–48 h. A loading dose of 20–35 mg/kg can be considered in critically ill adults, and obese adults receive 20–25 mg/kg by actual body weight to a maximum of 3,000 mg. Children aged 3 months to <12 years start at 60–80 mg/kg/day divided every 6 h, and those aged ≥12 years at 60–70 mg/kg/day divided every 6–8 h, with AUC-guided monitoring by Bayesian estimation (Rybak 2020).
- Evidence behind the 2020 vancomycin change. Trough monitoring was associated with more nephrotoxicity (Rybak 2020). In a meta-analysis of 57 studies, nephrotoxicity was 6.2% with AUC-guided and 17.0% with trough-guided monitoring (odds ratio 0.53) (Lim 2023). In a study cited by Lim 2023, every patient with a trough above 9 mg/L reached an AUC of at least 400 mg·h/L, and a trough target of 15–20 mg/L could give more AUC exposure than invasive MRSA infection requires (Lim 2023).
- Vancomycin pharmacodynamic index. Vancomycin efficacy against MRSA correlates with AUC24/MIC (Lim 2023). MIC testing is covered in Antimicrobial Susceptibility Testing, Breakpoints and Resistance Mechanisms.
Beta-lactam, antifungal and antiretroviral monitoring
Targets from the 2020 antimicrobial TDM position paper in critically ill adults.
| Drug | Panel position | Sampling | Target | Source |
|---|---|---|---|---|
| Beta-lactams | Routine monitoring recommended | Trough 24–48 h after starting; any time during continuous infusion | 100% fT>MIC; Css above MIC with continuous infusion | Abdul-Aziz 2020 |
| Voriconazole | Routine monitoring recommended | Trough at 2–5 days | Cmin 2–6 mg/L (prophylaxis or treatment) | Abdul-Aziz 2020 |
| Posaconazole | Neither recommended nor discouraged | Trough after 7 days | Cmin >0.5–0.7 mg/L (prophylaxis); >1 mg/L (treatment) | Abdul-Aziz 2020 |
| Itraconazole | Neither recommended nor discouraged | Trough within 5–7 days | Cmin >0.5–1 mg/L | Abdul-Aziz 2020 |
- Antimicrobials with recommended routine monitoring. The panel recommends routine monitoring of aminoglycosides, beta-lactams, linezolid, teicoplanin, vancomycin and voriconazole in critically ill patients (Abdul-Aziz 2020).
- Beta-lactams. Increased beta-lactam dosing for altered pharmacokinetics has produced excess exposure and toxicity. Beta-lactams are measured by HPLC with ultraviolet detection or by LC-MS/MS (Abdul-Aziz 2020).
- Voriconazole and CYP2C19. CYP2C19 ultrarapid metabolizers have low voriconazole troughs, and poor metabolizers have high troughs with more adverse events (Moriyama 2017). For ultrarapid and poor metabolizers, CPIC recommends an alternative agent not dependent on CYP2C19, such as isavuconazole, liposomal amphotericin B or posaconazole (Moriyama 2017).
- Antiretroviral drugs. Antiretroviral monitoring is not routine in HIV care. The stated barriers are the absence of evidence that it improves HIV outcomes and the absence of guideline endorsement (Wang 2025). The UGT1A1 genotype guides atazanavir prescribing because two decreased-function alleles (*28 or *37) carry the highest risk of discontinuation for hyperbilirubinemia (Gammal 2016).
Immunosuppressant monitoring
- Whole-blood specimen for calcineurin and mTOR inhibitors. Calcineurin inhibitors (tacrolimus and cyclosporine) and mTOR inhibitors (sirolimus and everolimus) are distributed mainly in red cells. They are measured in whole blood, and EDTA is the preferred anticoagulant (Udomkarnjananun 2026).
- Tacrolimus. The trough (C0) correlates with AUC(0–12) (r² 0.82–0.94) and is the recommended single measurement. AUC(0–12), target 100–150 ng·h/mL, is considered when rejection or toxicity occurs with C0 in range or when delayed absorption is suspected (Udomkarnjananun 2026). The IATDMCT second consensus report (2019), which updated the 2009 report, proposes AUC as the best option early after transplantation, during minimization and in special populations (Brunet 2019).
- Cyclosporine. Cyclosporine is monitored by C0 or by the 2-h post-dose level (C2) (Udomkarnjananun 2026). Monoclonal-antibody immunoassays reduced the metabolite cross-reactivity of earlier cyclosporine assays (Strydom 2024).
- mTOR inhibitors. Long half-lives and large Vd delay steady state to 4–6 days for everolimus and 5–7 days for sirolimus, and C0 is measured only after these intervals (Udomkarnjananun 2026). The IATDMCT second everolimus consensus (2025) updates the 2016 first version (Masuda 2025).
- Mycophenolic acid (MPA). MPA has nonlinear absorption and enterohepatic circulation. Tacrolimus increases and cyclosporine decreases MPA AUC. C0 correlates poorly with AUC (r² 0.16–0.63) and is not recommended. When monitoring is used, AUC(0–12) is estimated by limited sampling with Bayesian estimation or regression, with at least 2 time points for mycophenolate mofetil and 3–4 for enteric-coated mycophenolate sodium. The recommended target is 30–60 mg·h/L (Udomkarnjananun 2026).
- CYP3A interactions with calcineurin and mTOR inhibitors. Calcineurin and mTOR inhibitors share CYP3A metabolism. Azoles, diltiazem and verapamil raise calcineurin and mTOR inhibitor concentrations, and are coadministered to permit a lower dose. Rifampin induces UGTs and MRP2 and lowers MPA exposure (Udomkarnjananun 2026).
- CYP3A5. CYP3A5 expressers (at least one CYP3A51 allele) have lower tacrolimus concentrations at the same dose than nonexpressers (CYP3A53/*3) (Udomkarnjananun 2026; Birdwell 2015). A tacrolimus C0-to-daily-dose ratio below 1.05 ng/mL/mg at steady state indicates a fast metabolizer (Udomkarnjananun 2026).
Recommended maintenance immunosuppressant concentrations in kidney transplantation (Thai Transplant Care guideline 2026). Targets depend on the regimen and the time after transplantation (Udomkarnjananun 2026, Table 5).
| Time after transplant | Tacrolimus C0 with MPA (ng/mL) | Cyclosporine C0 / C2 with MPA (ng/mL) | Tacrolimus C0 with mTOR inhibitor (ng/mL) | Cyclosporine C0 / C2 with mTOR inhibitor (ng/mL) | mTOR inhibitor C0 (ng/mL) | Source |
|---|---|---|---|---|---|---|
| 0–3 months | 7–12 | 150–300 / 800–1,200 | 4–7 | 100–150 / 600–800 | 4–8 | Udomkarnjananun 2026 |
| 3–6 months | 6–10 | 100–200 / 600–1,000 | 2–5 | 50–100 / 300–600 | 4–8 | Udomkarnjananun 2026 |
| 6 months onward | 5–8 | 80–150 / 500–800 | 2–4 | 25–50 / 150–200 | 4–8 | Udomkarnjananun 2026 |
Digoxin and other cardioactive drug monitoring
- Digoxin pharmacokinetics. Digoxin has 60%–80% bioavailability, a mean half-life of 40 h, a Vd of 5–10 L/kg and 20% protein binding. Half-life exceeds 100 h in renal failure (Chan 2014). Digoxin is eliminated mainly by the kidneys (Andrews 2023).
- Digoxin therapeutic range. The conventional range is 0.8–2.0 ng/mL, and a narrower range of 0.5–0.8 ng/mL is increasingly favored in heart failure (Andrews 2023). In a post hoc analysis of the DIG trial, men with heart failure and digoxin of 0.5–0.8 ng/mL had 6.3% lower mortality than placebo, and those at ≥1.2 ng/mL had 11.8% higher mortality (Rathore 2003). A digoxin of 2 µg/L equals 2.6 nmol/L (Chan 2014).
- Digoxin sampling time. Distribution to tissue takes several hours. A concentration measured in the first hours after a dose reflects neither therapeutic activity nor toxicity, so at least 6 h, and preferably 8–12 h, separates the dose from the sample (Andrews 2023).
- Toxicity at therapeutic concentrations. Toxicity occurs within the therapeutic range. Hypokalemia, hypomagnesemia and hypercalcemia increase it, and renal impairment and dehydration are risk factors (Andrews 2023). When amiodarone is loaded in a patient taking digoxin, the digoxin dose is reduced first (Kang 2009).
- Digoxin-like immunoreactive substances. Mild to moderate renal failure and pregnancy showed no significant interference with that assay (Avendaño 1991).
- Digoxin immune Fab. A 40-mg vial binds 0.5 mg of digoxin. After Fab, free digoxin falls to almost zero within minutes (Chan 2014). Most immunoassays measure free plus bound digoxin, so total digoxin is misleading until Fab is cleared, which can take up to 3 weeks (Andrews 2023). Fab half-life is 19–30 h and exceeds 100 h in renal failure (Chan 2014). Fab indications and dosing in poisoning are covered in Toxic Alcohols, Acetaminophen, Salicylate and Other Poisonings: Laboratory Evaluation and Monitoring.
- Amiodarone. Amiodarone and desethylamiodarone decrease in gel-separator tubes, so tubes without gel are used (Hegstad 2022).
Digoxin immune Fab vial calculation.
| Basis | Formula | Notes | Source |
|---|---|---|---|
| Serum concentration | Vials = digoxin (ng/mL or µg/L) × weight (kg) × 0.005, rounded up to the nearest vial | Half of the full neutralizing dose | Andrews 2023 |
| Binding capacity | One 40-mg vial binds 0.5 mg digoxin | Basis of both full-neutralization formulas | Chan 2014 |
| Body load from serum level | Vials = [digoxin (µg/L) × Vd (L/kg) × weight (kg) ÷ 1,000] ÷ 0.5 | Full neutralizing dose | Chan 2014 |
| Body load from ingested dose | Vials = ingested digoxin (mg) ÷ 0.5 | Full neutralizing dose; calculated equimolar doses are high and expensive, half this dose has been proposed, and the lowest effective regimen is not established | Chan 2014 |
| Sampling | Level drawn at least 6 h after the last dose | Earlier levels reflect neither activity nor toxicity | Andrews 2023 |
Lithium and psychiatric drug monitoring
Lithium serum targets in bipolar disorder maintenance (ISBD/IGSLI 2019). Levels are 12-h troughs (Köhler-Forsberg 2025).
| Population | Standard target (mmol/L) | Adjustment | Source |
|---|---|---|---|
| Adults | 0.60–0.80 | 0.40–0.60 with good response and poor tolerance; 0.80–1.00 with insufficient response and good tolerance | Nolen 2019 |
| Children and adolescents | No consensus; majority endorsed the adult range | Not applicable | Nolen 2019 |
| Elderly | No consensus; majority endorsed 0.40–0.60 | Maximum 0.70–0.80 at ages 65–79 years; maximum 0.70 above 80 years | Nolen 2019 |
- Elimination and interactions. Lithium is removed almost exclusively by the kidneys. Thiazides raise lithium by 25%–40% after initiation. NSAIDs and ACE inhibitors impair elimination. Loop and potassium-sparing diuretics have minor variable effects. Osmotic diuretics and methylxanthines increase lithium clearance (Finley 1995). A patient starting a thiazide while taking lithium is monitored (Kang 2009).
- Lithium measurement. Lithium by dry slide and ion-selective electrode is covered in Analytical Methods and Immunoassays in Clinical Chemistry.
- Neuropsychiatric drugs. The AGNP consensus update 2026 replaced the 2017 edition. It lists therapeutic reference ranges for 160 neuropsychiatric drugs and strongly recommends obligatory monitoring for 15 drugs and recommends it for 39 (Hart 2026).
- Clozapine adherence. Three indices indicate partial or full nonadherence: a concentration-to-dose ratio below half the expected value, an inverted clozapine-to-norclozapine ratio and an undetectable concentration. In modeled patients the three indices appeared at about day 2, day 3 and days 9–11 after the last dose (Ruan 2024).
Methotrexate and other antineoplastic drug monitoring
- High-dose methotrexate (HDMTX). HDMTX is a dose above 500 mg/m² infused over 2–36 h with hydration and leucovorin rescue (Ramsey 2018). The osteosarcoma regimen of 8–12 g/m² over 4 h gives an end-of-infusion plasma concentration of about 1,000 µM (Ramsey 2018).
- Acute kidney injury. HDMTX-induced acute kidney injury is usually nonoliguric, and methotrexate clearance falls in proportion to GFR. A creatinine increase of more than 50% within 24–36 h has a sensitivity of 0.32 and a specificity of 0.99 for delayed elimination. A high plasma methotrexate indicates injury before creatinine rises (Ramsey 2018). Urine pH is kept above 7 and urine flow at 2,500 mL/m² per day or more (Ramsey 2018).
- Leucovorin. Leucovorin is given within 42 h of the start of the infusion. It is less effective when methotrexate exceeds 10 µM for 48 h or longer, and its dose is increased in proportion to the methotrexate concentration. Rescue is stopped when methotrexate falls to ≤0.1 or 0.2 µM in patients with normal renal function (Ramsey 2018).
- Glucarpidase. Glucarpidase (carboxypeptidase G2) cleaves methotrexate into DAMPA and glutamate, which are eliminated mainly by the liver. Plasma methotrexate falls by more than 95% within 15 min. A rebound can occur after 48 h as drug redistributes from tissues. Glucarpidase is given optimally within 48–60 h of the start of the infusion, because life-threatening toxicity may not be preventable later (Ramsey 2018).
- Catheter-lumen contamination. A falsely high methotrexate occurs when the sample is drawn through the catheter lumen used for the infusion. A high level with a normal creatinine is repeated on a new sample (Ramsey 2018).
- Immunoassay interference after glucarpidase. Most laboratories measure methotrexate by immunoassay. DAMPA has a half-life of about 9–10 h, which produces the 48-h interference in the table above. HPLC separates methotrexate from DAMPA and gives the accurate concentration in this period (Ramsey 2018).
Glucarpidase consensus thresholds for high-dose methotrexate (Ramsey 2018). Glucarpidase may be indicated at the thresholds below when serum creatinine is elevated relative to baseline. For 1–8 g/m² over 24–42 h, a level >120 µM at the end of a 24-h infusion, or a creatinine rise of ≥50%, prompts monitoring at 36 h. For 8–12 g/m² over ≤6 h (osteosarcoma), a level >1,500 µM (681 µg/mL) at the end of infusion prompts monitoring at 24 h. After a 36–42-h infusion, only the 48-h threshold applies (Ramsey 2018).
| Time from start of infusion | Threshold (µM) | Threshold (µg/mL) | Source |
|---|---|---|---|
| End of 24-h infusion, 1–8 g/m² (monitoring trigger) | >120 | >54.5 | Ramsey 2018 |
| End of infusion, 8–12 g/m² over ≤6 h (monitoring trigger) | >1,500 | >681 | Ramsey 2018 |
| 24 h (8–12 g/m² over ≤6 h only) | >50 | >22.7 | Ramsey 2018 |
| 36 h | >30 | >13.6 | Ramsey 2018 |
| 42 h | >10 | >4.54 | Ramsey 2018 |
| 48 h | >5 | >2.27 | Ramsey 2018 |
Methotrexate unit conversion and glucarpidase threshold check.
| Quantity | Formula or rule | Example | Source |
|---|---|---|---|
| Molar to mass | µg/mL = µM ÷ 2.2005 | 30 µM = 13.6 µg/mL | Ramsey 2018 |
| Mass to molar | µM = µg/mL × 2.2005 | 2.27 µg/mL = 5 µM | Ramsey 2018 |
| Threshold check | Compare the level with the threshold for its sampling time and check creatinine against baseline | 42-h level of 12 µM with rising creatinine exceeds the 10 µM threshold | Ramsey 2018 |
- 5-Fluorouracil (5-FU). The IATDMCT recommends a 5-FU AUC target of 20–30 mg·h/L, calculated from the steady-state plasma concentration and infusion duration. The previous target proposed by Gamelin was 20–24 mg·h/L for an 8-h infusion, used in a dose algorithm targeting 20–25 mg·h/L. For infusions every 2 weeks, toxicity begins at about 25–30 mg·h/L (Beumer 2019). DPYD genotyping is covered in the pharmacogenetics section.
- Busulfan. A 2019 Delphi consensus harmonized busulfan plasma exposure reporting to AUC in mg·h/L, endorsed by 10 professional societies. Before harmonization, AUC in µM·min was the most used unit, followed by AUC in mg·h/L and steady-state concentration in ng/mL (McCune 2019).
- Dosing basis. Carboplatin, busulfan and methotrexate are dosed by measures other than body surface area (Beumer 2019).
Theophylline and caffeine monitoring
- Theophylline range. Bronchodilation is minimal below 10 mg/L, and adverse effects exceed benefit above 25 mg/L. The range was 10–20 mg/L, and 5–15 mg/L has been proposed to avoid anorexia, nausea, headache and sleep disturbance (Goseva 2015).
- Theophylline clearance and its modifiers. Theophylline is metabolized mainly by CYP1A2. Smoking increases clearance by 58%–100% and shortens half-life by 63%. Smoking cessation for 1 week reduces elimination by 35%. Macrolides, barbiturates, oral contraceptives, heart and liver failure, pneumonia, viral infections and hypoxemia alter clearance (Goseva 2015). Adding erythromycin to theophylline is an indication for monitoring (Kang 2009).
- Theophylline toxicity by exposure pattern. In 356 patients with theophylline of ≥30 µg/mL (167 µmol/L), arrhythmias were more common after chronic overmedication than after acute intoxication (35% vs 10%), and 11 of 15 deaths followed chronic overmedication (Shannon 1999).
- Caffeine in apnea of prematurity. Caffeine is the methylxanthine of choice, with a wider therapeutic index and a longer half-life than theophylline (Long 2021). The effective range of 5–20 mg/L was set in 1977 by analogy with theophylline (Long 2021). In preterm infants, caffeine half-life is more than 10 times and clearance about one-tenth that of adults. The caffeine base dose is half the caffeine citrate dose (Long 2021).
Pharmacogenetics in drug monitoring
CPIC metabolizer phenotype terms. CPIC terms are ultrarapid, rapid, normal, intermediate and poor metabolizer. "Normal metabolizer" replaced "extensive metabolizer" in 2017 (Caudle 2017). "Rapid metabolizer" describes CYP2C19*1/*17, a genotype previously grouped with ultrarapid metabolizers (Moriyama 2017).
CPIC gene-drug recommendations relevant to drug monitoring.
| Gene | Drug | Phenotype effect | CPIC recommendation | Version (previous version) | Source |
|---|---|---|---|---|---|
| CYP2C9 and HLA-B | Phenytoin and fosphenytoin | CYP2C9 decreased activity raises exposure; HLA-B*15:02 raises SJS/TEN risk | HLA-B*15:02 positive and phenytoin-naive: another anticonvulsant unless benefit outweighs risk (carbamazepine and oxcarbazepine also avoided); CYP2C9 activity score 1: at least 25% lower maintenance dose; poor metabolizer: at least 50% lower; then dose by TDM | 2020 update (2014) | Karnes 2021 |
| CYP2C19 | Clopidogrel | Intermediate and poor metabolizers form less active metabolite and have more cardiovascular events | Avoid standard 75-mg clopidogrel if possible; prasugrel or ticagrelor at standard dose | 2022 update with expanded indications (2013) | Lee 2022 |
| CYP2C19 | Voriconazole | Ultrarapid: low troughs; poor: high troughs and adverse events | Alternative agent not dependent on CYP2C19 for ultrarapid and poor metabolizers | 2017 guideline | Moriyama 2017 |
| CYP2D6 | Codeine and tramadol | Ultrarapid: more morphine (45% higher AUC with codeine); poor: little active metabolite | Ultrarapid: avoid codeine because of serious toxicity; a non-tramadol opioid if an opioid is needed | 2021 guideline (2014 codeine guideline) | Crews 2021 |
| TPMT and NUDT15 | Mercaptopurine, azathioprine and thioguanine | Decreased function raises thioguanine nucleotides and myelosuppression | Intermediate: mercaptopurine 30–80% of standard starting dose; poor (malignancy): 10-fold lower dose given 3 days a week | 2025 update (2018) | Maillard 2026; Relling 2019 |
| DPYD | Fluoropyrimidines (5-FU) | Decreased DPD activity reduces 5-FU clearance | Activity score 1: 50% lower starting dose; 1.5: 25%–50% lower; 0 or 0.5: avoid 5-FU regimens | 2017 update | Amstutz 2018 |
| CYP3A5 | Tacrolimus | Expressers have lower dose-adjusted troughs | Genotype-based starting dose with TDM | 2015 guideline | Birdwell 2015 |
| UGT1A1 | Atazanavir | Two decreased-function alleles (*28 or *37) cause hyperbilirubinemia | Genotype-guided prescribing | 2016 guideline | Gammal 2016 |
| MT-RNR1 | Aminoglycosides | m.1095T>C, m.1494C>T and m.1555A>G raise the risk of aminoglycoside-induced hearing loss | Avoid unless infection severity outweighs the risk of permanent hearing loss and no safe or effective alternative exists | 2022 guideline | McDermott 2022 |
- TPMT/NUDT15 2025 update. The update replaces the November 2018 guideline. It gives recommendations by individual thiopurine, adds a TPMT/NUDT15 compound intermediate metabolizer phenotype and revises some allele function assignments (Maillard 2026). The 2018 guideline had introduced the "possible intermediate metabolizer" phenotype, one uncertain-function allele with one no-function allele (Maillard 2026). TPMT *2, *3B and *3C account for more than 90% of low-activity phenotypes. NUDT15 poor metabolizers occur in about 1 in 100 people of East Asian descent, compared with 0.19% TPMT poor metabolizers in people of European descent (Maillard 2026).
- DPYD variants. Four decreased-function variants are of primary relevance: c.1905+1G>A (*2A), c.1679T>G (*13), c.2846A>T and c.1129–5923C>G (HapB3). About 7% of Europeans carry at least one. c.557A>G has a carrier frequency of about 5% in people of African ancestry (Amstutz 2018). About 50% of carriers of decreased-function variants develop severe toxicity (Amstutz 2018). The 2024 AMP joint consensus recommendation (with ACMG, CPIC, CAP and others) defines a minimum (tier 1) and an extended (tier 2) DPYD variant set for clinical genotyping assays (Pratt 2024).
- CYP2C19 and clopidogrel. CYP2C19 genotype does not affect prasugrel or ticagrelor (Lee 2022).
- Pharmacogenetics covered elsewhere. Warfarin pharmacogenetics (CYP2C9 and VKORC1) is covered in Anticoagulant Monitoring, DOAC Measurement and Heparin-Induced Thrombocytopenia Testing. HLA-B57:01 (abacavir), HLA-B15:02 (carbamazepine) and HLA-B*58:01 (allopurinol) are covered in HLA Typing, HLA Antibody Testing, Crossmatch and Platelet and Neutrophil Antibody Testing.
phenytoin albumin correction calculator (Sheiner-Tozer and revised equations)
Drug Testing: Urine Drug Screening, Confirmation, Specimen Validity and Federal Workplace Rules
Definition. Drug testing detects drugs and their metabolites in urine, oral fluid, blood, hair, meconium and other matrices. An initial test, usually an immunoassay, sorts specimens as negative or presumptive positive at a set cutoff. A confirmatory test by mass spectrometry identifies and quantifies the specific analyte (UrMG 2023). Immunoassay positives are presumptive until a second, independent chemical technique confirms them (Saitman 2014). Federal workplace testing adds collection rules, chain of custody, specimen validity testing and review by a Medical Review Officer (MRO) under the HHS Mandatory Guidelines (UrMG 2023; OFMG 2023).
Related page: Analytical Methods and Immunoassays in Clinical Chemistry (competitive immunoassay principles, cross-reactivity, GC-MS and LC-MS/MS) Related page: Therapeutic Drug Monitoring: Pharmacokinetics, Sampling and Assays for Antiepileptic, Antimicrobial, Immunosuppressant, Cardioactive, Psychiatric and Antineoplastic Drugs (pharmacokinetics, sampling and assay interference for therapeutic drugs) Related page: Toxic Alcohols, Acetaminophen, Salicylate and Other Poisonings: Laboratory Evaluation and Monitoring (ethanol testing, toxidromes and the content and limits of an emergency "tox screen") Related page: Method Validation, Statistical Quality Control and Proficiency Testing in Clinical Chemistry (cutoff verification, proficiency testing and quality control) Related page: Endocrine Function Tests: Thyroid, Adrenal and Pituitary (serum testosterone measurement)
Clinical and federal workplace drug testing compared
| Feature | Clinical (medical) testing | Federal workplace (forensic) testing | Source |
|---|---|---|---|
| Purpose | Diagnosis of intoxication; adherence monitoring in pain and addiction treatment | Detection of illicit drug use in a regulated employee population | Bodor 2012; UrMG 2023 |
| Analytes | Laboratory-selected; often includes prescribed drugs (benzodiazepines, buprenorphine, methadone, tramadol) | Fixed HHS panel of Schedule I and II drugs | McMillin 2015; HHS panels 2025 |
| Initial test | Immunoassay, or LC-MS screening in a "hybrid" design | Immunoassay or an alternate technology such as spectrometry | McMillin 2015; UrMG 2023 |
| Confirmation | On request or by reflex; results often reported as presumptive | Mass spectrometric identification required before a positive is reported | Saitman 2014; UrMG 2023 |
| Cutoffs | Set by manufacturer or laboratory; opiate immunoassays commonly use 300 ng/mL | Set in the published federal panel (opiates 2,000 ng/mL) | Bodor 2012; HHS panels 2025 |
| Specimen validity | Optional | Creatinine, pH and an oxidant test on every urine; specific gravity when creatinine is <20 mg/dL | UrMG 2023 |
| Documentation | Ordinary specimen labeling | Federal Custody and Control Form (CCF), tamper-evident seals and laboratory chain of custody | UrMG 2023 |
| Result review | Ordering clinician | MRO interview before a positive is reported to the employer | UrMG 2023 |
Immunoassay screening and mass spectrometric confirmation
Immunoassay initial tests. Drug screening immunoassays are homogeneous competitive assays. Formats include EMIT, CEDIA and KIMS, described in Analytical Methods and Immunoassays in Clinical Chemistry. Specificity depends on the antibody and is independent of the signal system (Bodor 2012). Each assay is calibrated with one target analyte (HHS panels 2025). A result at or above the cutoff is presumptive positive. A result below it is reported negative even when drug is present, so the detection window shortens as the cutoff rises (Reisfield 2026).
Federal rules for grouped analytes. When two or more analytes in one class share an initial cutoff, the immunoassay is calibrated with the target analyte and must show ≥80% cross-reactivity with each other analyte in the group. Otherwise, separate immunoassays are required. The fentanyl immunoassay must show ≥5% cross-reactivity with norfentanyl (HHS panels 2025). A laboratory may run a second initial test with different specificity to exclude cross-reacting compounds (UrMG 2023).
Federal batch quality control.
| Test | Required calibrators and controls in each batch | Source |
|---|---|---|
| Initial drug test | One drug-free control; one positive control at 25% above the cutoff; one control at 75% of the cutoff; one blind control that appears as a donor specimen | UrMG 2023, Section 11.12 |
| Confirmatory drug test | Calibrator at the cutoff; one drug-free control; one positive control at 25% above the cutoff; one control at ≤40% of the cutoff | UrMG 2023, Section 11.15 |
| Both | Calibrators and controls make up ≥10% of the aliquots in the batch | UrMG 2023 |
Confirmatory tests. Federal confirmation requires mass spectrometric identification by GC-MS, LC-MS, GC-MS/MS, LC-MS/MS or an equivalent method, validated before use (UrMG 2023). Initial and confirmatory tests are performed on two separate aliquots (UrMG 2017). A split (B) specimen tested at a second laboratory is not held to the cutoffs. The second laboratory needs only to reconfirm the presence of the drug or metabolite reported in the primary (A) specimen (UrMG 2023).
Broad-spectrum mass spectrometry. Liquid chromatography time-of-flight mass spectrometry detected opioids, benzodiazepines, zolpidem, amphetamine-like stimulants and a methylphenidate metabolite (37 analytes) in one run. Immunoassays were kept for barbiturates, cannabinoid metabolite, carisoprodol, cocaine metabolite, ethyl glucuronide, methadone, phencyclidine and tramadol. This hybrid design shortened time to result and reduced the need for secondary confirmation (McMillin 2015).
Opiate immunoassay calibration. Opiate immunoassays are calibrated with morphine, commonly at a 300 ng/mL cutoff, and detect morphine and codeine at the cutoff. Morphine-3- and morphine-6-glucuronide cross-react about 60% in CEDIA, and the EMIT package insert does not state their cross-reactivity, so assays differ on the same specimen. Fentanyl, buprenorphine and methadone require separate drug-specific immunoassays (Bodor 2012).
Federal workplace drug testing panels and their previous versions
Since the 2023 UrMG, HHS publishes the authorized drug testing panel in a separate Federal Register notice. A biomarker testing panel is also authorized, but no biomarker test had been approved when the current panels were issued (UrMG 2023; HHS panels 2025). The Department of Transportation (DOT) must follow the HHS Mandatory Guidelines for its minimum drug list, which it sets in its own rule, 49 CFR part 40 (DOT NPRM 2025).
HHS urine drug testing panel (HHS Mandatory Guidelines using Urine, 88 FR 70768; panel notice 90 FR 4662, FR Doc 2025-00425, effective July 7, 2025; unchanged by 91 FR 12308, March 13, 2026), with the January 23, 2017 UrMG panel (82 FR 7920, effective October 1, 2017).
| Initial test analyte | Initial cutoff (ng/mL) | Confirmatory analyte | Confirmatory cutoff (ng/mL), current | Confirmatory cutoff (ng/mL), 2017 rule |
|---|---|---|---|---|
| Marijuana metabolite (Δ9THCC) | 50 | Δ9-tetrahydrocannabinol-9-carboxylic acid | 15 | 15 (abbreviated THCA) |
| Cocaine metabolite (benzoylecgonine) | 150 | Benzoylecgonine | 100 | 100 |
| Codeine/morphine | 2,000 | Codeine; morphine | Codeine 2,000; morphine 4,000 | 2,000 each |
| Hydrocodone/hydromorphone | 300 | Hydrocodone; hydromorphone | 100 each | 100 each |
| Oxycodone/oxymorphone | 100 | Oxycodone; oxymorphone | 100 each | 100 each |
| 6-Acetylmorphine | 10 | 6-Acetylmorphine | 10 | 10 |
| Phencyclidine | 25 | Phencyclidine | 25 | 25 |
| Fentanyl | 1 | Fentanyl; norfentanyl | 1 each | No fentanyl in the panel |
| Amphetamine/methamphetamine | 500 | Amphetamine; methamphetamine | 250 each | 250 each |
| MDMA/MDA | 500 | MDMA; MDA | 250 each | 250 each |
Initial cutoffs were the same in 2017 for every analyte listed there. For an alternate-technology initial test specific for benzoylecgonine, the confirmatory cutoff of 100 ng/mL applies (HHS panels 2025).
HHS oral fluid drug testing panel, undiluted (neat) oral fluid (HHS Mandatory Guidelines using Oral Fluid, 88 FR 70814, effective October 10, 2023; panel notice 90 FR 4662, effective July 7, 2025), with the first OFMG panel (84 FR 57554, FR Doc 2019-22684, effective January 1, 2020).
| Initial test analyte | Initial cutoff (ng/mL) | Confirmatory analyte | Confirmatory cutoff (ng/mL) | Change from the 2019 OFMG |
|---|---|---|---|---|
| Marijuana (Δ9THC) | 4 | Δ9-tetrahydrocannabinol | 2 | None |
| Cocaine/benzoylecgonine | 15 | Cocaine; benzoylecgonine | 8 each | None |
| Codeine/morphine | 30 | Codeine; morphine | 15 each | None |
| Hydrocodone/hydromorphone | 30 | Hydrocodone; hydromorphone | 15 each | None |
| Oxycodone/oxymorphone | 30 | Oxycodone; oxymorphone | 15 each | None |
| 6-Acetylmorphine | 4 | 6-Acetylmorphine | 2 | None |
| Phencyclidine | 10 | Phencyclidine | 10 | None |
| Fentanyl | 4 | Fentanyl | 1 | Added July 7, 2025 |
| Amphetamine/methamphetamine | 50 | Amphetamine; methamphetamine | 25 each | None |
| MDMA/MDA | 50 | MDMA; MDA | 25 each | None |
The oral fluid panel confirms parent Δ9THC and parent cocaine. The urine panel confirms the metabolites Δ9THCC and benzoylecgonine, and only the urine panel includes norfentanyl (HHS panels 2025).
Rule changes by date.
| Rule | Change | Source |
|---|---|---|
| 2008 Mandatory Guidelines, effective October 1, 2010 | Lowered the cocaine metabolite and amphetamine cutoffs; added MDMA and initial testing for 6-acetylmorphine | 73 FR 71858 |
| 2017 UrMG, effective October 1, 2017 | Added oxycodone, oxymorphone, hydrocodone and hydromorphone; removed MDEA; added MDA as an initial test analyte; raised the lower pH cutoff for adulteration from 3 to 4; MRO requalification at least every 5 years | 82 FR 7920 |
| 2019 OFMG, effective January 1, 2020 | First federal oral fluid guidelines and panel | 84 FR 57554 |
| 2023 UrMG, effective February 1, 2024 | Panels published separately; biomarker-based substitution; morphine confirmatory cutoff raised from 2,000 to 4,000 ng/mL with removal of the added codeine and morphine decision point; semiannual MRO reports | 88 FR 70768 |
| 2025 panel notice, effective July 7, 2025 | Fentanyl added to urine and oral fluid panels, norfentanyl to urine; MDMA and MDA proposed for removal and kept; Δ9THCC and Δ9THC nomenclature | 90 FR 4662 |
| 2026 panel notice | No changes to analytes, cutoffs or nomenclature; footnotes 1 and 2 of the panels edited for clarity | 91 FR 12308 |
The marijuana metabolite abbreviation changed from THCA to Δ9THCC. The new term separates the metabolite from Δ8-THC metabolites and from Δ9-tetrahydrocannabinolic acid, a non-psychoactive compound in the cannabis plant that is also abbreviated THCA (HHS panels 2025).
Pending proposals. HHS proposed revisions to the UrMG (91 FR 68398) and the OFMG (91 FR 68364) on October 29, 2026, with comments due December 28, 2026. The UrMG proposal would raise the invalid-result pH cutoff from 9.0 to 9.5, publish the panels only when revised, revise initial-test batch quality control, allow the MRO to authorize a biomarker test for a specimen invalid by creatinine and specific gravity, and allow a split laboratory to reconfirm substitution with a different authorized biomarker (HHS UrMG proposal 2026). DOT proposed adding fentanyl and norfentanyl to its 49 CFR part 40 panels on September 2, 2025 (DOT NPRM 2025). No final DOT rule had been published as of November 17, 2026.
Federal urine collection and chain of custody
- Split specimen. Every federal collection is a split collection. The collector pours at least 30 mL into bottle A and at least 15 mL into bottle B in the presence of the donor (UrMG 2023, Section 8.8).
- Temperature. The collector reads the specimen temperature within 4 minutes of receipt. The acceptable range is 32–38 °C (90–100 °F). A temperature outside this range is a reason to believe the specimen was adulterated or substituted, and a second specimen is collected under direct observation. Both specimens are sent to the laboratory (UrMG 2023, Section 8.5).
- Direct observed collection. Observation is required after an out-of-range temperature or signs of tampering such as unusual color, odor or excessive foaming. It is also required after a previous positive, adulterated or substituted result, or an invalid result without a legitimate medical explanation (UrMG 2023, Section 8.9).
- Seals and the Federal CCF. Tamper-evident seals from the Federal CCF are placed over each bottle cap in the presence of the donor and dated. The donor initials the seals and signs a certification statement (UrMG 2023, Section 8.8).
- Laboratory chain of custody. Internal and external chain of custody covers specimens and aliquots from receipt through testing, reporting, storage and final disposal. Each person who handles or transfers a specimen or aliquot signs the record, and the date and purpose of each transfer are recorded on paper or electronically (UrMG 2023, Section 11.8).
- Retention. Specimens reported positive, adulterated, substituted or invalid are kept for at least 1 year in secured frozen storage at −20 °C or lower for possible retesting in administrative or judicial proceedings (UrMG 2023, Section 11.20).
Specimen validity testing in federal urine testing
Required tests. Every federal urine specimen is tested for creatinine and pH and with one or more tests for oxidizing adulterants. Specific gravity is measured when creatinine is <20 mg/dL (UrMG 2023, Section 3.1). Creatinine is reported to one decimal place. Specific gravity for the initial and confirmatory tests is measured by a refractometer that reports four decimal places (UrMG 2023, Section 11.18).
Specimen validity categories for a primary (A) urine specimen (HHS Mandatory Guidelines using Urine, 88 FR 70768, FR Doc 2023-21734, effective February 1, 2024, Sections 3.6–3.9). The creatinine and specific gravity criteria are the same in the 2017 UrMG (82 FR 7920).
| Category | Creatinine (mg/dL) | Specific gravity | Other criteria | Laboratory testing rule |
|---|---|---|---|---|
| Dilute (laboratory or IITF) | >5 and <20 | ≥1.002 and <1.003 | None | Single aliquot |
| Dilute (laboratory only) | ≥2 and <20 | >1.0010 and <1.0030 | None | Four-decimal refractometer when creatinine is ≤5 mg/dL |
| Substituted | <2 on initial and confirmatory tests | ≤1.0010 or ≥1.0200 on initial and confirmatory tests | Or a biomarker absent, or present at a concentration inconsistent with human urine, on two tests | Two separate aliquots |
| Adulterated | Any | Any | pH <4 or ≥11; nitrite ≥500 µg/mL; chromium (VI), a halogen, glutaraldehyde, pyridine, a surfactant (≥100 µg/mL dodecylbenzene sulfonate equivalent) or another adulterant verified by a different confirmatory test | Initial test on the first aliquot and a different confirmatory test on the second |
| Invalid: inconsistent creatinine and specific gravity | <2 on both tests | >1.0010 and <1.0200 on either test | None | Two separate aliquots |
| Invalid: inconsistent creatinine and specific gravity | ≥2 on either test | ≤1.0010 on both tests | None | Two separate aliquots |
| Invalid: pH | Any | Any | pH ≥4 and <4.5, or ≥9 and <11 | pH meter for the confirmatory test |
| Invalid: oxidant or interference | Any | Any | Nitrite ≥200 and <500 µg/mL; possible chromium (VI), halogen, glutaraldehyde, oxidant or surfactant by the same test on two aliquots; interference with initial or confirmatory drug tests on two aliquots | Two separate aliquots |
- Dilute results are reported only together with the negative or positive drug result (UrMG 2023, Section 3.8).
- pH 9.0–9.5. For an invalid result with pH 9.0–9.5 and no other medical explanation, the MRO considers whether elapsed time and high temperature during transport and storage account for the pH (UrMG 2023, Section 13.5).
- Proficiency testing ranges. Validity proficiency samples contain nitrite at least 20% above the cutoff, pH 1.5–5.0 or 8.5–12.5, creatinine 0–20 mg/dL, or specific gravity ≤1.0050 or 1.0170–1.0230 (UrMG 2023, Section 9.5).
- Oral fluid validity. Oral fluid validity tests are performed on MRO request. A specimen is adulterated when an adulterant is verified by an initial test and a different confirmatory test, and substituted only by a biomarker test. It is invalid when drug tests show interference on two aliquots, when viscosity could damage instruments, when the A and B specimens clearly differ in appearance, or when a validity test indicates the specimen is unsuitable (OFMG 2023).
Medical Review Officer review of federal results
The MRO is a licensed physician (MD or DO) with knowledge of the pharmacology and toxicology of illicit drugs who has passed an approved certification examination and completes requalification training at least every 5 years (UrMG 2023, Section 13.1).
MRO actions by laboratory result (UrMG 2023, Section 13.5).
| Laboratory result | MRO action | Result reported to the agency |
|---|---|---|
| Negative | None | Negative |
| Negative/dilute | Directs an immediate recollection | Negative/dilute; a negative or negative/dilute recollection is reported negative |
| Positive | Interviews the donor for a legitimate medical explanation such as a valid prescription | Negative with a legitimate explanation; positive with an admission or without an explanation |
| Adulterated or substituted | Interviews the donor for a legitimate medical explanation | Refusal to test without an explanation; negative with one |
| Invalid | Interviews the donor; considers time and temperature for pH 9.0–9.5 | Test cancelled; recollection under direct observation when no legitimate explanation exists |
| Rejected for testing | None | Test cancelled; a new specimen of the same type is recommended |
- Explanations not accepted as legitimate. Passive exposure, food products containing a drug (including poppy seeds containing codeine or morphine) and a physician's authorization for a Schedule I substance are not legitimate medical explanations for a positive result (UrMG 2023).
- Codeine and morphine, previous rule. Under the 2017 UrMG, codeine or morphine <15,000 ng/mL without a legitimate explanation was reported positive only with clinical evidence of illegal use, unless 6-acetylmorphine was confirmed. At ≥15,000 ng/mL, food consumption was not accepted as an explanation (UrMG 2017). The 2023 UrMG removed this decision point and the clinical-evidence requirement (UrMG 2023).
- Split (B) specimen. For a positive, adulterated or substituted primary result, the donor may request, through the MRO and within 72 hours of notification, testing of the B specimen at a second HHS-certified laboratory (UrMG 2023, Section 13.9). When the drug is not reconfirmed, the second laboratory performs specimen validity tests to identify the reason (UrMG 2023, Section 14.2).
- Additional tests on MRO request. A laboratory may perform additional drug or validity tests case by case, such as tetrahydrocannabivarin. Determination of the d- and l-stereoisomers of amphetamine and methamphetamine is the one test a laboratory may perform routinely on MRO request without prior HHS authorization (UrMG 2023, Section 3.5).
- Semiannual reports. Since the 2023 UrMG, each MRO reports to HHS every January and July the federal specimens reported positive by the laboratory and verified negative, with the reason (UrMG 2023).
Opioid testing: opiates, semisynthetic and synthetic opioids
Opiates and their metabolites. Morphine is conjugated at the 3- or 6-position to glucuronides, and a small amount is excreted unchanged. Codeine is demethylated to morphine. Morphine is not converted to codeine in the body, and trace codeine after morphine therapy comes from impurity in the morphine preparation (Bodor 2012). Hydrocodone is metabolized to hydromorphone and norhydrocodone. Oxycodone is metabolized to oxymorphone and noroxycodone (Bodor 2012).
Heroin and 6-acetylmorphine. Heroin is deacetylated to 6-acetylmorphine (6-AM, also called 6-monoacetylmorphine) with a half-life of <60 minutes and then to morphine. The body cannot form 6-AM from any other source, so its presence proves heroin use (Bodor 2012; UrMG 2017).
Poppy seeds. Fifteen adults each ate one poppy seed pastry. At a 4,000 ng/mL cutoff, eight were codeine-positive at 8 hours and two remained positive at 24 hours. At 2,000 ng/mL, one participant was codeine-positive at 48 hours. At 300 ng/mL, seven were opiate-positive at 48 hours and four at 72 hours, and at the limits of detection four still had codeine or morphine at 108 hours (Reisfield 2026). Clinical programs with low opiate cutoffs therefore detect poppy seed ingestion for days. Thebaine has been proposed as an adjunctive marker of poppy seed ingestion (Reisfield 2026).
Opioid analytes in urine.
| Drug | Screening assay | Analytes for confirmation | Interpretation points | Source |
|---|---|---|---|---|
| Heroin | Opiate immunoassay (morphine); 6-AM immunoassay | 6-AM, morphine | 6-AM proves heroin use; short window | Bodor 2012 |
| Codeine | Opiate immunoassay | Codeine, morphine | Morphine from codeine metabolism; poppy seeds contain both | Bodor 2012; Reisfield 2026 |
| Hydrocodone | Opiate immunoassay at about 600 ng/mL (about 50% cross-reactivity); federal hydrocodone/hydromorphone assay | Hydrocodone, hydromorphone, norhydrocodone | Hydromorphone in urine can be a hydrocodone metabolite | Bodor 2012 |
| Oxycodone | Separate oxycodone assay | Oxycodone, oxymorphone, noroxycodone | Opiate immunoassay detects it only at about 2,500 ng/mL, giving false negatives at most therapeutic concentrations | Bodor 2012 |
| Fentanyl | Fentanyl immunoassay with norfentanyl cross-reactivity | Fentanyl, norfentanyl | Short half-life; norfentanyl extends detection | Bodor 2012; HHS panels 2025 |
| Methadone | Methadone or EDDP immunoassay | Methadone, EDDP, EMDP | Rapid metabolizers may have no parent drug; EDDP is measured before nonadherence is concluded | Bodor 2012 |
| Buprenorphine | Buprenorphine immunoassay | Buprenorphine, norbuprenorphine | Low norbuprenorphine-to-buprenorphine ratio suggests drug added to the urine | Suzuki 2017 |
- Methadone and EDDP. Methadone half-life ranges from 4 to 190 hours, typically 15–60 hours, and methadone is metabolized by CYP3A4, CYP2B6 and CYP2D6 (Bodor 2012). Normalizing EDDP to urine creatinine improved the fit of EDDP to methadone dose (adjusted R² 0.95 in the pilot group, compared with 0.49 for EDDP alone) (Larson 2009).
- Buprenorphine. In 2,275 urine specimens from 168 patients in office-based treatment, 8 specimens (0.35%) were judged spiked. A norbuprenorphine-to-buprenorphine ratio <0.02 prompted review, and every suspected specimen had buprenorphine >2,000 ng/mL with a mean norbuprenorphine of 11.9 ng/mL (Suzuki 2017).
- Tramadol. Tramadol caused false-positive results in point-of-care buprenorphine immunoassays and in the CEDIA buprenorphine assay at a 5 ng/mL calibration cutoff. Seven of 10 immunoassay-positive specimens were negative for buprenorphine and norbuprenorphine by LC-MS/MS (Shaikh 2008). Tramadol itself is detected by its own immunoassay or by mass spectrometry (McMillin 2015).
- Fentanyl analogs. Four commercial fentanyl immunoassays were challenged with 216 fentanyl analogs and synthetic opioids. All four detected 106 compounds, and 28 were detected by none, 17 of them emerging synthetic opioids. Remifentanil, alfentanil and norsufentanil were not detected. At 1 ng/mL the assays detected between 5 and 74 compounds (Wolf 2025).
- Naloxone. Naloxone interfered with an oxycodone immunoassay in oral fluid in three cases (Silva 2022).
Amphetamines, MDMA, cocaine and synthetic cathinones
Amphetamine immunoassay false positives confirmed by mass spectrometry.
| Cross-reacting drug or compound | Finding | Source |
|---|---|---|
| Pseudoephedrine | Of 27,400 military urine specimens screened at 500 ng/mL, the DRI amphetamine assay gave 1,104 presumptive positives; 1.99% confirmed for amphetamine, methamphetamine, MDA or MDMA. Pseudoephedrine was present in all 833 unconfirmed specimens that contained a sympathomimetic amine. A KIMS assay gave 317 presumptive positives with 7.94% confirmed. | Stout 2004 |
| Bupropion metabolites | Two of four amphetamine ELISA kits gave false positives at bupropion metabolite concentrations >500 ng/mL; GC-MS found no amphetamines | Reidy 2011 |
| Trazodone (meta-chlorophenylpiperazine metabolite) | Amphetamines II (Roche) immunoreactivity correlated with m-CPP concentration (r = 0.990); at least 8 trazodone-associated false positives in 26 days at one institution | Baron 2011 |
| Labetalol | False-positive amphetamine and methamphetamine immunoassays in spiked meconium; no positive immunoassay or LC-MS/MS result in spiked urine, plasma or umbilical cord tissue | Bithi 2023 |
| Synthetic cathinones | Methylone at 10 µg/mL and 3-chloromethcathinone at 100 µg/mL gave false-positive MDMA results; 2-methylmethcathinone at 50 µg/mL gave a false-positive amphetamine result (EMIT). In 2,033 emergency and ICU urines, cathinones caused 16.3% of positive amphetamine and 17.1% of positive MDMA results. | Willeman 2025 |
| Selegiline | Metabolized to l-methamphetamine and l-amphetamine; positive methamphetamine screen | Shin 2021 |
Enantiomer (chiral) analysis. Routine confirmatory methods identify amphetamine and methamphetamine without distinguishing the d- and l-enantiomers. Most federal initial immunoassays target d-methamphetamine, and l-methamphetamine and the amphetamine enantiomers cross-react (MRO Manual 2025). Some nonprescription nasal inhalers contain l-methamphetamine (levmetamfetamine). Selegiline is metabolized to l-methamphetamine and l-amphetamine, and benzphetamine to d-methamphetamine and d-amphetamine (MRO Manual 2025). In reexamined workplace methamphetamine-positive specimens, one contained pure d-isomers, most contained skewed racemates and none contained pure l-methamphetamine (Cooke 1994). Chiral derivatization followed by GC-MS separates the isomers (Cooke 1994; Shin 2021). In a selegiline user, the amphetamine-to-methamphetamine ratio was 0.27, within the range expected after selegiline, and both drugs were l-isomers (Shin 2021). After controlled use of a nonprescription l-methamphetamine inhaler at recommended doses in 22 adults, no d-methamphetamine or d-amphetamine was detected. The median peak l-methamphetamine was 62.8 µg/L (range 11.0–1,440). l-Amphetamine was detectable in 2 subjects, at ≤4% of the parent maximum, and the EMIT II Plus amphetamines immunoassay gave 2.2% false-positive screens (Smith 2014).
MRO interpretation of methamphetamine enantiomers. The HHS MRO Guidance Manual (effective July 7, 2025) treats >80% l-methamphetamine as consistent with use of a nonprescription inhaler. More than 20% d-methamphetamine indicates a source other than the inhaler, and the result is verified as positive. A trace of d-methamphetamine can come from the inhaler product or from the analytical procedure. The presence of an l-isomer does not by itself rule out illegal use (MRO Manual 2025).
Cocaine. With ethanol, cocaine undergoes hepatic transesterification to cocaethylene, an active metabolite. About 24% of intravenous, 34% of oral and 18% of smoked cocaine was converted to cocaethylene after oral ethanol 1.0 g/kg (Herbst 2011).
Cannabinoid testing
Cannabinoid analytes. Urine tests target 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THCCOOH, federal abbreviation Δ9THCC), the terminal metabolite of Δ9-tetrahydrocannabinol (THC) (HHS panels 2025; McCartney 2026).
Cannabinoid detection after use. Low single doses of THC (1.0–5.0 mg), particularly oral, sometimes exceeded the 15 ng/mL workplace threshold. Weekly to daily users could remain above 15 ng/mL for weeks after stopping (McCartney 2026). In 33 chronic users under 24-hour supervised abstinence, THC was measurable in urine for up to 24 days, and THCCOOH and 11-OH-THC were detectable for at least 24 days in one heavy user. Urinary THC therefore does not identify recent use in chronic users (Lowe 2009). The World Anti-Doping Agency (WADA) decision limit for total THCCOOH is 180 ng/mL (McCartney 2026).
Creatinine-normalized ratios for new use. Each THCCOOH result is divided by creatinine, and a later specimen (U2) is compared with an earlier one (U1). With a 15 ng/mL cutoff and no new use, the maximum U2/U1 ratio was 3.05 for collections ≤24 hours apart and 0.215 for collections 96–119.9 hours apart. A ratio above these limits suggests new use (Smith 2009).
Hemp-derived cannabinoids. Six commercial urine cannabinoid immunoassays cross-reacted with Δ8-THC and its metabolites, Δ10-THC and hexahydrocannabinol (HHC) carboxylic acid analogs, 6-OH-CBD, 7-OH-CBD and olivetol. They did not cross-react with cannabidiol (CBD) or 7-COOH-CBD (Wolf 2023).
Dronabinol. Synthetic THC in dronabinol is identical to plant THC, so THCCOOH does not distinguish them. Tetrahydrocannabivarin (THCV) occurs in most cannabis products and not in dronabinol. Its metabolite THCV-COOH appeared in urine only after cannabis and not after oral or smoked dronabinol (ElSohly 2001).
Synthetic cannabinoids. Synthetic cannabinoid immunoassays target specific metabolites. An ELISA calibrated to the UR-144 pentanoic acid metabolite at 5 ng/mL detected UR-144 and XLR-11 metabolites and showed no measurable cross-reactivity with other synthetic cannabinoids at <1,000 ng/mL (Mohr 2014).
Cannabinoids in hair. THC in hair can come from external contamination. THCCOOH in hair, even without THC, was accepted as evidence of use; wash tests of 100 THCCOOH-only hair samples were negative. Cutoffs were THC ≥50 pg/mg and THCCOOH ≥0.2 pg/mg (Ramirez Fernandez 2026).
Benzodiazepines, GHB, zolpidem and gabapentinoids
Benzodiazepine immunoassays and glucuronide hydrolysis. In one evaluation the benzodiazepine immunoassay cutoff was 200 ng/mL of nordiazepam. FDA-cleared assays without hydrolysis cross-react poorly with glucuronidated metabolites. Against LC-MS/MS in 258 clinical urines, clinical sensitivity was 100% for an assay with β-glucuronidase, 95.2% for a laboratory-developed assay with β-glucuronidase and 66.7% for an assay without it. Specificity was 100% for all three. The assay with β-glucuronidase detected lorazepam glucuronide best (Ge 2024).
Clonazepam. In 180 patients taking clonazepam as their only benzodiazepine, a benzodiazepine immunoassay with a 200 ng/mL cutoff was positive in 21%. LC-MS/MS for 7-aminoclonazepam, the main and drug-specific metabolite, was positive in 70% at a 200 ng/mL cutoff and 87% at 40 ng/mL (West 2010).
Designer benzodiazepines. Designer benzodiazepines are structurally similar to prescribed benzodiazepines, so immunoassays do not distinguish the two groups. Identification requires mass spectrometry (Bazydlo 2025). Flualprazolam co-occurred in 13.5% of nitazene deaths in Tennessee (Roberts 2022).
Other sedative analytes.
| Drug or group | Screening | Confirmation or identification | Interpretation points | Source |
|---|---|---|---|---|
| Barbiturates | Immunoassay | Mass spectrometry | False-positive immunoassay results are reported | McMillin 2015; Saitman 2014 |
| Zolpidem | Time-of-flight mass spectrometry in a hybrid design | Identified in the same run | Detected with opioids and benzodiazepines in one mass spectrometric run | McMillin 2015 |
| GHB | Not in routine panels | GC-MS | Endogenous compound; short window | Haller 2006 |
| Pregabalin and gabapentin | Not in routine panels | LC-MS/MS | Pregabalin in 15–18% of tested urines annually; often the only drug present | Aksun 2025 |
GHB. After 50 mg/kg sodium oxybate, peak urine GHB averaged 150–200 mg/L in the 0–3 hour collection. At a proposed 10 mg/L cutoff separating endogenous from exogenous GHB, 12.5% of specimens from 3–6 hours, 81.3% from 6–12 hours and 100% from 12–24 hours were below the cutoff (Haller 2006).
Gabapentinoids. At one hospital (2019–2024), pregabalin was sometimes found more often than methamphetamine, and patients using pregabalin alone were reported negative by panels that exclude it (Aksun 2025).
Novel psychoactive substances and adulterants in the illicit opioid supply
Novel psychoactive substances and adulterants: laboratory data.
| Substance | Class and laboratory point | Reported data | Source |
|---|---|---|---|
| Xylazine | Nonopioid sedative not approved for human use, found with illicitly manufactured fentanyl; detected by expanded postmortem testing | Share of fentanyl-involved deaths with xylazine rose from 2.9% to 10.9% (276%) in 21 jurisdictions, January 2019–June 2022 | Kariisa 2023 |
| Nitazenes | 2-Benzylbenzimidazole synthetic opioids never approved in the United States; isotonitazene, protonitazene and etonitazene exceed fentanyl in potency, and metonitazene is similar | 52 deaths in Tennessee, 2019–2021 (none in 2019, 10 in 2020, 42 in 2021); 85.7% of 2021 deaths involved metonitazene; fentanyl present in 59.6% | Roberts 2022 |
| Medetomidine | Nonopioid sedative not approved for human use, mixed with opioids | Chicago, May 11–17, 2024: 12 confirmed, 26 probable and 140 suspected cases; fentanyl in every specimen with medetomidine; bradycardia and no or partial naloxone response | Nham 2025 |
Naloxone reversed nitazene overdoses, sometimes only after several doses (Roberts 2022).
Detection windows and alternative specimens
Detection time depends on dose, route, duration of use, the matrix, the target analyte, the method's sensitivity, urine or oral fluid pH and concentration, and individual clearance. It is longest in hair, followed by urine, sweat, oral fluid and blood (Verstraete 2004).
Detection windows by matrix.
| Matrix | Typical detection window | Laboratory features | Source |
|---|---|---|---|
| Blood or plasma | 1–2 days for most drugs at low ng/mL concentrations | Shortest window of the matrices compared | Verstraete 2004 |
| Urine | 1.5–4 days after a single dose; about 1 week in chronic users; longer for chronic cannabis and cocaine use | Federal specimen validity testing applies | Verstraete 2004; UrMG 2023 |
| Oral fluid | 5–48 hours at low ng/mL concentrations | Parent drugs; collection under direct observation; at least 1 mL of neat oral fluid per tube; 10-minute wait before collection | Verstraete 2004; OFMG 2023 |
| Hair | Longest of all matrices | Proximal and distal segments analyzed separately; external contamination for THC | Verstraete 2004; Ramirez Fernandez 2026 |
| Sweat patch | Cumulative over the wear period | Drugs applied to the outside of the membrane penetrated it, and skin contamination persisted after 6 days of normal hygiene | Kidwell 2001 |
| Meconium | In utero exposure from about 12 weeks' gestation; first-trimester exposure missed | Passed in the first few days of life; higher drug concentrations than cord tissue | Price 2018; Pandya 2023 |
| Umbilical cord tissue | In utero exposure | Available at birth; faster turnaround than meconium | Pandya 2023 |
- Detection windows outside the typical range. GHB has a shorter window than other drugs. After a single 1–2 mg dose of flunitrazepam, sensitive methods detected 7-aminoflunitrazepam in urine for up to 4 weeks (Verstraete 2004).
- Oral fluid collection devices. A device that uses a diluent must still collect at least 1 mL of neat fluid in each of tubes A and B, and federal oral fluid cutoffs apply to neat fluid (OFMG 2023; HHS panels 2025).
Neonatal drug exposure testing in meconium and umbilical cord tissue. Neonatal urine detects only recent maternal drug use (Price 2018). Meconium begins to form at about 12 weeks' gestation, as fetal swallowing of amniotic fluid begins, so it cannot detect first-trimester exposure. Meconium can be passed in utero and can contain drugs given during labor. Drug exposure and low birth weight delay its passage, so it is not immediately available for a newborn in distress (Price 2018). Umbilical cord tissue is collected at birth. Dilution of meconium by milk stool and small cord specimens with little Wharton's jelly reduce detection (Pandya 2023).
- Matrix comparison depends on the assay. In 4,036 paired specimens, opioid concentrations were higher in meconium (median morphine 202.5 ng/g, compared with 8.3 ng/g in cord tissue). Positivity was significantly higher in cord tissue for every opioid analyte except oxycodone (buprenorphine or norbuprenorphine 15.6% vs 9.1%). Cord tissue was tested by LC-MS/MS at much lower cutoffs, and meconium by an immunoassay screen followed by LC-MS/MS confirmation. In 2,112 pairs tested for THC-COOH, positivity was higher in meconium (35.0% vs 25.3%) (Pandya 2023). An earlier comparison found meconium more sensitive than cord tissue for 5 of 6 drug classes, with agreement from 76% (cannabinoids) to 100% (barbiturates) (Colby 2017).
Hair collection and segmental analysis. Head hair is cut as close to the scalp as possible from the posterior vertex, the region with the least variation in growth rate, and the root end is identified. An approximate head hair growth rate of 1.0 cm per month is accepted for segmental analysis, although individual rates vary. Segmentation of body hair is generally not recommended, and body hair has a higher proportion of dormant (telogen) hairs (SoHT 2022). Hair cutoffs apply to head hair in segments no longer than 3 cm. They are not applied in drug-facilitated crimes, single-exposure cases or children, where the limit of quantification is used. Hair concentration cannot be used to determine the quantity of drug consumed (SoHT 2021).
Society of Hair Testing cutoffs for drugs of abuse in head hair (2021 SoHT consensus on drugs of abuse testing in hair, agreed November 16, 2021).
| Drug group | Analytes | Cutoff (pg/mg) | Interpretation |
|---|---|---|---|
| Opiates | Morphine, codeine, dihydrocodeine | 200 | Heroin use is separated from codeine or morphine use by 6-acetylmorphine or heroin |
| Opiates | 6-Acetylmorphine, heroin | 200 | Indicates heroin use |
| Cocaine | Cocaine | 500 | Benzoylecgonine, norcocaine, cocaethylene, hydroxycocaines or hydroxybenzoylecgonine are considered to confirm use; anhydroecgonine methyl ester for crack cocaine |
| Amphetamines | MDMA, MDEA, MDA, methamphetamine, amphetamine | 200 | No confirming metabolite specified |
| Cannabinoids | THC | 50 | THCCOOH strongly supports use; minimum LOQ for THCCOOH 0.2 pg/mg |
| Cannabinoids | CBD | 50 | No confirming metabolite specified |
| Opioids | Tramadol | 200 | Desmethyltramadol proves use |
| Opioids | Oxycodone | 100 | No confirming metabolite specified |
| Methadone | Methadone | 200 | EDDP proves use |
| Buprenorphine | Buprenorphine | 10 | Norbuprenorphine proves use |
| Ketamine | Ketamine | 200 | Norketamine proves use |
Postmortem toxicology
Postmortem redistribution. Drug concentrations after death need not reflect concentrations at the time of death. Cardiac blood shows early postmortem increases, probably by redistribution along large vessels from drug reservoirs in the lungs, aided by rapid postmortem acidification of blood. A longer postmortem interval and decomposition increase diffusion (Borra 2026). Redistribution is generally expected for basic, lipophilic drugs with a volume of distribution >3 L/kg, although the literature is not consistent. The central-to-peripheral blood ratio and the liver-to-peripheral blood ratio are markers of redistribution, and the liver ratio may be more reliable (Gkarmiri 2026). Redistribution studies compare samples from defined sites such as the femoral vein, jugular vein and aortic arch (Gkarmiri 2026).
Postmortem ethanol formation. Ethanol can form in postmortem blood when glucose and microorganisms are present, and vitreous humor is commonly used to verify blood ethanol (Peterson 2026). Vitreous humor can also contain ethanol absent from blood. In 858 cases with vitreous ethanol and none in paired blood, 79% had 10–49 mg/dL. Acetone or isopropanol was present in 54%, β-hydroxybutyrate ≥250 µg/mL in 92% of those tested and vitreous glucose ≥200 mg/dL in 37% of those tested, consistent with ketoacidosis or hyperglycemia. Ethanol can form in unpreserved vitreous specimens, and the authors support testing of more than one matrix (Peterson 2026).
Vitreous humor chemistry. Vitreous potassium, calcium, creatinine and lactate rose with postmortem interval in serial samples, but nonlinear trends limited estimation of the interval. Vitreous sodium, chloride and glucose varied with cardiovascular and infectious conditions, and urea and creatinine were raised in renal or multiorgan failure (Kaehler 2025).
Anabolic steroids in sports drug testing
- Governing body. WADA sets the antidoping rules and laboratory decision limits used in competitive sport (McCartney 2026; Li 2026).
- Testosterone/epitestosterone (T/E) ratio. A urinary T/E ratio >4.0 is the traditional threshold for suspected testosterone use (Schulze 2009; Strahm 2015). A deletion polymorphism of UGT2B17 lowers urinary testosterone glucuronide. After testosterone enanthate (125–500 mg), every subject carrying the enzyme reached a T/E of 4, and no subject with the del/del genotype did (Strahm 2015). Bayesian individual cutoffs that include the genotype increase the sensitivity of the T/E test (Schulze 2009).
- Athlete Biological Passport. The steroidal module of the passport evaluates changes in an athlete's own steroid profile over time (Li 2026). Testosterone administration increased the steroids in the module and decreased epitestosterone (Strahm 2015).
- Carbon isotope ratio mass spectrometry. Gas chromatography–combustion–isotope ratio mass spectrometry (GC-C-IRMS) determines whether testosterone and its metabolites are exogenous. It detected testosterone use independent of UGT2B17 genotype (Strahm 2015). Suspect or atypical profiles proceed to GC-C-IRMS for confirmation (Li 2026).
- Confounders of the steroid profile. UGT2B17 deletion, sex, menstrual cycle phase, pregnancy, medication and sample degradation alter marker concentrations and ratios (Li 2026).
Toxic Alcohols, Acetaminophen, Salicylate and Other Poisonings: Laboratory Evaluation and Monitoring
Definition. Poisoning is the presence of clinical manifestations, or of laboratory or electrocardiographic abnormalities, that result from exposure to a xenobiotic (Mégarbane 2020). The laboratory confirms the toxin, measures drug concentrations that set antidote and extracorporeal treatment thresholds, and monitors organ injury. Concentration-based decisions apply to acetaminophen, salicylate, lithium, digoxin, toxic alcohols and iron (Mégarbane 2020; Ghannoum 2023).
Related page: Water, Electrolytes, Osmolality and Acid-Base Disorders (anion gap, osmolal gap normal value, delta ratio, lactate, co-oximetry and pulse oximetry limits, the mixed acid-base pattern of salicylate) Related page: Analytical Methods and Immunoassays in Clinical Chemistry (calculated osmolality formula, ethanol contribution to the osmolal gap, freezing point and vapor pressure osmometry, immunoassay cross-reactivity, GC-MS and LC-MS/MS) Related page: Therapeutic Drug Monitoring: Pharmacokinetics, Sampling and Assays for Antiepileptic, Antimicrobial, Immunosuppressant, Cardioactive, Psychiatric and Antineoplastic Drugs (therapeutic ranges and sampling times for lithium and digoxin, lithium heparin tube artifact, digoxin-like immunoreactive substances and post-Fab digoxin measurement) Related page: Drug Testing: Urine Drug Screening, Confirmation, Specimen Validity and Federal Workplace Rules (urine drug screen panels, immunoassay false positives, confirmation, chain of custody and postmortem ethanol) Related page: Hemoglobin Variant Analysis and Laboratory Diagnosis of Thalassemia (hemoglobin species, Evelyn-Malloy method, cytochrome b5 reductase deficiency and hemoglobin M) Related page: Hemolytic Anemias: Red Cell Membrane and Enzyme Defects and Paroxysmal Nocturnal Hemoglobinuria (G6PD deficiency and oxidant drug risk) Related page: Diagnostic Enzymes and Serum Tumor Markers (butyrylcholinesterase, dibucaine number and cholinesterase variants) Related page: Liver, Kidney and Gastrointestinal Function Tests (aminotransferase patterns and liver function in acetaminophen injury) Related page: Microcytic Anemias and Iron Studies (serum iron, TIBC and ferritin methods)
Laboratory approach to the poisoned patient
- Targeted assays. French intensive care and emergency societies require drug assays when acetaminophen, acetylsalicylic acid, valproic acid, digoxin or lithium is suspected. These assays are automated, are performed on serum or plasma (plasma without lithium heparin for lithium) and report within 120 minutes (Mégarbane 2020).
- Indications for screening. The French guideline suggests against routine screening. Screening is indicated when the clinical diagnosis is not established, when findings conflict with the history, and in circulatory failure or unexplained coma. A screen is followed by targeted blood assays, because blood concentrations correlate more closely with toxicity (Mégarbane 2020). Serum or plasma and urine collected at admission are retained when the cause is not established or the patient is severely ill (Mégarbane 2020).
- What a screen detects and misses. Rapid immunological and enzymatic screens detect illicit drug classes or metabolites in urine, such as cocaine, amphetamines and opiates, without a concentration. They have limited sensitivity and specificity for drug classes and miss new psychoactive substances. Drug class immunoassays such as benzodiazepine and tricyclic screens cross-react with other drugs of the class. Chromatographic targeted screening with mass spectrometry covers up to 1,200 molecules and metabolites and reports in less than 24 hours. Only high-resolution mass spectrometry performs non-targeted screening and identifies unknown structures. Urine results do not give toxicity thresholds (Mégarbane 2020). Toxins not commonly detected by routine drug screening include carbon monoxide, cyanide, ethylene glycol, methanol, iron, lithium, heavy metals, organophosphates, oral hypoglycemics and isoniazid (Shannon 2007). Urine drug screen panels, cutoffs and false positives are taught in Drug Testing: Urine Drug Screening, Confirmation, Specimen Validity and Federal Workplace Rules.
- First-line tests for discharge without admission. Discharge without admission requires a clinical evaluation, with an ECG and laboratory tests that include serum acetaminophen when indicated. Acetaminophen screening is also indicated in unconscious or unreliable patients (Mégarbane 2020).
First-line laboratory evaluation of the poisoned patient.
| Test | Indication or finding | Source |
|---|---|---|
| Serum electrolytes, glucose, urea nitrogen, creatinine, calcium, complete blood count, prothrombin time and urinalysis | Routine in every significant poisoning; urinalysis detects early acute kidney injury and myoglobinuria | Shannon 2007 |
| Anion gap, measured serum osmolality for the osmolal gap (formula in Analytical Methods and Immunoassays in Clinical Chemistry) and urine pH | Evaluation of metabolic acidosis; causes of a high anion gap include ethylene glycol, methanol, iron, isoniazid, cyanide, metformin and salicylates | Shannon 2007 |
| Arterial blood gas | Respiratory status and acid–base disorders, particularly in coma or seizures | Shannon 2007 |
| Serum acetaminophen and salicylate | Added in overdose of an unknown substance, because both are frequent coingestants and components of combination products | Shannon 2007; Wu 2003 |
| Ethanol | Widely tested in the emergency department; breath testing performed there requires laboratory oversight | Wu 2003 |
| 12-lead ECG | Every significant poisoning; widened QRS in cyclic antidepressant overdose and prolonged QT | Shannon 2007; Mégarbane 2020 |
| Urine pregnancy test | All women of childbearing age | Shannon 2007 |
| Creatine kinase and troponin | Rhabdomyolysis and myocardial injury in amphetamine, synthetic cathinone and cocaine poisoning | Mégarbane 2020 |
| Co-oximetry, cholinesterase, iron, lithium and digoxin | Stat assays the laboratory provides for the emergency department | Wu 2003 |
- Toxic alcohol confirmation. Definitive detection of toxic alcohols requires gas or liquid chromatography, which is labor-intensive, expensive and not available in all laboratories (Kraut 2015). In 963 suspected toxic alcohol poisonings reported to two US poison centers, the center with a 12–24 hour testing turnaround had a shorter median length of stay than the center with a 5–7 day turnaround (48 versus 65 hours) and gave fewer fomepizole doses (Chen S 2026).
- Poison centers. No study of sufficient quality has established that poison centers improve outcome. Poison centers identify the toxin class from the toxidrome and identify tablets at any hour (Mégarbane 2020).
Toxidromes and their distinguishing signs (Dutta 2025).
| Toxidrome | Typical findings | Distinguishing feature |
|---|---|---|
| Anticholinergic | Dry skin, mydriasis, urinary retention, ileus, delirium, hyperthermia, tachycardia, flushed skin, hallucinations | Absent diaphoresis separates it from sympathomimetic toxicity |
| Sympathomimetic | Hypertension, tachycardia, hyperthermia, agitation, mydriasis, tremor, diaphoresis, seizures, rhabdomyolysis | Diaphoresis is present |
| Opioid | Miosis, respiratory depression, bradycardia, hypotension, coma | Triad of miosis, respiratory depression and loss of consciousness |
| Cholinergic | Diarrhea, urination, miosis, bradycardia, bronchorrhea, emesis, lacrimation, salivation, sweating | Muscarinic and nicotinic signs together |
| Sedative-hypnotic | Central nervous system depression | No miosis and no clonus |
| Serotonin toxicity | Agitation, clonus, hyperreflexia, mydriasis, hyperthermia, diarrhea, tremor | Inducible or spontaneous clonus with a serotonergic agent (Hunter criteria) |
| Neuroleptic malignant syndrome | Hyperthermia, lead-pipe rigidity, altered mental status, autonomic instability | Rigidity and bradyreflexia |
Ethanol measurement and alcohol biomarkers
- Enzymatic method. Hospital laboratories measure serum or plasma ethanol with yeast alcohol dehydrogenase (ADH). ADH oxidizes ethanol to acetaldehyde and reduces NAD⁺ to NADH, which is read at 340 nm. The reaction runs at pH 9.0–9.2 with a trapping agent such as semicarbazide or Tris that removes acetaldehyde (Ialongo 2025).
- Linearity and detection limits of the ADH ethanol assay. Automated assays are linear from 0.02 to 4.0 g/L. The limit of detection is about 5 mg/dL (0.05 g/L) and the limit of quantitation is 10–20 mg/dL (Ialongo 2025). CLIA acceptance limits for ethanol were ±25% in 1988 and are ±20% after the 2022 update (Ialongo 2025).
- Lactate and LD interference. Lactate dehydrogenase (LD) in the specimen oxidizes lactate and generates NADH, which the assay reads as ethanol. Current assays require LD >25,000 IU/L with lactate >14 mmol/L, or LD >40,000 IU/L with lactate >4 mmol/L. Spurious ethanol results ranged from 0.2 to 2.0 g/L. Protein removal or LD inhibition by oxamate prevents the interference (Ialongo 2025). Two children had positive hospital ADH ethanol results in perimortem specimens and negative headspace gas chromatography (Bishop-Freeman 2020).
- Hemolysis and lipemia. Free hemoglobin absorbs near 340 nm, and bichromatic over-blanking lowers results by 6%–16%. Triglycerides absorb at 340 nm and cause positive bias (Ialongo 2025).
- Cross-reactivity of other alcohols in the ethanol assay. Isopropanol biased results on the older DuPont ACA enzyme. Current ADH methods have minimal cross-reactivity with isopropanol, methanol or ethylene glycol (Ialongo 2025; Wu 2026).
- Serum, plasma and whole-blood ethanol ratios. Plasma and serum contain about 90%–92% water and whole blood about 78%–80%, so the mean serum/whole-blood ethanol ratio is about 1.15 (Jones 2023). Plasma or serum ethanol is about 15% higher than whole-blood ethanol, with a range of 10%–20% (Ialongo 2025).
- Statutory blood alcohol limits and reporting units. Statutory driving limits are defined in whole blood. Most countries set 0.5 g/L (50 mg/dL), and limits range from 0.2 to 0.8 g/L (Ialongo 2025). Some US state statutes define the per se limit as 0.08 percent by weight. Laboratories report mass per volume, and treating g/dL as percent by weight overreports blood alcohol by about 5.5%–6% because whole blood density is about 1.06 g/mL (Olson 2026).
- Breath alcohol conversion factor. Breath analyzers report g/210 L and convert to blood alcohol with a 2100:1 blood-to-breath ratio (Olson 2026).
- Ethanol molecular weight and unit conversion. Ethanol has a molecular weight of 46.05 g/mol, and 0.1 g/L equals 2.17 mmol/L (Ialongo 2025). Endogenous blood ethanol in healthy individuals is about 0.001 g/L (Ialongo 2025).
- Phosphatidylethanol (PEth). PEth forms only in the presence of ethanol and has a terminal half-life of 8–13 days, so it reflects alcohol consumption up to 4 weeks before collection. The 2022 Basel consensus sets PEth 16:0/18:1 at 20 ng/mL as the decision limit between abstinence or low consumption and alcohol consumption. The upper decision limit is 200 ng/mL (Bantle 2025; Luginbühl 2022).
- Ethyl glucuronide and ethyl sulfate. Urine EtG and EtS rise after low-level alcohol consumption. In a predominantly transplant population, PEth identified alcohol consumption in 88.7% of instances and EtG/EtS in 39.9%. The EtG immunoassay screen gave 4.0% false positives (Snozek 2026).
- Carbohydrate-deficient transferrin. The IFCC uses 2-sialo-transferrin as the sole measurand with a decision threshold of 2.0% by HPLC. The earlier Sebia capillary electrophoresis cutoff was 2.3%, and conversion to IFCC-aligned results raised positivity at either cutoff (Debunne 2026).
Conversion of serum or plasma ethanol to whole-blood ethanol.
| Quantity | Formula | Source |
|---|---|---|
| Expected whole-blood ethanol (mean ratio) | Serum or plasma ethanol ÷ 1.15 | Jones 2023 |
| Conservative whole-blood ethanol for legal use | Serum or plasma ethanol ÷ 1.2 (overestimation in 1 of 2,000 cases) | Jones 2023 |
| Ethanol, mmol/L | Ethanol (g/L) × 21.7 | Ialongo 2025 |
| Ethanol, mg/dL | Ethanol (g/L) × 100 | Ialongo 2025 |
Alcohol biomarkers and their decision limits.
| Marker | Specimen and method | Detection window or decision limit | Source |
|---|---|---|---|
| Ethanol | Serum or plasma by ADH; whole blood by headspace GC for forensic use | Limit of detection about 5 mg/dL | Ialongo 2025 |
| PEth 16:0/18:1 | Whole blood or dried blood spot by LC-MS/MS | Up to 4 weeks; 20 ng/mL and 200 ng/mL decision limits | Bantle 2025; Luginbühl 2022 |
| EtG and EtS | Urine by LC-MS/MS; EtG screen by immunoassay | Laboratory cutoffs 500/250 ng/mL or 250/100 ng/mL | Snozek 2026 |
| CDT (2-sialo-transferrin) | Serum by HPLC or capillary electrophoresis | 2.0% (IFCC); 2.3% earlier Sebia cutoff | Debunne 2026 |
Toxic alcohols: osmolal gap, anion gap and confirmation
- Metabolism of the toxic alcohols and glycols. Ethylene glycol is metabolized to glycolate and oxalate. Glycolate contributes to the acidemia, and calcium oxalate deposition causes acute kidney injury and neurologic complications (Ghannoum 2023). Methanol toxicity results mainly from formic acid and from lactic acid produced by cellular hypoxia (Kraut 2016). Isopropanol is metabolized to acetone (Wu 2026). Diethylene glycol is metabolized to diglycolic acid, which causes proximal tubular necrosis (de Almeida Araújo 2023).
- Time course of the osmolal and anion gaps. The parent alcohol raises the osmolal gap, and the acid metabolites raise the anion gap (Kraut 2016). Ethylene glycol causes inebriation first, and metabolic acidemia appears after a latent period of about 3–6 hours (Ghannoum 2023). The osmolal gap is normal, or below 0, once ethylene glycol is metabolized or after a small ingestion, so the gap does not exclude poisoning at low values (Ghannoum 2023). Either gap is absent depending on the alcohol, the time since exposure and ethanol coingestion (Kraut 2016).
- Glycolate and the lactate gap. Glycolate falsely raises lactate on some analyzers (Ghannoum 2023). A patient with ethylene glycol poisoning had a falsely high lactate on a point-of-care blood gas analyzer. A lactate gap between a glycolate-sensitive and a glycolate-insensitive method indicates advanced ethylene glycol poisoning (Verelst 2009). Interpretation of the lactate gap requires the specific analyzer's glycolate cross-reactivity (Ghannoum 2023).
- Calcium oxalate crystals. Needle-shaped calcium oxalate monohydrate crystals in urine indicate the acute phase. In one patient the crystals changed to dumbbell-shaped monohydrate and octahedral dihydrate forms by day 14 of recovery (Ito 2026).
- Isopropanol. Isopropanol raises the osmolal gap and produces ketosis without an elevated anion gap or acidosis. Acetone is detected by some ketone assays. Severe toxicity is associated with serum isopropanol of 25 mmol/L or more. Fomepizole is contraindicated because it prolongs isopropanol elimination (Wu 2026).
- Isopropanol and ketoacidosis. In severe alcoholic ketoacidosis, trace serum isopropanol can arise from acetone by the reversible action of ADH. A markedly increased isopropanol with a low acetone:isopropanol ratio indicates isopropanol ingestion (Dwyer 2013).
- Diethylene glycol. Poisoning causes gastrointestinal symptoms and an anion gap metabolic acidosis, followed by renal failure and later encephalopathy and neuropathy (de Almeida Araújo 2023).
- Propylene glycol. Of absorbed propylene glycol, 12%–45% is eliminated by the kidneys, and the remainder is metabolized in the liver to lactate, acetate and pyruvate. The terminal half-life is 1.4–3.3 hours in adults with normal liver and kidney function and a mean of 19.3 hours (range 10.8–30.5) in infants. In a study of patients receiving intravenous lorazepam cited by Lim, an osmolal gap ≥10 predicted elevated propylene glycol, and a gap ≥12 predicted clinical changes of toxicity. Infants and patients with renal or hepatic insufficiency are at risk, and toxicity includes hyperosmolality, hemolysis and lactic acidosis (Lim 2014). High-dose intravenous lorazepam delivers propylene glycol, which raised the osmolal gap in a critically ill patient, and hemodialysis corrected the gap (Parker 2002). D-lactic acidosis from propylene glycol is taught in Water, Electrolytes, Osmolality and Acid-Base Disorders.
- Alcohol dehydrogenase inhibitors. Ethanol and fomepizole inhibit ADH and prevent formation of toxic metabolites (Kraut 2016). They prolong the apparent elimination half-life of ethylene glycol (Ghannoum 2023).
Laboratory pattern of alcohol and glycol poisonings.
| Agent | Toxic metabolite | Osmolal gap | Anion gap acidosis | Other laboratory findings | Source |
|---|---|---|---|---|---|
| Methanol | Formic acid | Raised early | Present after metabolism | Lactic acid from cellular hypoxia | Kraut 2016 |
| Ethylene glycol | Glycolate and oxalate | Raised early; can be normal after metabolism | Present after a latent period of about 3–6 hours | Falsely high lactate on some analyzers; calcium oxalate crystals; acute kidney injury in 30%–70% | Ghannoum 2023; Verelst 2009 |
| Isopropanol | Acetone | Raised | Absent | Ketosis; acetone detected by some ketone assays | Wu 2026 |
| Diethylene glycol | Diglycolic acid | Raised by the parent compound | Present | Proximal tubular necrosis with anuria | de Almeida Araújo 2023; Kraut 2015 |
| Propylene glycol | Lactate, acetate and pyruvate (hepatic metabolism; 12%–45% eliminated by the kidneys) | Raised; during lorazepam infusion a gap ≥10 predicted elevated propylene glycol | Lactic acidosis | Infants and renal or hepatic insufficiency at risk; parenteral sources such as high-dose lorazepam | Lim 2014; Parker 2002 |
Ethylene glycol and glycolate half-lives by treatment (Ghannoum 2023).
| Condition | Ethylene glycol half-life (hours) | Glycolate half-life (hours) |
|---|---|---|
| No antidote, normal kidney function | 2–5 | 2–7 |
| Ethanol, normal kidney function | 8.5–14 | 1–3 |
| Ethanol, kidney injury | 20–40 | 15–40 |
| Fomepizole, normal kidney function | 12–18 | 3–5 |
| Fomepizole, kidney injury | 40–80 | 10–15 |
EXTRIP criteria for extracorporeal treatment (ECTR) in ethylene glycol and methanol poisoning (ethylene glycol, Ghannoum 2023, Crit Care 27:56, published February 2023, very low-quality evidence for every recommendation; osmolal gap in SI units adjusted for ethanol; anion gap calculated as Na⁺ + K⁺ − Cl⁻ − HCO₃⁻; methanol, Roberts 2015, Crit Care Med 43:461).
| Poison | Criterion | Threshold | Strength | Source |
|---|---|---|---|---|
| Ethylene glycol | Ethylene glycol concentration or osmolal gap, no antidote available | >10 mmol/L (>62 mg/dL) or osmolal gap >10 | Recommended | Ghannoum 2023 |
| Ethylene glycol | Ethylene glycol concentration or osmolal gap, with fomepizole | >50 mmol/L or osmolal gap >50 | Suggested | Ghannoum 2023 |
| Ethylene glycol | Ethylene glycol concentration or osmolal gap, with ethanol | >50 mmol/L or osmolal gap >50 | Recommended | Ghannoum 2023 |
| Ethylene glycol | Ethylene glycol concentration or osmolal gap, with ethanol | 20–50 mmol/L (124–310 mg/dL) or osmolal gap 20–50 | Suggested | Ghannoum 2023 |
| Ethylene glycol | Glycolate or anion gap | Glycolate >12 mmol/L or anion gap >27 mmol/L | Recommended | Ghannoum 2023 |
| Ethylene glycol | Glycolate or anion gap | Glycolate 8–12 mmol/L or anion gap 23–27 mmol/L | Suggested | Ghannoum 2023 |
| Ethylene glycol | Severe clinical features | Coma, seizures or acute kidney injury (KDIGO stage 2 or 3) | Recommended | Ghannoum 2023 |
| Ethylene glycol | Chronic kidney disease | eGFR <45 mL/min/1.73 m² | Suggested | Ghannoum 2023 |
| Ethylene glycol | Reported dose alone | Not an indication | Recommended against | Ghannoum 2023 |
| Ethylene glycol | Stopping ECTR | Anion gap <18 mmol/L (recommended); ethylene glycol <4 mmol/L (25 mg/dL) or corrected acid–base abnormalities (suggested) | Stop | Ghannoum 2023 |
| Methanol | Methanol concentration with fomepizole | >700 mg/L (21.8 mmol/L) | Recommended | Roberts 2015 |
| Methanol | Methanol concentration with ethanol | >600 mg/L (18.7 mmol/L) | Recommended | Roberts 2015 |
| Methanol | Methanol concentration without an ADH blocker | >500 mg/L (15.6 mmol/L) | Recommended | Roberts 2015 |
| Methanol | Severe poisoning | Coma, seizures, new visual deficits, pH ≤7.15, persistent acidosis, anion gap >24 mmol/L or impaired kidney function | Recommended | Roberts 2015 |
| Methanol | Stopping ECTR | Methanol <200 mg/L (6.2 mmol/L) with clinical improvement | Stop | Roberts 2015 |
- Ethylene glycol outcomes. Among 446 patients, mortality was 18.7%. With glycolate ≤12 mmol/L (or anion gap ≤28 mmol/L), mortality was 3.6%, and ECTR did not improve outcome in that subgroup (Ghannoum 2023).
- Ethylene glycol concentration and toxicity. No concentration threshold for toxicity is established. A peak above 3.2 mmol/L (20 mg/dL) has been cited as a risk threshold, and toxicity did not occur in 7 untreated patients with concentrations below 4.8 mmol/L (30 mg/dL) (Ghannoum 2023). The molecular weight of ethylene glycol is 62 Da (Ghannoum 2023).
- Methanol concentration unavailable. When a methanol concentration is unavailable, the osmolal gap may be informative (Roberts 2015).
- Extracorporeal modality for ethylene glycol and methanol. Intermittent hemodialysis is preferred for ethylene glycol and methanol, and continuous modalities are alternatives (Ghannoum 2023; Roberts 2015). Antidote doses are adjusted during ECTR (Ghannoum 2023). In methanol poisoning, ADH inhibitors and folic or folinic acid continue during ECTR (Roberts 2015).
Acetaminophen toxicity: nomogram, 2023 consensus rules and acetylcysteine
- NAPQI formation and hepatotoxicity. Hepatotoxicity results from accumulation of N-acetyl-p-benzoquinone imine (NAPQI), which depletes glutathione and causes oxidative hepatocellular injury. Chronic alcohol use, fasting and enzyme-inducing drugs increase the risk (Athbhaiya 2026). Hepatotoxicity is defined as AST or ALT >1,000 U/L (Watson 2026).
- Nomogram use and limits. The Rumack-Matthew nomogram applies to a single ingestion at a known time, with the concentration drawn at or after 4 hours (Mégarbane 2020). The 2023 US and Canadian consensus defines acute ingestion as presentation 4 to 24 hours after the ingestion began (Dart 2023). The nomogram has never been validated in randomized trials, and the treatment threshold differs between countries. France and most Western countries other than the United Kingdom and Denmark use 150 mg/L at 4 hours (Mégarbane 2020).
- High-risk ingestion. The 2023 consensus replaced the term "massive ingestion" with "high-risk ingestion" and denoted it by a specific nomogram line (Dart 2023). The high-risk line plots twice the treatment concentration, 300 µg/mL at 4 hours (Watson 2026). Massive ingestion has been described as a concentration above the 300 µg/mL line or ingestion of >30 g (Chen F 2026). Ingestion of >600 mg/kg causes coma, acidosis and hypothermia within hours through direct mitochondrial toxicity (Sivilotti 2022).
- Repeated supratherapeutic ingestion, unknown time and late presentation. The 2020 French guideline gives acetylcysteine without the nomogram for an unknown time of intake or impaired consciousness and for risk factors such as chronic liver disease or nutritional deficiency, and continues it while serum acetaminophen is detectable or ALT is elevated. Acetylcysteine is also given for repeated supratherapeutic use and for admission more than 24 hours after exposure with elevated ALT (Mégarbane 2020).
- Risk factors. Repeated toxic ingestion and delayed presentation are associated with poor prognosis. Underlying liver disease, chronic alcohol use and cytochrome P450 enzyme inducers increase the risk of toxicity (Mégarbane 2020).
- Acetaminophen-protein adducts. Adducts are specific markers of NAPQI exposure. In patients with ALT >1,000 U/L, an adduct concentration ≥1.0 nmol/mL identifies acetaminophen as the cause. On presentation, 0.58 nmol/mL was 100% sensitive and 91% specific for later hepatotoxicity (Chiew 2020).
Acetaminophen treatment thresholds and acetylcysteine rules (2023 US and Canadian consensus, Dart 2023, JAMA Netw Open 6:e2327739, published August 2023; French guideline, Mégarbane 2020; EXTRIP, Gosselin 2014, Clin Toxicol 52:856).
| Situation | Rule | Source |
|---|---|---|
| Single acute ingestion, known time | Acetylcysteine if acetaminophen is above 150 µg/mL (150 mg/L) at 4 hours on the Rumack-Matthew nomogram; the consensus defines acute ingestion as presentation 4–24 hours after the ingestion began | Mégarbane 2020; Dart 2023 |
| Previous treatment line | The original Rumack-Matthew line started at 200 µg/mL at 4 hours; the US line was lowered to 150 µg/mL | Dart 2023; owner review, board-certified pathologist |
| High-risk ingestion (formerly "massive ingestion") | Concentration above the high-risk line, 300 µg/mL at 4 hours | Dart 2023; Watson 2026 |
| Extended-release product | If the first concentration (4–12 hours) is >10 µg/mL but below the treatment line, a second concentration is drawn 4–6 hours later | Dart 2023; owner review, board-certified pathologist |
| Coingested anticholinergic or opioid | A repeat concentration is drawn only if clinical effects of the coingestant are present | Dart 2023; owner review, board-certified pathologist |
| Repeated supratherapeutic ingestion (2023 consensus) | Acetylcysteine if acetaminophen is >20 µg/mL or AST/ALT is abnormal | Dart 2023; owner review, board-certified pathologist |
| Repeated supratherapeutic use, unknown time or presentation after 24 hours | Acetylcysteine without the nomogram; continued while acetaminophen is detectable or ALT is elevated | Mégarbane 2020 |
| Standard acetylcysteine regimen | 300 mg/kg over 20–21 hours as three bags: 150 mg/kg over 1 hour, 50 mg/kg over 4 hours (12.5 mg/kg/h), 100 mg/kg over 16 hours (6.25 mg/kg/h) | Watson 2026; Mégarbane 2020 |
| Dosing weight | 58.1% of surveyed US institutions capped the dosing weight at 100 kg, consistent with the FDA-approved regimen; 38.2% used no cap | Thomas 2024 |
| ECTR, acetylcysteine not given | Acetaminophen >1,000 mg/L (1D), or >700 mg/L with signs of mitochondrial dysfunction, that is, early altered mental status and severe metabolic acidosis (1D) | Gosselin 2014 |
| ECTR, acetylcysteine given | Acetaminophen >900 mg/L with signs of mitochondrial dysfunction (1D); intermittent hemodialysis is the preferred modality (1D) | Gosselin 2014 |
Rumack-Matthew nomogram interpretation rules (4–24 hours).
| Input or step | Rule | Source |
|---|---|---|
| Eligibility | Single ingestion at a known time; concentration drawn 4–24 hours after ingestion began | Dart 2023; Mégarbane 2020 |
| Treatment line | 150 µg/mL at 4 hours; values at later hours read from the published nomogram | Mégarbane 2020 |
| High-risk line | Twice the treatment line at the same time point | Watson 2026 |
| Acetaminophen ratio | Measured concentration ÷ treatment line value at the same time | Watson 2026 |
- Acetylcysteine monitoring and end of treatment. The original protocols specified a fixed treatment duration of 20 hours. Current practice uses serial testing. Acetylcysteine is stopped when acetaminophen is undetectable, liver function tests are improving and the patient is not encephalopathic. Acetaminophen falls tenfold every 12 hours when absorption is complete and liver function is normal (Sivilotti 2022).
- Extended infusions. Additional 16-hour maintenance infusions at 6.25 mg/kg/h are given for elevated aminotransferases, coagulopathy, encephalopathy or persistently elevated acetaminophen (Watson 2026). In 127 high-risk ingestions treated within 8 hours, high-dose and standard acetylcysteine needed a similar number of additional infusions (0.53 versus 0.38) (Watson 2026).
- Adjuncts in high-risk ingestion. Higher acetylcysteine doses are recommended for persistently elevated acetaminophen, and fomepizole is given in the highest-risk patients (Sivilotti 2022).
Salicylate toxicity: acid-base pattern, serial levels and assays
- Effect of intubation on the acid-base pattern. Intubation abolishes the respiratory alkalosis of salicylate toxicity and increases the incidence of acidemia (Mégarbane 2020). The mixed pattern is taught in Water, Electrolytes, Osmolality and Acid-Base Disorders.
- Salicylate unit conversion. Salicylate 100 mg/dL equals 7.2 mmol/L (Juurlink 2015).
- Undetectable early levels. Of 313 patients with salicylate >30 mg/dL, 11 (3.5%) had an initially undetectable concentration. These first samples were drawn earlier (89 versus 137 minutes), and the peak came later (640 versus 321 minutes). The longest interval between ingestion and an undetectable result was 225 minutes (Moss 2019).
- Enteric-coated aspirin. In one enteric-coated aspirin overdose, salicylate was undetectable at 1 and 3 hours and peaked at 35.8 mg/dL at 24 hours (Wortzman 1987).
- Done nomogram. The Done nomogram had a predictive index of 0.42 for adult acute intoxication and overpredicted moderate and severe toxicity (Dugandzic 1989). The nomogram gave no benefit in sustained-release overdose (Wortzman 1987). Management is based on the clinical presentation and serial concentrations (Dugandzic 1989).
- Predictors of severe outcome in salicylate poisoning. In adult acute poisoning the initial salicylate concentration did not predict severe outcome. Age, respiratory rate and lactate predicted it, and lactate above 2.25 mmol/L had 78% sensitivity and 67% specificity (Shively 2017).
- Trinder method. The Trinder colorimetric method is affected by bilirubin. With the same reagent, high bilirubin gave falsely low salicylate on one analyzer (560/700 nm) and falsely high salicylate on another (546 nm without a secondary wavelength). Fluorescence polarization immunoassay was unaffected by bilirubin up to 427.5 µmol/L (Dasgupta 2003).
- Enzymatic method. Salicylate hydroxylase converts salicylate and NAD(P)H to catechol, and the fall in absorbance at 340 nm is measured. The method showed no interference from 61 drugs and tolerates lipemic, icteric and hemolyzed samples (You 1984). The enzymatic technique was specific and more expensive than colorimetric methods (Jarvie 1987).
- Urinary alkalinization. Alkaline diuresis is suggested in symptomatic poisoning, because tubular reabsorption of salicylate falls as urine pH rises (Mégarbane 2020).
EXTRIP criteria for ECTR in salicylate poisoning (Juurlink 2015, Ann Emerg Med 66:165, published August 2015).
| Criterion | Threshold | Grade | Source |
|---|---|---|---|
| Salicylate, normal kidney function | >7.2 mmol/L (100 mg/dL) | Recommended (1D) | Juurlink 2015 |
| Salicylate, normal kidney function | >6.5 mmol/L (90 mg/dL) | Suggested (2D) | Juurlink 2015 |
| Salicylate, impaired kidney function | >6.5 mmol/L (90 mg/dL) | Recommended (1D) | Juurlink 2015 |
| Salicylate, impaired kidney function | >5.8 mmol/L (80 mg/dL) | Suggested (2D) | Juurlink 2015 |
| Altered mental status, at any concentration | Present | Recommended (1D) | Juurlink 2015 |
| Acute respiratory distress syndrome requiring supplemental oxygen | Present | Recommended (1D) | Juurlink 2015 |
| Standard therapy failing | Present | Recommended (1D) | Juurlink 2015 |
| Severe acidemia without other indications | pH ≤7.20 | Suggested (2D) | Juurlink 2015 |
Intermittent hemodialysis is the preferred modality, and hemoperfusion and continuous renal replacement are alternatives (Juurlink 2015).
Lithium and digoxin poisoning
Therapeutic ranges, sampling times, lithium heparin tube artifact, digoxin immunoassay interferences, digoxin measurement after Fab and the Fab vial calculation are taught in Therapeutic Drug Monitoring: Pharmacokinetics, Sampling and Assays for Antiepileptic, Antimicrobial, Immunosuppressant, Cardioactive, Psychiatric and Antineoplastic Drugs.
- Lithium poisoning patterns. Lithium poisoning is acute, acute-on-chronic or chronic. In a 1-year poison center series, there were 12 acute, 174 acute-on-chronic and 19 chronic poisonings. No acute patient required hemodialysis, and sequelae occurred only in chronic poisoning. The Hansen and Amdisen grading correlated poorly with outcome and with lithium concentration (Bailey 2000).
- Lithium dialyzability. Lithium is dialyzable (level of evidence A). Hemodialysis is the preferred ECTR, and continuous renal replacement is acceptable (Decker 2015).
- Activated charcoal in lithium and iron poisoning. Lithium and iron are not adsorbed onto activated charcoal (Mégarbane 2020).
EXTRIP criteria for ECTR in lithium poisoning (Decker 2015, Clin J Am Soc Nephrol 10:875, published May 2015). Lithium mEq/L equals mmol/L.
| Criterion | Threshold | Grade | Source |
|---|---|---|---|
| Impaired kidney function with high lithium | >4.0 mmol/L | Recommended (1D) | Decker 2015 |
| Decreased consciousness, seizures or life-threatening dysrhythmias | Any lithium concentration | Recommended (1D) | Decker 2015 |
| High lithium | >5.0 mmol/L | Suggested (2D) | Decker 2015 |
| Significant confusion | Present | Suggested (2D) | Decker 2015 |
| Expected time to reach <1.0 mmol/L | >36 hours | Suggested (2D) | Decker 2015 |
| Stopping ECTR | Clinical improvement or lithium <1.0 mmol/L | Recommended (1D) | Decker 2015 |
| Duration when lithium cannot be measured promptly | At least 6 hours | Recommended (1D) | Decker 2015 |
- Digoxin toxicity patterns. Most digoxin toxicity is chronic and occurs in older patients with declining renal function. Hypokalemia, hypomagnesemia, hypercalcemia and dehydration increase the risk (Andrews 2023).
- Digoxin sampling in suspected poisoning. A concentration drawn before distribution is complete (about 6 hours) overestimates the body load. Treatment of life-threatening toxicity is not delayed for the result (Chan 2014; Andrews 2023).
- Hyperkalemia in digoxin toxicity. Hyperkalemia indicates severity, and most strongly in acute toxicity (Andrews 2023). Hyperkalemia, advanced age, heart disease, male sex and high-degree atrioventricular block are prognostic factors for death (Taboulet 1993).
- Time to reversal after Fab. Reversal of toxicity takes 30–45 minutes after digoxin Fab (Chan 2014).
- Potassium after Fab. Hypokalemia after Fab resolves within hours, and potassium is measured at intervals during the first 6 hours (Andrews 2023).
- EXTRIP position on ECTR in digoxin poisoning. EXTRIP recommends against ECTR in severe digoxin poisoning when Fab is available, and suggests against ECTR when Fab is unavailable. ECTR does not remove the digoxin-Fab complex (Mowry 2016).
Indications for digoxin Fab by source. Vial calculation is covered in Therapeutic Drug Monitoring: Pharmacokinetics, Sampling and Assays for Antiepileptic, Antimicrobial, Immunosuppressant, Cardioactive, Psychiatric and Antineoplastic Drugs.
| Source | Indications | Dose |
|---|---|---|
| Andrews 2023 (European consensus) | Ventricular tachycardia or fibrillation; asystole or symptomatic high-degree atrioventricular block; potassium >6.5 mmol/L; hypotension with end-organ dysfunction; digoxin >12 ng/mL without life-threatening signs | Cardiac arrest: 5 vials, repeated once if no response after 30 minutes. Other life-threatening toxicity: 1–2 vials, repeated by response |
| Chan 2014 (systematic review) | Life-threatening arrhythmias, potassium >6 mmol/L or hemodynamic instability with digoxin >2 µg/L (2.6 nmol/L) | Acute: 80 mg bolus, repeated as needed. Chronic: 40 mg (1 vial), repeated after 60 minutes |
| Mégarbane 2020 (French guideline) | Half-molar neutralization: bradycardia ≤50/min refractory to atropine, any atrioventricular block or potassium ≥4.5 mmol/L. Molar neutralization: ventricular arrhythmia, bradycardia ≤40/min, potassium ≥5.5 mmol/L, mesenteric infarction or cardiogenic shock | Calculated from plasma digoxin >2.6 nmol/L |
Carbon monoxide and cyanide
- Carboxyhemoglobin measurement. Carboxyhemoglobin (COHb) is measured by co-oximetry, whose principle and interferences are taught in Water, Electrolytes, Osmolality and Acid-Base Disorders.
- Baseline carboxyhemoglobin in smokers. Baseline pulse CO-oximetry COHb (SpCO) averaged 3.07% in smokers and 1.77% in nonsmokers. Of 136 smokers, 83% had a baseline below 5% and 2 (1.47%) were above 9%, so the 9% intoxication threshold for smokers is not supported by these baseline data (Kocaoğlu 2025).
- Pulse oximetry failure. Pulse oximetry overestimates arterial oxyhemoglobin saturation when COHb is raised. During veno-venous ECMO, 72.5% of patients developed COHb >3%, and SaO₂ fell 1.1% for every 1% rise in COHb (Nisar 2020).
- Methylene chloride. Inhaled methylene chloride is metabolized to carbon monoxide and raises COHb. Concurrent carbon monoxide exposure increases COHb formation (Mahmud 1999).
- Cyanide and lactate. In 11 patients with pure cyanide poisoning, plasma lactate correlated with blood cyanide. Lactate ≥8 mmol/L (72 mg/dL) was 94% sensitive and 70% specific for blood cyanide ≥1.0 mg/L. Specificity rose to 85% in patients not receiving catecholamines (Baud 2002).
- Smoke inhalation. Blood cyanide in fire victims who died averaged 116.4 µmol/L, and 74% exceeded 40 µmol/L. Cyanide correlated with carbon monoxide. Plasma lactate >10 mmol/L was a sensitive indicator of blood cyanide >40 µmol/L (Baud 1991).
- Hydroxocobalamin. Hydroxocobalamin binds cyanide to form cyanocobalamin and colors skin and body fluids red (Datar 2019). Spiked at a concentration equal to one therapeutic dose, hydroxocobalamin biased at least one instrument for 64% of 73 analytes, and 47% of 187 tests were biased by more than 10%. Photometric assays were affected. Immunoassays and ion-selective electrode measurements were unaffected. Blood is drawn before hydroxocobalamin, and the laboratory is informed of the treatment (Carlsson 2011).
- Analytes affected by hydroxocobalamin. On two chemistry platforms, ALT, amylase, total bilirubin, cholesterol, creatine kinase, creatinine, magnesium and uric acid were affected. Direct bilirubin, iron, phosphate, total protein and triglycerides were affected on one platform. The bias was positive for some analytes and negative for others (Ranjitkar 2015).
- Hydroxocobalamin and dialysis machine blood leak detectors. Hydroxocobalamin triggered repeated false blood leak alarms that prevented hemodialysis, and continuous renal replacement therapy was used (Datar 2019).
- Cyanide and thiocyanate during nitroprusside infusion. In children after cardiac surgery, toxic cyanide concentrations occurred in 11%, and a mean nitroprusside dose of 1.8 µg/kg/min predicted elevated cyanide with 89% sensitivity and 88% specificity. Clinical signs did not predict elevated cyanide (Moffett 2008). Thiocyanate accumulated during nitroprusside infusion in a patient with renal insufficiency and fell with continuous venovenous hemodiafiltration (Nessim 2006).
Laboratory interferences from cyanide and carbon monoxide treatment and exposure.
| Agent | Laboratory effect | Source |
|---|---|---|
| Hydroxocobalamin | Positive or negative bias in photometric chemistry assays; ion-selective electrodes and immunoassays unaffected | Carlsson 2011; Ranjitkar 2015 |
| Hydroxocobalamin | Interference with spectrophotometric co-oximetry | Baird 2013 |
| Hydroxocobalamin | False blood leak alarm on hemodialysis machines | Datar 2019 |
| Carbon monoxide | Pulse oximetry overestimates oxyhemoglobin saturation | Nisar 2020 |
| Methylene chloride | Endogenous carbon monoxide and raised COHb | Mahmud 1999 |
Acquired methemoglobinemia
Hemoglobin species, the Evelyn-Malloy method, cytochrome b5 reductase deficiency and hemoglobin M are taught in Hemoglobin Variant Analysis and Laboratory Diagnosis of Thalassemia.
- Causes of acquired methemoglobinemia by frequency. In the US National Poison Data System from 2019 to 2025, the leading causes were non-pharmaceutical nitrates and nitrites (31%), dapsone (26%), phenazopyridine (15%) and local anesthetics (10%). Nitrates and nitrites accounted for 56% of the 96 deaths. Acetaminophen and rasburicase were among the ten most frequent causes (Wahrenbrock 2026). Benzocaine and lidocaine are the most common drug causes in the European recommendations. Amyl nitrite and cocaine adulterants produce methemoglobin above 90% (Iolascon 2021).
- Primaquine and rasburicase as causes. Primaquine caused methemoglobinemia in a transplant recipient with normal G6PD activity, and oxyhemoglobin fell despite a normal PaO₂ (Leite Cruz 2025). Rasburicase caused hemolytic anemia and methemoglobinemia in a child with G6PD deficiency (Klein 2026).
- Oximetry in acquired methemoglobinemia. Pulse oximeter behaviour, the saturation gap and co-oximetry are taught in Water, Electrolytes, Osmolality and Acid-Base Disorders.
- Methemoglobin treatment thresholds. In acquired methemoglobinemia, treatment is indicated at 20% in symptomatic patients and 30% in asymptomatic patients. Patients with impaired oxygen delivery, such as anemia, lung or heart disease or carbon monoxide poisoning, are treated at 10%–30%. Methemoglobin above 70% is potentially lethal (Iolascon 2021). The French guideline gives methylene blue at ≥20% or with signs of tissue hypoxia (Mégarbane 2020).
- Methylene blue dosing. The starting dose is 1–2 mg/kg intravenously over 3–5 minutes, repeated at 1 mg/kg if methemoglobin does not fall within 30–60 minutes. Doses above a total of 7 mg/kg are toxic. Methemoglobin rebounds after therapy, and dapsone-induced methemoglobinemia requires repeat doses every 6–8 hours for 2–3 days (Iolascon 2021).
- Methylene blue and G6PD deficiency. Methylene blue accepts an electron from NADPH to form leukomethylene blue, which reduces ferric to ferrous iron. Patients with G6PD deficiency may not produce enough NADPH, so methylene blue may be ineffective, and it causes Heinz body hemolytic anemia in these patients. Ascorbic acid or, in severe cases, exchange transfusion is the alternative (Iolascon 2021). All symptomatic patients without a known history of methemoglobinemia are tested for G6PD deficiency (Iolascon 2021). G6PD enzyme activity is unreliable with hyperleukocytosis and after transfusion (Klein 2026).
- Methylene blue and serotonin toxicity. Methylene blue precipitates serotonin toxicity with serotonergic antidepressants, because it inhibits monoamine oxidase (Iolascon 2021).
- Methylene blue and oximetry. Methylene blue interferes with spectrophotometric co-oximetry measurements (Baird 2013). In dogs, methylene blue changed plasma light absorbance with a peak effect at 660–670 nm and caused a dose-dependent fall in pulse oximetry and co-oximetry readings for up to 30 minutes. The fall was greater and longer lasting with pulse oximetry (Sidi 1987).
Tricyclic antidepressant overdose: QRS duration and immunoassay cross-reactivity
- QRS duration. In 49 acute overdoses, no seizures or ventricular arrhythmias occurred with a maximal limb-lead QRS <0.10 second. With QRS ≥0.10 second, seizures occurred in 34% and ventricular arrhythmias in 14%. Ventricular arrhythmias occurred only with QRS ≥0.16 second (Boehnert 1985).
- Serum tricyclic concentration and outcome. Serum tricyclic concentrations did not predict seizures or ventricular arrhythmias (Boehnert 1985).
- Sodium bicarbonate. A QRS ≥120 ms is an indication for hypertonic sodium bicarbonate, 1–2 mL/kg of 8.4% solution as an initial bolus (Mégarbane 2020).
Cross-reactivity in tricyclic antidepressant immunoassays.
| Cross-reacting drug | Specimen and assay | Finding | Source |
|---|---|---|---|
| Quetiapine | Plasma; quantitative fluorescence polarization assay | Cross-reactivity from 5 ng/mL; 640 ng/mL quetiapine read as 379–385 ng/mL tricyclic | Caravati 2005 |
| Quetiapine | Plasma; qualitative assays with a 300 ng/mL cutoff | Positive at 160 ng/mL (one assay) and 320 ng/mL (another) | Caravati 2005 |
| Carbamazepine | Serum tricyclic screen | Carbamazepine overdose produced a positive tricyclic result | Fleischman 2001 |
| Cyclobenzaprine | Urine; colloidal metal immunoassay, 1,000 ng/mL cutoff | Significant cross-reactivity at 1,000 ng/mL; no significant cross-reactivity from 32 other common drugs | Poklis 1997 |
Organophosphate and carbamate poisoning: cholinesterase testing
- Acetylcholinesterase inhibition and its reversal. Organophosphates inhibit acetylcholinesterase (AChE). Treatment antagonizes muscarinic effects with atropine and reactivates inhibited AChE with oximes (Aurbek 2009).
- Red cell AChE. Erythrocyte AChE is a surrogate for synaptic AChE and is suitable for monitoring oxime therapy. It is not available in all laboratories (Aurbek 2009; Jalady 2013). Erythrocyte AChE indicates the severity of poisoning and the efficacy of oximes (Jalady 2013). Oximes are stopped once inhibited AChE has aged completely, and are continued while poison remains and reactivation is possible (Thiermann 2007).
- Plasma butyrylcholinesterase. Plasma butyrylcholinesterase (BChE) is the routine assay. Plasma BChE gives a rapid diagnosis and indicates persistence of the toxicant in blood (Jalady 2013). Oximes reactivate inhibited BChE poorly, so BChE activity is unsuitable for monitoring oxime therapy (Aurbek 2009).
- Chronic occupational exposure. Serial AChE monitoring of farmers detects low-level exposure only when a reliable baseline is available (Cotton 2018).
- Urine organophosphate metabolites. Urine organophosphate metabolites are measured when the exposure is unknown, and an AChE assay confirms the diagnosis (Dutta 2025).
- Inherited low BChE. Butyrylcholinesterase variants and the dibucaine number are taught in Diagnostic Enzymes and Serum Tumor Markers.
Cholinesterase assays in organophosphate poisoning.
| Assay | Specimen | Reflects | Use | Source |
|---|---|---|---|---|
| Acetylcholinesterase | Red blood cells | Synaptic AChE inhibition | Severity; oxime efficacy | Aurbek 2009; Jalady 2013 |
| Butyrylcholinesterase | Plasma | Exposure and persistence of the toxicant | Rapid diagnosis; not oxime monitoring | Aurbek 2009; Jalady 2013 |
Iron poisoning: serum iron and assay interference
- Deferoxamine criteria. The French guideline gives deferoxamine for an ingested dose ≥150 mg/kg, signs of poisoning, serum iron ≥500 µg/dL (90 µmol/L) at 2–4 hours or metabolic acidosis (Mégarbane 2020).
- Peak serum iron in pediatric ingestion. In 54 children younger than 7 years, the median peak serum iron was 49 µmol/L, and none had severe toxicity. Symptomatic children had a median peak of 66 µmol/L and asymptomatic children 12 µmol/L. The suspected ingested dose did not predict toxicity (Crofton 2021).
- Serum iron thresholds in parenteral overdose. The 500 µg/dL threshold comes from oral poisoning. In parenteral overdose, patients with 825 to above 2,000 µg/dL were asymptomatic, and one patient with about 112 µg/dL developed shock and multiorgan failure (Chen HH 2026).
- Serum iron in non-iron acute liver injury. In non-iron acute liver injury with ALT >500 U/L, serum iron did not change (median 23 versus 27 µg/dL), and ferritin rose (Mudan 2022).
- TIBC method failure in iron overdose. Alumina column TIBC methods measure falsely high TIBC when free iron is present. A homogeneous TIBC method underestimates TIBC when iron exceeds 500 µg/dL (90 µmol/L) (Roberts 1999).
- Deferoxamine interference. Deferoxamine at clinically achievable concentrations (8,400 µg/dL) reduced iron recovery by up to 50% in all three methods studied. None of the methods measured iron or TIBC reliably in the presence of deferoxamine (Roberts 1999).
- Dialyzability of deferoxamine and ferrioxamine. Deferoxamine and ferrioxamine are dialyzable, and the French guideline suggests against routine renal replacement in anuric patients receiving deferoxamine (Mégarbane 2020).
Antidotes and the laboratory results that guide them.
| Poison | Antidote or treatment | Guiding laboratory result | Source |
|---|---|---|---|
| Acetaminophen | Acetylcysteine | Acetaminophen concentration against the nomogram; AST and ALT | Dart 2023; Sivilotti 2022 |
| Ethylene glycol, methanol | Fomepizole or ethanol; ECTR | Toxic alcohol concentration, osmolal gap, anion gap, glycolate | Ghannoum 2023; Roberts 2015 |
| Salicylate | Alkaline diuresis; ECTR | Salicylate concentration, pH | Juurlink 2015; Mégarbane 2020 |
| Lithium | ECTR | Lithium concentration, kidney function | Decker 2015 |
| Digoxin | Digoxin Fab | Digoxin concentration, potassium | Andrews 2023 |
| Methemoglobin-forming drugs | Methylene blue; ascorbic acid | Methemoglobin by co-oximetry, G6PD | Iolascon 2021 |
| Cyanide | Hydroxocobalamin | Plasma lactate | Baud 2002 |
| Iron | Deferoxamine | Serum iron at 2–4 hours | Mégarbane 2020 |
| Organophosphates | Atropine and oximes | Red cell AChE | Aurbek 2009 |
Toxic Metals and Trace Elements: Lead, Arsenic, Mercury, Implant Metals, Copper and Wilson Disease
Definition. Toxic metal and trace element testing measures elements in whole blood, plasma, serum, urine and occasionally hair or tissue, most often by inductively coupled plasma mass spectrometry (ICP-MS). Results depend on the specimen matrix, the chemical form of the element, collection materials free of contaminating metals and, for urine, normalization to creatinine. Toxic elements include lead, arsenic, mercury, thallium, cadmium, aluminum, cobalt and chromium. Essential trace elements include copper, zinc, selenium, manganese and iodine.
Related page: Microcytic Anemias and Iron Studies (lead hematology, basophilic stippling and zinc protoporphyrin) Related page: Analytical Methods and Immunoassays in Clinical Chemistry (ICP-MS and atomic absorption principles) Related page: Preanalytic Variables, Specimen Integrity and Point-of-Care Testing in Clinical Chemistry (collection tubes, additives and urine collection completeness) Related page: Method Validation, Statistical Quality Control and Proficiency Testing in Clinical Chemistry (CLIA proficiency testing limits) Related page: Porphyrias and Vitamin Testing (lead and urinary porphyrins) Related page: Toxic Alcohols, Acetaminophen, Salicylate and Other Poisonings: Laboratory Evaluation and Monitoring (poisoning workup and acquired methemoglobinemia)
Specimen collection and analytical interferences in trace element testing
- Contamination from collection materials. Vacuum tubes with rubber stoppers added an average of 76 µg/dL of zinc to serum. Tubes with rubber stoppers and clot activator added 198 µg/dL (Ralstin 1979). Polypropylene CSF tubes leached molybdenum and selenium in every tube and aluminum, titanium, manganese, thallium and zinc in 25% or fewer of tubes (Bitzer 2025).
- Hemolysis. Hemolyzed specimens are rejected or interpreted with caution (Laur 2020). The elements raised by hemolysis are listed in Analytical Methods and Immunoassays in Clinical Chemistry.
- Skin contamination of capillary specimens. Fingerstick and heelstick blood lead specimens are often contaminated by lead on the skin. Venous collection is less likely to be contaminated (Ruckart 2021).
- Gadolinium contrast. Gadolinium forms doubly charged and polyatomic ions that interfere with selenium and platinum on quadrupole ICP-MS. In urine collected after gadolinium contrast, measured selenium and platinum were up to several orders of magnitude above expected values. Sector field ICP-MS identified the interfering gadolinium species (Steuerwald 2013). A patient with plasma selenium of 65 µmol/L at ⁷⁸Se (reference interval 0.45–1.40 µmol/L) had 1.43 µmol/L at ⁸²Se on the same quadrupole method. The authors recommend monitoring a second selenium isotope to detect the interference (Ryan 2014). On sector field ICP-MS, gadolinium species interfered with every major selenium isotope, ⁸²Se included (Steuerwald 2013).
- Urine creatinine normalization. Spot urine results are adjusted to creatinine to correct for dilution. Urine creatinine varies with age, sex, race and ethnicity, body mass index and fat-free mass, so a creatinine-adjusted result is compared with reference ranges from a matching demographic group (Barr 2005).
- Hair analysis. A split hair sample sent to 6 commercial laboratories gave results that differed more than 10-fold for 12 minerals. Reference ranges conflicted, and the classifications (high, normal or low) disagreed for nearly all minerals. The authors recommend against hair mineral analysis for nutritional status or suspected exposure (Seidel 2001).
- Provoked (chelation-challenge) urine testing. A chelating agent such as DMSA, DMPS or EDTA is given before urine collection. No standard or validated challenge test exists, and no reference ranges exist for provoked urine. Urinary mercury rises after a chelator regardless of exposure history. The American College of Medical Toxicology recommends that these tests not be used (Ruha 2013). In a prospective registry, provoked urine testing had a positive predictive value of 4.3% for heavy metal toxicity diagnosed by a medical toxicologist (Weiss 2022).
Creatinine-normalized urine concentration (Barr 2005).
| Quantity | Formula | Units | Source |
|---|---|---|---|
| Creatinine-normalized analyte | Analyte concentration ÷ urine creatinine concentration | µg/L ÷ g/L = µg/g creatinine | Barr 2005 |
| Molar form | Analyte (nmol/L) ÷ creatinine (mmol/L) | nmol/mmol creatinine | Ye 2016 |
Specimens and methods for toxic metals
| Element | Preferred specimen | Main analytical point | Source |
|---|---|---|---|
| Lead | Venous whole blood | Capillary specimens are screening tests; elevated capillary results are confirmed on venous blood | Ruckart 2021; CDC 2025 |
| Arsenic | Urine with speciation | HPLC-ICP-MS separates arsenobetaine, methylarsonic acid (MMA), dimethylarsinic acid (DMA) and inorganic arsenic | Glabonjat 2024 |
| Mercury | Whole blood for methylmercury; urine for elemental and inorganic mercury | Total mercury in blood and hair are biomarkers after methylmercury exposure; urine does not reflect organic mercury | Ye 2016 |
| Thallium | Blood and urine | Hair dates the period of exposure and was negative early in acute poisoning | Zavaliy 2021 |
| Cadmium | Creatinine-adjusted urine | Urinary cadmium correlates with kidney cortex cadmium (r = 0.70) | Akerstrom 2013 |
| Aluminum | Serum | Deferoxamine (DFO) test for overload in dialysis patients | Chen 2022 |
| Cobalt and chromium | EDTA whole blood | Same sample type, method and laboratory for serial measurements | FDA 2019 |
| Selenium | Plasma | Gadolinium interference at ⁷⁸Se on quadrupole ICP-MS | Ryan 2014 |
Lead toxicity: testing, case management and occupational rules
The hematologic findings of lead poisoning (basophilic stippling, microcytosis and zinc protoporphyrin) are taught in Microcytic Anemias and Iron Studies. Lead-induced porphyrinuria is taught in Porphyrias and Vitamin Testing.
CDC blood lead reference value and its previous value
The CDC blood lead reference value (BLRV) of 3.5 µg/dL (2021) and the previous value of 5 µg/dL (2012) are taught in Microcytic Anemias and Iron Studies. The 2021 value comes from NHANES 2015–2016 and 2017–2018, and the 2012 value came from NHANES 2007–2008 and 2009–2010 (Ruckart 2021).
- Meaning of the BLRV. About 2.5% of US children aged 1–5 years have blood lead at or above 3.5 µg/dL. The BLRV is population based. It is neither a health-based standard nor a toxicity threshold (Ruckart 2021).
- Effect of the change. Children with blood lead of 3.5 to <5 µg/dL now receive an environmental history and nutritional counseling. Before 2021 these actions began at 5 µg/dL (Ruckart 2021).
- Laboratory consequences. Laboratories may need lower reporting limits and limits of detection, new repeat-testing practices and control of lead in consumables. The federal proficiency testing criterion for blood lead is ±4 µg/dL or ±10%, whichever is greater (Ruckart 2021).
- Screening policy. Medicaid-enrolled children are tested at 12 and 24 months, or at 24–72 months if not previously screened (Ruckart 2021).
Capillary blood lead screening and venous confirmation
- In Minnesota (2011–2017), 60% of children with a capillary blood lead of at least 5 µg/dL had a venous result below 5 µg/dL within 90 days. A model with no interval between tests predicted 55% false-positive capillary results (Wang 2019).
- A capillary result at or above the BLRV is confirmed with a venous specimen within the time set by the capillary level (CDC 2025).
CDC recommended actions by blood lead level in children (CDC, Recommended Actions Based on Blood Lead Level, updated August 21, 2025; accessed 2026-11-17).
| Blood lead (µg/dL) | Venous confirmation after a capillary result | Early follow-up testing (first 2–4 tests) | Later follow-up after the level declines | Actions added at this level |
|---|---|---|---|---|
| <3.5 | Not applicable | Age-based screening | Age-based screening | Education on lead sources; developmental and dietary review at well-child visits |
| 3.5–9 | Within 3 months | 3 months | 6–9 months | Report to the health department; environmental exposure history; investigation as required by the jurisdiction; testing and treatment for iron deficiency; nutrition and developmental review |
| 10–19 | Within 1 month | 1–3 months | 3–6 months | Same as 3.5–9 µg/dL |
| 20–44 | Within 2 weeks | 2 weeks–1 month | 1–3 months | History and physical examination; environmental investigation and lead hazard reduction; abdominal radiograph to be considered; contact with a Pediatric Environmental Health Specialty Unit or poison control |
| ≥45 | Within 48 hours | As soon as possible | As soon as possible | Detailed neurologic examination; abdominal radiograph; hospital admission when symptoms are present; consultation with a medical toxicologist about decontamination or chelation |
The CDC page gives no numeric chelation threshold. It directs consultation about chelation at ≥45 µg/dL (CDC 2025).
Adult and occupational lead exposure
- Surveillance case definition for lead in blood. The Council of State and Territorial Epidemiologists (CSTE) position statement 22-EH-01 (2022) renamed the condition from "elevated blood lead level" to "lead in blood". A confirmed case is a venous blood lead ≥3.5 µg/dL measured by graphite furnace atomic absorption spectrometry (GFAAS) or ICP-MS, at any age. In children younger than 16 years, two capillary results ≥3.5 µg/dL within 12 weeks also confirm a case, and a single capillary result is a suspect case. A specimen of unknown type counts as venous at age 16 years or older (CSTE 2022).
- History of the adult threshold. CSTE defined an elevated blood lead level as ≥10 µg/dL for children and adults in 2009, lowered it to ≥5 µg/dL in 2015 and lowered the adult threshold to 3.5 µg/dL in 2022, when CDC calculated the adult 97.5th percentile in NHANES as 3.49 µg/dL (CSTE 2022). The NIOSH Adult Blood Lead Epidemiology and Surveillance (ABLES) program reduced its case definition from 25 µg/dL to 10 µg/dL in 2011 (NIOSH ABLES 2026). The NIOSH blood lead guidance page states that ABLES uses 5 µg/dL to indicate an elevated level for surveillance and lists the CSTE reference value of 3.5 µg/dL for adults and children (NIOSH BLL 2026).
- Adult health effects below 40 µg/dL. Hypertension, effects on renal function, cognitive dysfunction and adverse female reproductive outcomes occur in adults with blood lead below 40 µg/dL (Kosnett 2007).
- Recommendations for exposed adults (Kosnett 2007).
- Removal from occupational exposure for a single blood lead above 30 µg/dL, or for two successive levels ≥20 µg/dL over 4 weeks.
- Quarterly blood lead testing for levels of 10–19 µg/dL and semiannual testing for sustained levels below 10 µg/dL.
- Avoidance of exposure that would raise blood lead above 5 µg/dL in pregnancy.
- No chelation for asymptomatic individuals with low blood lead.
OSHA general industry lead standard, 29 CFR 1910.1025 (eCFR, up to date as of 2026-11-13, accessed 2026-11-17; original rule 43 FR 53007, November 14, 1978).
| Provision | Requirement | Paragraph |
|---|---|---|
| Permissible exposure limit | 50 µg/m³ of air, 8-hour time-weighted average | (c)(1) |
| Action level | 30 µg/m³, 8-hour time-weighted average | (b) |
| Medical surveillance | Employees exposed at or above the action level for more than 30 days per year | (j)(1)(i) |
| Blood lead and ZPP monitoring | At least every 6 months | (j)(2)(i)(A) |
| Monitoring at ≥40 µg/100 g | At least every 2 months until two consecutive results are below 40 µg/100 g | (j)(2)(i)(B) |
| Monitoring during removal | At least monthly | (j)(2)(i)(C) |
| Follow-up test | Within 2 weeks after the employer receives a result at or above the 60 µg/100 g removal criterion | (j)(2)(ii) |
| Laboratory accuracy | Within ±15% or 6 µg/100 mL, whichever is greater, at 95% confidence | (j)(2)(iii) |
| Written notice to the employee | Within 5 working days for blood lead ≥40 µg/100 g | (j)(2)(iv) |
| Chelation | Prophylactic chelation of any employee is prohibited | (j)(4)(i) |
OSHA medical removal decision from serial blood lead results (29 CFR 1910.1025(k)).
| Step | Rule | Result |
|---|---|---|
| 1 | Periodic and follow-up blood lead both ≥60 µg/100 g | Removal |
| 2 | Mean of the last three results, or of all results in the past 6 months if that period is longer, ≥50 µg/100 g | Removal unless step 3 applies |
| 3 | Last result below 40 µg/100 g | No removal under step 2 |
| 4 | Two consecutive results below 40 µg/100 g after removal | Return to former job |
Biological exposure index. The ACGIH biological exposure index for blood lead is 20 µg/dL and is advisory. The OSHA removal levels are binding. The EU limit is 30 µg/dL until the end of 2028 and 15 µg/dL from 2029 under Directive 2024/869 (Lee 2026).
- Stricter state rule. Cal/OSHA requires medical removal for a single blood lead ≥30 µg/dL or the last two results ≥20 µg/dL and permits return below 15 µg/dL. Its airborne limit fell to 0.01 mg/m³ on January 1, 2025 (Lee 2026).
- Status of the federal standard. OSHA published an advance notice of proposed rulemaking on lowering the blood lead triggers for medical surveillance and medical removal in June 2022 (OSHA 2022). A separate 2025 proposed rule on the lead standards revises substance-specific respirator requirements (OSHA 2025), and its record was reopened for comment on July 22, 2026 (OSHA 2026). The eCFR text up to date as of November 13, 2026 retains the 60 µg/100 g removal and 40 µg/100 g return criteria (OSHA).
Arsenic: speciation and interpretation
- Exposure and toxicity. Sources of arsenic exposure are contaminated groundwater, mining and industrial processes, and traditional remedies. Arsenic trioxide is used to treat acute promyelocytic leukemia. Acute poisoning begins with nausea, vomiting, abdominal pain and severe diarrhea. Encephalopathy and peripheral neuropathy follow. Chronic toxicity is multisystem, and arsenic is a human carcinogen (Ratnaike 2003).
- Mees lines. Transverse white nail bands (Mees lines) are a clinical clue to arsenic poisoning (Carvalho Neto 2026).
- Urinary species. HPLC-ICP-MS separates arsenobetaine, MMA, DMA and inorganic arsenic. Detection limits are 0.02–0.03 µg/L for each species (Glabonjat 2024).
- Arsenobetaine from fish. Arsenobetaine was the most prevalent arsenic species in urine and blood of the general Korean population, and fish consumption raised arsenobetaine in both (Choi 2022). Abstaining from seafood for 3 days did not change urinary arsenite, arsenate, MMA or DMA (Hsueh 2002).
- Methylation after acute poisoning. After suicidal ingestion of arsenic trioxide or sodium arsenate, urinary total arsenic was 1.6–18.7 mg/L. DMA became the predominant species after 3–4 days, consistent with methylation as detoxification (Lovell 1985).
- Specimen choice. Whole blood arsenic is not used for initial evaluation, because arsenic is rapidly cleared from blood into tissues and is detectable only immediately after ingestion. A single urine specimen with urine creatinine is the mainstay, and seafood within 3 days of testing raises total urinary arsenic, up to 300 µg/24 h. Total urinary arsenic includes the nontoxic organic forms. Hair and nails record past exposure after urine has normalized but lack standardization (Jegen 2023).
- Interpretation. A high total urinary arsenic is speciated before it is attributed to toxic exposure, because arsenobetaine from fish contributes to total arsenic (Choi 2022; Glabonjat 2024).
Mercury: chemical forms and specimen choice
| Form | Main source and distribution | Specimen | Source |
|---|---|---|---|
| Methylmercury (organic) | Accumulates in fish and shellfish; largest share of mercury in blood | Whole blood; hair for long-term exposure | Ye 2016 |
| Elemental (metallic) mercury | Crosses the blood–brain barrier | Urine | Ye 2016 |
| Inorganic mercury salts | Respiratory absorption, 2–10% gastrointestinal absorption; does not cross the blood–brain barrier; accumulates in kidney; half-life about 2 months | Urine | Ye 2016 |
- Thresholds proposed from CDC, EPA and ACGIH data. Proposed normal values are blood mercury ≤4.6 µg/L and urine mercury ≤4.0 nmol/mmol creatinine. Levels for investigation of exposure sources are 10.0 µg/L in blood and 19.8 nmol/mmol creatinine in urine. Clinical intervention was proposed at blood mercury ≥40.0 µg/L (Ye 2016).
- Hair. Hair mercury is proportional to blood mercury (Ye 2016).
- Chelation by form. DMSA increases urinary excretion of methylmercury and inorganic mercury. Penicillamine is used for metallic and inorganic mercury, and it is not used for organic mercury (Ye 2016).
Thallium, cadmium, aluminum and other toxic metals
- Thallium. In 44 people with acute oral poisoning, blood thallium was 8.3–26.7 µg/L in the hospitalized group and 0.3–6.1 µg/L in the group treated at home. Alopecia appeared on days 17–23. Blood and urine thallium were the informative tests. Hair thallium was negative early in poisoning and is tested no earlier than 7 days after exposure (Zavaliy 2021). Serum thallium half-life during treatment was 3.8–5.7 days, and sensory symptoms preceded alopecia (Chen 2026).
- Cadmium.
- The kidney holds a major part of the cadmium body burden. Creatinine-adjusted urinary cadmium correlated with kidney cortex cadmium (r = 0.70) more closely than blood cadmium (r = 0.44). The kidney half-time was 18–44 years (Akerstrom 2013).
- Occupational cadmium exposure is associated with higher urinary β2-microglobulin and retinol-binding protein (tubular reabsorption markers), higher urinary N-acetyl-β-D-glucosaminidase and kidney injury molecule-1, and higher serum β2-microglobulin and creatinine (Kalahasthi 2025).
- Aluminum in dialysis.
- Aluminum excess causes dialysis dementia, erythropoietin-resistant microcytic anemia and bone disease. Aluminum toxicity affects about 2% of US hemodialysis patients (Chen 2022).
- The DFO test is positive when serum aluminum rises ≥50 µg/L after deferoxamine 5 mg/kg (Chen 2022). In 99 dialysis patients tested, 47 (47.5%) were positive, and none had encephalopathy (Chen 2022).
- Reported sources include dialysis fluid, oral aluminum hydroxide, plasma exchange, infant formula and intravesical exposure (Coulson 2022).
- Cobalt and chromium from metal-on-metal hip implants.
- The FDA recommends cobalt and chromium testing in EDTA whole blood by a validated method that meets CLIA criteria. Serial results use the same sample type, method and laboratory. The FDA recommends collection kits free of significant metal contamination (FDA 2019).
- The FDA sets no US threshold, because a metal ion level in isolation does not correlate with local lesions, outcomes or revision. Routine testing is not supported in asymptomatic patients with a well-functioning implant (FDA 2019).
- The UK Medicines and Healthcare products Regulatory Agency (MHRA) issued guidance in 2010 and updated it in 2017 to follow all patients with metal-on-metal bearings regardless of symptoms (Hughes 2019). At the 7 µg/L threshold used under MHRA guidance, cobalt and chromium had sensitivities of 82.1% and 53.5% and positive predictive values of 43.8% and 67.6% for adverse reaction to metal debris (Kiran 2017).
- Manganese. Manganese-containing trace element additives and contamination of parenteral nutrition can oversupply manganese. In 16 home parenteral nutrition patients with high whole-blood manganese, 81% had brain MRI findings. Removing manganese lowered whole-blood manganese by a mean of 38.1%, and MRI abnormalities resolved in 6 of 8 patients (Jin 2018).
Wilson disease and copper testing
- Genetics. Wilson disease is an autosomal recessive disorder of hepatic copper metabolism caused by ATP7B variants on chromosome 13q14.3. No single test confirms or excludes it (Ferenci 2003).
- Guidelines. The 2022 AASLD practice guidance (Schilsky 2023) and the 2025 EASL-ERN guideline (EASL 2025) are current. The EASL-ERN guideline bases diagnosis on clinical features, ceruloplasmin, 24-hour urinary copper, liver copper content and molecular analysis. It recommends the Leipzig score and relative exchangeable copper for diagnosis (EASL 2025).
- Leipzig score. A working party at the 8th International Meeting on Wilson disease and Menkes disease in Leipzig developed the score (Ferenci 2003), and the meeting took place in 2001 (Martínez-Morillo 2022). The AASLD guidance states that it is validated in adults and children (Schilsky 2023).
Leipzig score for Wilson disease (AASLD 2022 practice guidance, ES-Table 7, adapted from Ferenci 2003; Schilsky 2023).
| Parameter | Finding | Points |
|---|---|---|
| Kayser–Fleischer rings | Present / absent | 2 / 0 |
| Neuropsychiatric symptoms suggestive of Wilson disease (or typical brain MRI) | Present / absent | 2 / 0 |
| Coombs-negative (nonimmune) hemolytic anemia, with high serum copper | Present / absent | 1 / 0 |
| 24-hour urinary copper (no acute hepatitis) | Normal; 1–2 × ULN; >2 × ULN; normal but >500 µg/day 1 day after two 500-mg doses of D-penicillamine | 0; 1; 2; 2 |
| Liver copper | Normal (ULN 50 µg/g dry weight); up to 5 × ULN; >5 × ULN | −1; 1; 2 |
| Rhodanine-positive hepatocytes (only when quantitative copper is unavailable) | Present / absent | 1 / 0 |
| Serum ceruloplasmin (nephelometric assay; lower limit of normal 20 mg/dL) | Normal; 10–20 mg/dL; <10 mg/dL | 0; 1; 2 |
| ATP7B disease-causing variants | Both chromosomes / one / none | 4 / 1 / 0 |
A total ≥4 makes Wilson disease highly likely, 2–3 probable with more tests needed, and 0–1 unlikely. A parameter that is not available scores 0. The upper limit of normal for urinary copper is taken as 40 µg/day for children and adults. The guidance states that the penicillamine-challenge criterion is likely not stringent enough; the original threshold was >1,600 µg/24 h (Schilsky 2023). A review of the score as used by EASL and the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) gives ≥4 as diagnosis established, 3 as likely and ≤2 as very unlikely (Martínez-Morillo 2022).
- Hepatic copper. Quantitative hepatic parenchymal copper is preferred to histochemical copper stains, which have poor sensitivity. Copper >250 µg/g dry weight provides critical diagnostic information, and normal hepatic copper (<50 µg/g dry weight) almost always excludes Wilson disease in untreated patients (Schilsky 2023).
- D-penicillamine challenge. The challenge test is validated only in children. It may be performed in symptomatic children whose basal 24-hour urinary copper is <100 µg, and it is not sufficiently sensitive in asymptomatic Wilson disease (Schilsky 2023).
- 24-hour urinary copper. Basal urinary copper is typically >100 µg (>1.6 µmol)/24 h in symptomatic Wilson disease. A lower value of >40 µg (>0.6 µmol)/24 h may indicate Wilson disease in asymptomatic individuals and children (Schilsky 2023). In pediatric series, a cutoff of 40 µg/24 h had 79% sensitivity and 88% specificity, and a cutoff of 100 µg/24 h had 50–80% sensitivity and 76–97% specificity (Martínez-Morillo 2022).
Ceruloplasmin methods in Wilson disease
- A normal serum ceruloplasmin does not exclude Wilson disease (Schilsky 2023). Ceruloplasmin can be normal or raised with significant liver inflammation (Djebrani-Oussedik 2025).
- Ceruloplasmin oxidase activity (o-dianisidine substrate) at a cutoff of 55 U/L had 93.6% sensitivity and 100% specificity against healthy controls. The immunologic assay at 0.19 g/L had 93.6% sensitivity and 78.8% specificity. With patients with other liver disease added to controls, specificity fell to 84.5% for the enzymatic assay and 68.9% for the immunologic assay (Merle 2009).
- Enzymatic and immunologic results correlated less closely in Wilson disease (r = 0.70) than in healthy controls (r = 0.94) (Merle 2009).
- After a change of ceruloplasmin assay, results below 200 mg/L rose from 7 of 338 patients to 100 of 461 patients, while serum copper did not change. Cutoffs are therefore assay specific (Twomey 2008).
Exchangeable copper and relative exchangeable copper
- Definitions. Exchangeable copper (CuEXC) is the non-ceruloplasmin-bound copper fraction measured directly after EDTA chelation and ultrafiltration. Relative exchangeable copper (REC) is CuEXC divided by total serum copper (Lorenzen 2025).
Copper tests in Wilson disease diagnosis.
| Test | Cutoff | Sensitivity | Specificity | Population | Source |
|---|---|---|---|---|---|
| REC | 14% | 95.6% | 99.8% | 204 patients, 359 heterozygous carriers, 215 controls | Djebrani-Oussedik 2025 |
| REC | ≥13.8% | 100% | 99.6% | Newly diagnosed patients versus non-Wilsonian liver disease | Lorenzen 2025 |
| REC | ≥10.6% | 88.4% | 91.7% | 299 patients with liver disease, treated and untreated | Köhrer 2026 |
| Ceruloplasmin (immunologic) | <0.2 g/L | 95.2% | 81.9% | French reference center cohort | Djebrani-Oussedik 2025 |
| 24-hour urinary copper | >0.6 µmol/24 h | 88% | 95% | French reference center cohort | Djebrani-Oussedik 2025 |
- Reference intervals. CuEXC 0.50–1.38 µmol/L (earlier interval 0.62–1.15 µmol/L). REC in controls has a median of 5.1% and a reference interval of 2.6–9.5% (Djebrani-Oussedik 2025).
- Values in patients. Median REC was 23.6% in Wilson disease and 4.9% in all other groups combined (Lorenzen 2025).
- Acute liver failure. REC separated Wilson disease from other causes in 2 of 2 adults with acute liver failure. Both had hepatic copper above 250 µg/g dry weight (Köhrer 2026).
- Monitoring. CuEXC fell in treatment-naive patients after therapy began. It separated poorly between stable and unstable treated patients (Köhrer 2026). EASL-ERN monitoring uses urinary copper excretion and exchangeable copper (EASL 2025).
Essential trace elements: copper deficiency, zinc, selenium and iodine
- Copper deficiency.
- Acquired copper deficiency causes anemia, neutropenia and a myelopathy that resembles subacute combined degeneration from vitamin B12 deficiency. Risk factors are upper gastrointestinal surgery, zinc overload and malabsorption. Cytopenias occurred in 78% of 55 reported cases, and some cases were misdiagnosed as a myelodysplastic neoplasm (Jaiser 2010).
- Low serum copper and ceruloplasmin confirm the diagnosis. Urinary copper is typically low, which separates copper deficiency from Wilson disease (Jaiser 2010).
- After Roux-en-Y gastric bypass, the prevalence of copper deficiency was 9.6% and the incidence was 18.8%. Plasma copper and ceruloplasmin activity fell over 6 and 24 months, while plasma zinc did not change (Gletsu-Miller 2012).
- Zinc.
- Plasma or serum zinc decreases with inflammation. Population surveys adjust zinc by excluding individuals with CRP >5 mg/L or α-1-acid glycoprotein >1 g/L, by correction factors or by regression correction (McDonald 2020).
- Plasma zinc correlated with CRP (rs = −0.404) and albumin (rs = 0.588). The zinc/albumin ratio was similar across CRP categories, so albumin adjustment largely corrected zinc for inflammation (Ghashut 2016).
- Selenium. Plasma selenium correlated with CRP (rs = −0.489) and albumin (rs = 0.600). The selenium/albumin ratio fell as CRP rose, so albumin adjustment did not correct selenium for inflammation (Ghashut 2016).
- Iodine. Urinary iodine reflects recent intake over days, thyroglobulin reflects weeks to months, and goiter rate reflects months to years. Spot urinary iodine varies from day to day and is used for populations; it does not classify the iodine status of an individual (Zimmermann 2008).
Porphyrias and Vitamin Testing
Definition. The porphyrias are inherited or acquired defects of the eight-step heme synthesis pathway. Symptoms depend on the intermediate that accumulates before the defective step (Wang 2023). Deficiencies early in the pathway cause accumulation of the neurotoxic precursors δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) and present as acute neurovisceral attacks. Defects of later enzymes cause accumulation of photoactive porphyrins and present with cutaneous photosensitivity (Vu 2026). Vitamin testing measures the vitamin, its active form or a functional marker.
Related page: Microcytic Anemias and Iron Studies (iron studies, hereditary hemochromatosis, lead hematology and zinc protoporphyrin) Related page: Macrocytic Anemias and Vitamin B12 and Folate Testing (vitamin B12 and folate testing) Related page: Analytical Methods and Immunoassays in Clinical Chemistry (biotin interference in streptavidin-based immunoassays) Related page: Calcium, Parathyroid Hormone, Vitamin D, Magnesium and Phosphate (vitamin D) Related page: Toxic Metals and Trace Elements: Lead, Arsenic, Mercury, Implant Metals, Copper and Wilson Disease (blood lead testing and occupational lead rules) Related page: Newborn Screening and Biochemical Genetics: Amino Acid, Organic Acid, Fatty Acid Oxidation, Urea Cycle, Lysosomal and Peroxisomal Disorders (succinylacetone and tyrosinemia type I)
Heme synthesis enzymes and the porphyrias
Heme synthesis steps, enzyme defects and first-line tests.
| Step | Enzyme (gene) | Porphyria | Inheritance | Main accumulated compounds | First-line test | Source |
|---|---|---|---|---|---|---|
| 1 | ALA synthase 1, hepatic (ALAS1) | None; target of givosiran | Not applicable | Not applicable | Not applicable | Wang 2023 |
| 1 | ALA synthase 2, erythroid (ALAS2) | X-linked protoporphyria (gain of function) | X-linked dominant | Protoporphyrin IX, 50–85% metal free | Erythrocyte protoporphyrin with fractionation | Vu 2026; Gou 2015 |
| 2 | ALA dehydratase (ALAD) | ALAD deficiency porphyria | Autosomal recessive; fewer than a dozen cases | ALA (PBG normal) | Spot urine ALA, PBG and creatinine | Wang 2023 |
| 3 | Hydroxymethylbilane synthase (HMBS) | Acute intermittent porphyria (AIP) | Autosomal dominant | ALA, PBG | Spot urine ALA, PBG and creatinine | Wang 2023 |
| 4 | Uroporphyrinogen III synthase (UROS; rarely GATA1) | Congenital erythropoietic porphyria (CEP) | Autosomal recessive | Uroporphyrin I, coproporphyrin I | Urine, plasma and erythrocyte porphyrins | Vu 2026 |
| 5 | Uroporphyrinogen decarboxylase (UROD) | Porphyria cutanea tarda (PCT); hepatoerythropoietic porphyria (HEP) | Acquired (type I); autosomal dominant (type II); biallelic in HEP | Uroporphyrin, heptacarboxyl porphyrin | Plasma and urine porphyrins | Vu 2026 |
| 6 | Coproporphyrinogen oxidase (CPOX) | Hereditary coproporphyria (HCP) | Autosomal dominant | ALA, PBG; fecal coproporphyrin III | Spot urine ALA, PBG and creatinine; fecal porphyrins | Wang 2023; Allen 2005 |
| 7 | Protoporphyrinogen oxidase (PPOX) | Variegate porphyria (VP) | Autosomal dominant | ALA, PBG; plasma porphyrin with emission peak at 624–628 nm | Spot urine ALA, PBG and creatinine; plasma fluorescence scan | Wang 2023; Aarsand 2025 |
| 8 | Ferrochelatase (FECH) | Erythropoietic protoporphyria (EPP) | Autosomal dominant with incomplete penetrance (95%); autosomal recessive (4%) | Metal-free protoporphyrin IX, 85–100% of total | Erythrocyte protoporphyrin with fractionation | Vu 2026; Gou 2015 |
Clinical groups.
- Acute hepatic porphyrias: AIP, VP, HCP and ALAD deficiency porphyria (Wang 2023).
- Blistering cutaneous porphyrias: PCT, HEP, CEP, VP and HCP. The skin lesions of PCT are clinically identical to those of VP, HCP and late-onset CEP (Vu 2026).
- Nonblistering cutaneous porphyrias: EPP and X-linked protoporphyria (XLP) (Vu 2026).
Specimen handling for porphyrin and precursor tests
- All specimens for ALA, PBG, total urine porphyrins and plasma porphyrins are protected from light. Results from specimens exposed to light for more than 4 hours are interpreted with caution, and a repeat specimen is requested. Specimens are stored at 4 °C before transport, and ambient transit is kept below 24 hours (Gallagher 2024).
- Urine ALA is relatively stable, with less than 10% decrease after 7 days at room temperature. Urine PBG is unstable because it forms uroporphyrin and glycine conjugates (Aarsand 2025).
- Plasma porphyrins in EPP specimens fell by 19% after 6 hours light protected in a refrigerator, 36% after 24 hours light protected at room temperature, 67% within 1 hour of light exposure and 33% after one freeze-thaw cycle. Erythrocyte porphyrins were stable for 96 hours. Erythrocyte protoporphyrin is therefore measured with plasma porphyrins whenever protoporphyria is to be excluded (Schulenburg-Brand 2026).
Creatinine-normalized spot urine ALA and PBG.
| Quantity | Formula | Upper reference limit (one center) | Source |
|---|---|---|---|
| PBG | PBG (mg/L) ÷ urine creatinine (g/L) = mg/g creatinine | >2 mg/g creatinine | Schmolly 2025 |
| ALA | ALA (mg/L) ÷ urine creatinine (g/L) = mg/g creatinine | >5.4 mg/g creatinine | Schmolly 2025 |
| Acute attack | Patient result ÷ upper reference limit | ≥5-fold elevation in an acute attack | Wang 2023 |
Reference limits of porphyrin and precursor tests (European Porphyria Network recommendations, Aarsand 2025; limits are method and laboratory specific).
| Specimen and marker | Method | Reference limit | Main use |
|---|---|---|---|
| Urine PBG | Anion exchange chromatography with Ehrlich reagent | <0.8 and <1.45 µmol/mmol creatinine (two laboratories) | Acute attack of AIP, VP or HCP |
| Urine PBG | LC-MS | <0.137 and <0.2 µmol/mmol creatinine (two laboratories) | Acute attack of AIP, VP or HCP |
| Urine ALA | Cation exchange chromatography with Ehrlich reagent | <5 µmol/mmol creatinine | Acute attack, including ALAD deficiency porphyria |
| Urine total porphyrins | Fluorometry, spectrophotometry or HPLC | <35 nmol/mmol creatinine | PCT, HEP and CEP |
| Plasma total porphyrins | Fluorometry or HPLC | <19 nmol/L | Cutaneous porphyrias; PCT monitoring |
| Plasma ALA and PBG | LC-MS | ALA <0.41 and <0.13 µmol/L; PBG <0.12 and <0.05 µmol/L | Acute attack in anuria or severe chronic kidney disease |
| Erythrocyte total protoporphyrin | Fluorometry or HPLC | 0.4–1 and <1.5 µmol/L erythrocytes | EPP and XLP |
| Erythrocyte metal-free protoporphyrin | Fluorometry (emission peak 630 nm) or HPLC | <15% of total protoporphyrin; >80% in EPP | EPP and XLP |
| Erythrocyte zinc protoporphyrin | Fluorometry (emission peak 587 nm) or HPLC | <0.9 µmol/L erythrocytes | XLP, HEP, CEP; iron deficiency and lead exposure |
| Fecal total porphyrins | Spectrophotometry, fluorometry or HPLC | <72 and <192 nmol/g dry weight | Typing; raised nonspecifically by diet and gastrointestinal bleeding |
| Fecal isocoproporphyrin | HPLC | <1 nmol/g dry weight | PCT and HEP |
Acute hepatic porphyrias: diagnosis, typing and treatment monitoring
Biochemical diagnosis of an acute porphyria attack
- Indications for testing. Women aged 15–50 years with unexplained recurrent severe abdominal pain after an initial workup are screened for an acute hepatic porphyria. About 90% of symptomatic patients are women (Wang 2023).
- First-line test. ALA, PBG, porphyrins and creatinine are measured on a random urine specimen. During attacks ALA and PBG are elevated at least 5-fold, so a 24-hour collection is unnecessary (Wang 2023). Normalization to creatinine prevents a false-negative result in a dilute specimen (Balwani 2017).
- PBG in the subtypes. PBG is elevated in every acute hepatic porphyria except ALAD deficiency porphyria (Wang 2023). A normal urine PBG in a symptomatic patient excludes AIP, VP and HCP as the cause (Balwani 2017).
- Porphyrins are a separate test. ALA and PBG are porphyrin precursors and are not included in porphyrin assays, which separate porphyrins by HPLC with fluorescence detection. Urine porphyrins alone are not used to screen (Wang 2023). Urine total porphyrins can rise in an acute porphyria from in vitro polymerization of PBG to uroporphyrin, so a total porphyrin result is misleading as a first-line test for acute symptoms (Aarsand 2025).
- Timing. In AIP, ALA and PBG can stay elevated for months to years after an attack. In HCP and VP they can fall quickly (Wang 2023) and are more likely normal between attacks (Balwani 2017). Between attacks, 15–44% of patients with sporadic AIP have normal urine ALA and PBG. Patients with recurrent attacks usually have elevated ALA and PBG at baseline (Wang 2023).
- Hemin. Urine for ALA, PBG and creatinine is collected before hemin is started (Wang 2023).
- Turnaround. Quantitative ALA and PBG are performed in reference laboratories, often with a 1–2 week turnaround. Rapid qualitative PBG tests (Hoesch and Watson-Schwartz) have existed since the 1950s, and a new rapid PBG test was approved in the United States (Wang 2023).
- Electrolytes. Attacks can cause hyponatremia and hypomagnesemia from hypovolemia and inappropriate antidiuretic hormone secretion (Wang 2023).
- Case-control data. In one center, qualifying results were random urine ALA >5.4 mg/g creatinine, PBG >2 mg/g creatinine or elevated urinary porphyrins; 71% of patients with acute hepatic porphyria and urine results had at least one (Schmolly 2025).
Typing of acute hepatic porphyrias
- Genetic confirmation. Sequencing of ALAD, HMBS, CPOX and PPOX identifies 95–99% of cases. Genetic testing confirms a positive biochemical result. It is not recommended for initial screening (Wang 2023).
- Penetrance. Pathogenic HMBS variants occur in 1 in 1,300 to 1 in 1,785 people, while symptomatic disease affects about 1 in 100,000. Penetrance is about 1% in carriers and above 20% in families with a symptomatic patient (Wang 2023).
- Plasma fluorescence scanning. With excitation at 405 nm, an emission peak at 624–628 nm establishes variegate porphyria. EPP and XLP peak at 626–634 nm, PCT, HEP and CEP at 615–618 nm, and AIP and HCP are negative or at 615–622 nm (Aarsand 2025). A normal scan does not exclude AIP or HCP (Aarsand 2025). Older series placed VP at 626–628 nm, EPP at 636 nm and PCT with normal subjects at 618–622 nm (Enriquez de Salamanca 1993; Di Pierro 2021).
- Fecal coproporphyrin isomers. An increased fecal coproporphyrin III:I ratio was present in all 13 latent carriers of an HCP variant older than 10 years. Plasma fluorescence scanning was not useful for HCP family studies (Allen 2005). The proportion of coproporphyrin isomer I in feces is high in erythropoietic porphyrias, and isomers III, II and IV are high in acute hepatic porphyrias (Jacob 1995).
- Fecal porphyrins in VP. Fecal protoporphyrin exceeds coproporphyrin in VP, and the fecal coproporphyrin III:I ratio is often increased in VP as well as in HCP. HCP is therefore diagnosed from an increased ratio after the plasma scan has excluded VP (Aarsand 2025).
- Erythrocyte PBG deaminase activity. The reference interval is 6.1–20 nmol·s⁻¹·L⁻¹. Activity is normal in nonerythroid forms of AIP, overlaps between HMBS variant carriers and healthy individuals, and can rise during an acute attack. The assay is reserved for cases in which genetic analysis is unavailable or inconclusive (Aarsand 2025).
Acute hepatic porphyria treatment and its laboratory monitoring
- Hemin. Intravenous hemin 3–4 mg/kg daily, usually for 4 days, downregulates hepatic ALAS1. Chronic hemin (9% iron by weight) causes iron overload. With hemin at least monthly, ferritin and iron are monitored every 3–6 months. The AGA update advises therapeutic phlebotomy for ferritin >1,000 ng/mL (Wang 2023).
- Givosiran. Givosiran is a small interfering RNA against ALAS1 mRNA, conjugated to N-acetylgalactosamine for hepatocyte uptake (Wang 2023). In ENVISION, the mean annualized attack rate in AIP was 3.2 with givosiran and 12.5 with placebo, a 74% reduction (Balwani 2020). At 36 months, the median annualized attack rate during givosiran treatment was 0.4 (Kuter 2023). Givosiran lowered urinary ALA and PBG, and the reduction was sustained through 36 months (Balwani 2020; Kuter 2023). Elevated serum aminotransferases and changes in serum creatinine and eGFR were more frequent with givosiran than with placebo (Balwani 2020).
- Givosiran monitoring. Liver enzymes, urea nitrogen, creatinine, homocysteine, amylase and lipase are monitored. ALT above 3 times the upper limit has occurred in the first 3–6 months, so liver enzymes are checked monthly during that period (Wang 2023).
- Homocysteine on givosiran. Hyperhomocysteinemia is reported in acute hepatic porphyria, and givosiran further raises homocysteine in some patients. Reduced cystathionine β-synthase activity is the proposed mechanism (Keibler 2024). Plasma cystathionine β-synthase activity fell during givosiran treatment, and homocysteine and methionine correlated inversely with it (Keibler 2024). One patient developed homocysteine >400 µmol/L that required stopping givosiran; long-term vitamin B6 normalized homocysteine and allowed givosiran to continue (Redonnet-Vernhet 2024).
- Long-term surveillance. Liver ultrasound every 6 months begins at age 50 years for hepatocellular carcinoma. Creatinine and eGFR are checked at least annually (Wang 2023).
- Precipitating factors. Progesterone, cytochrome P450-inducing drugs, acute illness, stress, alcohol, tobacco and caloric deprivation induce hepatic ALAS1 (Wang 2023). Barbiturates, hydantoins, carbamazepine and valproic acid are contraindicated. Magnesium sulfate, benzodiazepines and levetiracetam appear safe for seizures (Wang 2023).
- Porphyrinogenic drug database. The AGA update cites online lists of safe and unsafe drugs (Wang 2023). The Drug Database for Acute Porphyrias of the Norwegian Porphyria Centre (NAPOS; https://www.drugs-porphyria.org/), maintained in cooperation with the International Porphyria Network, classifies drugs by their potential to provoke attacks in AIP, VP, HCP and ALAD deficiency porphyria. The classes are not porphyrinogenic (NP), probably not porphyrinogenic (PNP), possibly porphyrinogenic (PSP), probably porphyrinogenic (PRP), porphyrinogenic (P) and not yet classified (NC) (NAPOS 2026). The United Porphyrias Association recommends this database as the most current source for the acute hepatic porphyrias (UPA 2026).
Porphyria cutanea tarda and hepatoerythropoietic porphyria
- Enzyme defect. PCT results from hepatic UROD deficiency below 20% of normal (Singal 2019). It is the most common porphyria, with a prevalence of about 1 in 10,000 in Norway and 1 in 25,000 in the United States (Vu 2026).
- Type I (sporadic, about 80%). UROD inhibition is acquired and limited to hepatocytes, and erythrocyte UROD activity is normal (Vu 2026).
- Type II (familial). A heterozygous UROD variant lowers erythrocyte UROD activity to about 50% (Frank 2010). Susceptibility factors are still required for disease (Singal 2019).
- Susceptibility factors. Alcohol, smoking, hepatitis C, HIV, iron overload with HFE variants and estrogens (Singal 2019; Vu 2026).
- Biochemistry. Plasma and urine porphyrins are elevated with predominance of uroporphyrin and heptacarboxyl porphyrin (Vu 2026). Fecal isocoproporphyrin supports the diagnosis (Frank 2010). Hepta-, penta- and isocoproporphyrins predominate in feces (Aarsand 2025).
- Skin biopsy. Subepidermal blisters, festooning of dermal papillae and thickened basement membranes and vessel walls are nonspecific. Pseudoporphyria shows the same histology, so a biopsy does not establish PCT (Vu 2026).
- Treatment. Repeated phlebotomy or hydroxychloroquine 100 mg twice a week are equally effective (Singal 2019). Serum ferritin is followed after phlebotomy to detect relapse (Vu 2026). Ultrasound screening for hepatocellular carcinoma is recommended, especially with advanced fibrosis or cirrhosis (Singal 2019).
- HEP. Biallelic UROD variants reduce UROD activity below 10% and cause childhood-onset disease. Urine and plasma porphyrins show uroporphyrin and heptacarboxyl porphyrin, and erythrocyte zinc protoporphyrin is elevated (Vu 2026).
Erythropoietic protoporphyria, X-linked protoporphyria and congenital erythropoietic porphyria
Erythrocyte protoporphyrin fractionation in the protoporphyrias (Gou 2015; Vu 2026; Aarsand 2025).
| Disorder | Total erythrocyte protoporphyrin | Metal-free fraction | Gene |
|---|---|---|---|
| Reference | <80 µg/dL erythrocytes (Gou 2015) | <15% of total (Aarsand 2025) | Not applicable |
| EPP | 300–5,000 µg/dL erythrocytes | 85–100% (Gou 2015); >80% (Aarsand 2025) | FECH |
| XLP | Similar increase | 50–85% | ALAS2 |
- Hematofluorometry. Hematofluorometers are intended to screen for lead poisoning. They calculate results from assumed hematocrits and report "free" and "zinc" protoporphyrin without separate measurement. Some EPP and XLP results by hematofluorometry were 4.3- to 46.7-fold lower than results from the Porphyrias Consortium laboratories, and diagnoses were missed (Gou 2015).
- Urine. Protoporphyrin is not water soluble and is excreted in bile and feces, so urinary porphyrins are normal in EPP and XLP (Vu 2026; Aarsand 2025).
- Clinical features. EPP and XLP cause nonblistering burning pain of sun-exposed skin within minutes of exposure, beginning in early childhood. Males with XLP had a mean age of onset of 2.7 years and patients with EPP 4.1 years. Anemia occurs in about 30% of males and 75% of females with XLP (Vu 2026).
- Homozygous VP as a mimic. Two children with homozygous PPOX variants had photosensitivity and elevated erythrocyte protoporphyrin and were first diagnosed with EPP. Fractionation showed slight zinc predominance, and plasma porphyrins were mainly protoporphyrin (Wang 2026).
- CEP. UROS deficiency diverts hydroxymethylbilane to uroporphyrinogen I and coproporphyrinogen I. Uroporphyrin and coproporphyrin are elevated in urine, plasma and erythrocytes, and coproporphyrin is elevated in stool. Presentation ranges from nonimmune hydrops fetalis to late-onset mild photosensitivity. Features include red urine, erythrodontia, hemolytic anemia and photomutilation. About 220 cases are reported (Vu 2026).
Lead and secondary porphyrinurias
- Lead. Total urinary coproporphyrin was about 30-fold above control values in acute lead intoxication and in ALAD deficiency porphyria, with increased proportions of coproporphyrin III and the atypical isomers II and IV (Jacob 1999). In miners exposed to lead, urinary ALA and porphyrins were used as effect biomarkers together with metal levels (Serrazina 2018). Lead testing and occupational rules are taught in Toxic Metals and Trace Elements: Lead, Arsenic, Mercury, Implant Metals, Copper and Wilson Disease.
- ALA in lead poisoning and tyrosinemia. Urinary ALA is less specific than PBG. It can rise markedly in lead intoxication and hereditary tyrosinemia type I, which can present with symptoms resembling an acute porphyria (Aarsand 2025). Succinylacetone testing for tyrosinemia type I is taught in Newborn Screening and Biochemical Genetics: Amino Acid, Organic Acid, Fatty Acid Oxidation, Urea Cycle, Lysosomal and Peroxisomal Disorders.
- Secondary porphyrinurias. Mild nondiagnostic increases of urinary porphyrins are common and are often misinterpreted as acute porphyria (Wang 2023).
- Pseudoporphyria. Urinary porphyrins are normal in drug- or UV-induced pseudoporphyria (NSAIDs, antibiotics, diuretics), which separates it from PCT despite identical histology (Aarsand 2025; Vu 2026).
- Oral ALA. After an oral ALA load, total urinary coproporphyrin rose 10- to 15-fold within 12–24 hours and normalized after another 24 hours (Jacob 1999).
Vitamin deficiency syndromes and their laboratory tests
Vitamin deficiency syndromes with classic findings and the laboratory test for each.
| Vitamin | Deficiency syndrome | Classic findings | Laboratory test and specimen | Source |
|---|---|---|---|---|
| Thiamine (B1) | Wernicke encephalopathy; wet, dry and infantile beriberi | Wernicke triad of abnormal eye movements, gait ataxia and cognitive impairment; wet beriberi with heart failure and edema; dry beriberi with peripheral neuropathy; shoshin beriberi with cardiogenic shock and lactic acidosis | Thiamine diphosphate in EDTA or heparin whole blood or erythrocytes; erythrocyte transketolase activation coefficient (ETKAC) 1.15–1.25 moderate and >1.25 high risk, with beriberi symptoms generally at >1.4 | Whitfield 2018 |
| Vitamin C | Scurvy | Gingival bleeding, follicular hyperkeratosis, corkscrew hairs, perifollicular hemorrhage and impaired wound healing | Plasma vitamin C; <11 µmol/L is compatible with the clinical manifestations of scurvy | Cadeau-Comte 2026 |
| Vitamin A | Night blindness and xerophthalmia | Xerophthalmia includes night blindness, corneal scarring and Bitot spots | Serum retinol <0.70 µmol/L (<20 µg/dL) | Song 2023 |
| Niacin (B3) | Pellagra | Dermatitis, diarrhea, dementia and death | Spot urine 2-PYR and 1-MN relative to creatinine | Williams 2020; Creeke 2007 |
| Vitamin K | Vitamin K deficiency bleeding, including that of the newborn | Bleeding; risk with restricted diet, lipid malabsorption, cancer, renal disease, the neonatal period and old age | Serum phylloquinone; plasma PIVKA-II | Card 2020 |
| Vitamin E | Ataxia with vitamin E deficiency (TTPA) | Progressive ataxia and sensory loss from the first or second decade, resembling Friedreich ataxia | Serum α-tocopherol with lipid ratios; TTPA testing when vitamin E is low with sensory ataxia | Agarwal 2023; Adam 2026 |
- Vitamin E deficiency mechanism. In ataxia with vitamin E deficiency, dietary α-tocopherol is absorbed normally, but loss of α-tocopherol transfer protein prevents its transfer to hepatic VLDL and delivery to tissues (Agarwal 2023).
- Vitamin K and coagulation. Factor patterns, the PT response and PIVKA-II sensitivity in vitamin K deficiency are taught in Clotting Factor Assays, Factor Inhibitors and Interference by Hemophilia Therapies.
- Vitamin B12 and folate. Deficiency syndromes and testing are taught in Macrocytic Anemias and Vitamin B12 and Folate Testing.
Water-soluble vitamin testing
Water-soluble vitamin tests.
| Vitamin | Preferred test | Interpretation and handling | Source |
|---|---|---|---|
| Thiamine (B1) | Thiamine diphosphate (TDP) in whole blood or erythrocytes by HPLC | Reference intervals 275–675 ng/g hemoglobin in whole blood and 280–590 ng/g hemoglobin in erythrocytes; whole blood and erythrocyte TDP correlated (r = 0.97); compared with the erythrocyte transketolase activation test | Talwar 2000 |
| Riboflavin (B2) | Erythrocyte glutathione reductase activation coefficient (EGRAC) | Ratio of FAD-stimulated to basal activity of an FAD-dependent erythrocyte enzyme | Parkington 2023 |
| Vitamin B6 | Plasma pyridoxal 5′-phosphate (PLP) | Lowered by inflammation, alkaline phosphatase activity, low albumin, renal function and inorganic phosphate; functional markers and ratios reduce confounding | Ueland 2015 |
| Niacin (B3) | Urinary 1-methylnicotinamide (1-MN) and 2-pyridone (2-PYR) | Low in pellagra; whole-blood NAD and NADP were not depressed | Creeke 2007 |
- Thiamine. No readily accessible and widely agreed biomarker of thiamine status exists (Whitfield 2018).
- Vitamin B6 and inflammation. Plasma PLP is consistently low in inflammatory conditions, with a parallel fall in liver PLP and minor change in erythrocyte PLP and functional markers (Ueland 2017).
- Niacin. Combined cutoffs of 2-PYR <3.0 µmol/mmol creatinine and 1-MN <1.3 µmol/mmol creatinine had 91% sensitivity and 72% specificity for pellagra (Creeke 2007).
- Biotin. Biotin supplements interfere with streptavidin–biotin immunoassays. The mechanism, the direction of error and the FDA troponin communication are taught in Analytical Methods and Immunoassays in Clinical Chemistry.
- Vitamin C interference.
- Ascorbic acid interferes with oxidase-peroxidase chemistry assays. After ascorbate-containing bowel preparation, triglyceride fell by 27.21%, which exceeded the CLIA criterion of ±15%. Ascorbate oxidase pretreatment changed several analytes, and interference was not predicted by ascorbate concentration (Yoo 2026).
- High-dose intravenous vitamin C falsely raised glucose on two of three hospital glucose meters. The third meter gave error messages above a threshold concentration (Katzman 2021).
Fat-soluble vitamin testing
Fat-soluble vitamin tests.
| Vitamin | Test | Interpretation and handling | Source |
|---|---|---|---|
| Vitamin A | Serum retinol or retinol-binding protein (RBP) | RBP falls in the acute-phase response; inflammation adjustment excludes CRP >5 mg/L or α-1-acid glycoprotein >1 g/L or applies correction factors or regression | Larson 2017 |
| Vitamin E | α-Tocopherol with lipid ratios | Vitamin E to cholesterol ratio <3.7 and vitamin E to triglyceride ratio <8.5 (CALIPER, HPLC) | Adam 2026 |
| Vitamin K | Serum phylloquinone; PIVKA-II | Phylloquinone <0.15 µg/L indicates deficiency and reflects recent intake; PIVKA-II (reference range 17.4–50.9 mAU/mL, Abbott Architect) is a retrospective indicator of hepatic vitamin K status | Card 2020 |
- Light and temperature. In LC-MS/MS studies, vitamins D and E changed less than 4% under all tested conditions. Retinol in blood and serum fell 6.8% and 6.5% after more than 48 hours of light exposure, within the allowable change. Extracted retinol fell 18.4% after 48 hours of light. Serum and extracts were stable for 1 month at −20 °C (Albahrani 2016).
- Vitamin E and lipids. Serum α-tocopherol depends on lipids. In children with chronic liver disease, 31.4% of those with a normal absolute vitamin E were reclassified as low by the vitamin E to cholesterol ratio (Adam 2026).
- Vitamin K. The prothrombin time lacks sensitivity and specificity for vitamin K status. PIVKA-II is used to support the diagnosis of vitamin K deficiency bleeding of the newborn and to monitor exposure to vitamin K antagonists (Card 2020).
Newborn Screening and Biochemical Genetics: Amino Acid, Organic Acid, Fatty Acid Oxidation, Urea Cycle, Lysosomal and Peroxisomal Disorders
Definition. Newborn screening (NBS) is a state public health program that tests dried blood spots (DBS) and performs point-of-care screens to find treatable heritable conditions before symptoms. Tandem mass spectrometry (MS/MS) measures amino acids and acylcarnitines, and enzyme assays measure lysosomal enzyme activities. A positive screen is followed by second-tier testing on the same DBS or by confirmatory diagnostic testing. States and territories screen over 3.6 million newborns each year and identify about 12,900 infants with heritable conditions (HRSA 2026).
Related page: Analytical Methods and Immunoassays in Clinical Chemistry (tandem mass spectrometry principles) Related page: Hemoglobin Variant Analysis and Laboratory Diagnosis of Thalassemia (hemoglobin newborn screening) Related page: Laboratory Evaluation of Inborn Errors of Immunity and Secondary Immunodeficiency (TREC screening for severe combined immunodeficiency) Related page: Endocrine Function Tests: Thyroid, Adrenal and Pituitary (17-hydroxyprogesterone in the newborn period, 21-hydroxylase deficiency and confirmatory thyroid tests) Related page: Liver, Kidney and Gastrointestinal Function Tests (ammonia specimen handling) Related page: Diabetes and Glycemic Markers: Glucose, HbA1c, Ketones and the Hypoglycemia Workup (neonatal and hypoketotic hypoglycemia) Related page: Macrocytic Anemias and Vitamin B12 and Folate Testing (cobalamin disorders and vitamin B12 deficiency) Related page: Porphyrias and Vitamin Testing (succinylacetone and heme synthesis)
The Recommended Uniform Screening Panel and newborn screening programs
- Definition of the RUSP. The Recommended Uniform Screening Panel (RUSP) is the list of conditions that the Secretary of Health and Human Services recommends for state NBS. Conditions are chosen on evidence of net benefit of screening, the ability of states to screen and the availability of effective treatment (HRSA 2025a).
- State choice. States decide which conditions they screen. Adding a condition to the RUSP does not require a state to begin screening for it (HRSA 2025a).
- Insurance coverage. RUSP conditions are part of the HRSA-supported preventive guidelines under section 2713 of the Public Health Service Act. Non-grandfathered plans cover these screens without cost sharing for plan years beginning 1 year after the Secretary adopts a condition (HRSA 2025a).
- Size of the panel. The RUSP contains 40 core conditions and 26 secondary conditions. As of May 2026, 85% of NBS programs screened for 35 of the 40 core conditions (HRSA 2026).
- Conditions screened outside the laboratory. Critical congenital heart disease is a point-of-care test performed at birthing facilities (Singh 2023). Universal newborn hearing screening is performed at the point of care. In one regional program, well infants had transient otoacoustic emissions at 24 hours, and infants with audiological risk factors or a failed first test had automated auditory brainstem response testing. The Joint Committee on Infant Hearing 2019 statement sets screening by 1 month, identification of hearing loss by 3 months and intervention by 6 months, with coverage ≥95% and referral <4% (Gambacorta 2022).
Conditions added to the RUSP since 2010.
| Condition | Date added | Source |
|---|---|---|
| Severe combined immunodeficiency | May 2010 | Singh 2023 |
| Critical congenital heart disease | September 2011 | Singh 2023 |
| Glycogen storage disease type II (Pompe disease) | March 2015 | Singh 2023 |
| Mucopolysaccharidosis type I | February 2016 | Singh 2023 |
| X-linked adrenoleukodystrophy | February 2016 | Singh 2023; Bonaventura 2022 |
| Spinal muscular atrophy | 2018 | Singh 2023 |
| Mucopolysaccharidosis type II | 2022 | Singh 2023; Millington 2022 |
| Guanidinoacetate methyltransferase deficiency | January 2023 (ACHDNC recommendation May 2022) | Ream 2023 |
| Infantile Krabbe disease (low galactocerebrosidase with psychosine ≥10 nM) | 2024 (ACHDNC recommendation 2024; accepted by the Secretary about 6 months later), after a nomination was rejected in February 2023 | Ream 2025; Matern 2024 |
| Duchenne muscular dystrophy | Accepted December 16, 2025 | HRSA 2025a |
| Metachromatic leukodystrophy | Accepted December 16, 2025 | HRSA 2025b |
RUSP condition review: the ACHDNC process and the 2025 change
- Previous process. The Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) reviewed nominated conditions. Its Evidence Review Group summarized the net benefit, state readiness and treatment evidence, and the ACHDNC made recommendations to the Secretary (HRSA 2025a).
- 2025 change. The ERG completed its reviews of Duchenne muscular dystrophy (DMD) and metachromatic leukodystrophy (MLD), and the ACHDNC was terminated before it issued recommendations. HRSA requested public comment on August 14, 2025 (90 FR 39197 and 90 FR 39196). HRSA then recommended both additions, and the Secretary accepted them on December 16, 2025 (90 FR 59840, FR Doc 2025-23573; 90 FR 59847, FR Doc 2025-23574; December 22, 2025) (HRSA 2025a; HRSA 2025b).
- DMD screening. One comment opposing addition cited false-positive results and unclear cutoffs. HRSA noted that second-tier testing on the same bloodspot or DNA analysis reduces false positives (HRSA 2025a).
- Current pathway. HRSA funded the Association of Public Health Laboratories to convene a national NBS workgroup that supports a new pathway for RUSP review, with independent evidence reviews supported by HRSA (HRSA 2026).
Newborn screening for congenital hypothyroidism and congenital adrenal hyperplasia
- Congenital hypothyroidism (CH): screening analyte. TSH is the most sensitive test for primary CH, and the screening priority is detection of all forms of primary CH (van Trotsenburg 2021).
- CH: screening strategies. Programs first measured total T4 plus or followed by TSH, and later TSH alone, with specimens collected at least 48 hours after birth. Strategies that measure T4, with or without T4-binding globulin, can also detect central CH (van Trotsenburg 2021).
- CH: infants with false-negative risk. Preterm, low birth weight and sick infants can pass the first screen and later develop mild CH. For these groups the guideline proposes a second specimen at about 10–14 days of age, and it proposes a second screen in same-sex twins (van Trotsenburg 2021).
- CH: confirmation. An abnormal screen is followed by serum free T4 and TSH. Where serum thyroid tests are not readily available, levothyroxine is started when filter paper TSH is >40 mU/L (van Trotsenburg 2021). Interpretation of confirmatory thyroid tests is taught in Endocrine Function Tests: Thyroid, Adrenal and Pituitary.
- Congenital adrenal hyperplasia (CAH): first tier. Screening for classic 21-hydroxylase deficiency measures 17-hydroxyprogesterone (17-OHP) on the DBS by immunoassay with gestational age-adjusted cutoffs (Stroek 2021; Cavarzere 2022).
- CAH: cutoffs by gestational age and birth weight. The Türkiye program collects DBS at 3–5 days of life and screens newborns above 32 weeks and 1,500 g. First-tier fluoroimmunoassay 17-OHP cutoffs were 10 ng/mL at ≥36 weeks and/or ≥2,500 g and 15 ng/mL at 32–36 weeks and/or 1,500–2,500 g (Güran 2025). In the first program year, the 99.8th percentile of first-tier 17-OHP in unaffected infants was below 50 ng/mL at 32–36 weeks and/or 1,500–2,500 g and below 17.5 ng/mL at ≥36 weeks and/or ≥2,500 g (Güran 2025).
- CAH: second-tier LC-MS/MS.
- Türkiye measured 17-OHP, 21-deoxycortisol, cortisol and 11-deoxycortisol by LC-MS/MS and referred infants with (21-deoxycortisol + 17-OHP)/cortisol ≥1 for 21-hydroxylase deficiency and 11-deoxycortisol >10 ng/mL for 11β-hydroxylase deficiency. The recall rate was 0.31%, and classical 21-hydroxylase deficiency occurred in 1 in 12,044 (Güran 2025).
- In the Netherlands, second-tier 21-deoxycortisol was elevated in all 37 infants with classic CAH and undetectable in all 33 false positives. Applied to inconclusive first results, it reduced false positives to 11 and prevented 286 second heel punctures (Stroek 2021).
- In north-eastern Italy, an LC-MS/MS second tier introduced in 2017 reduced the recall rate and raised the positive predictive value. Over 20 years and 862,521 newborns, the incidence of 21-hydroxylase deficiency was 1 in 25,368, sensitivity was 97% and specificity 99.4% (Cavarzere 2022).
Dried blood spot collection and causes of false results
- Collection age. Most programs in an international PKU survey collect specimens at 48–72 hours of age (Trampuž 2025). Most tyrosinemia type I screening specimens are collected between 36 and 72 hours (Kuypers 2024).
- Red cell transfusion. Transfusion can impair detection of sickle cell disease, galactosemia and biotinidase deficiency. In four infants with sickle cell disease and delayed diagnosis after neonatal transfusion, none had the recommended repeat screen at least 120 days after the last transfusion (Reed 2000). Hemoglobin-specific retesting after transfusion is taught in Hemoglobin Variant Analysis and Laboratory Diagnosis of Thalassemia.
- Parenteral nutrition. Blood contaminated by parenteral nutrition shows dextrose markers at m/z 325, 399 and 473 in the acylcarnitine profile and can give false-positive amino acid results (Chace 2011). In one program, infants on parenteral nutrition have a DBS before it starts, at 48 hours of age and 72 hours after it ends (Pieragostino 2020).
- Prematurity and birth weight. Infants with MCAD deficiency and low birth weight had lower C8 values (Bentler 2016). False-positive low free carnitine (C0) was associated with gestational age below 37 weeks, low birth weight, cesarean delivery and exclusive breastfeeding (Turturo 2025).
- Maternal conditions.
- Elevated propionylcarnitine (C3) can reflect acquired vitamin B12 deficiency of mother and infant (Held 2022).
- Low C0 can reflect a maternal disorder (Turturo 2025).
- Pivaloylcarnitine from maternal pivalate-containing antibiotics is isomeric with isovalerylcarnitine and gives false-positive C5 results (Abdenur 1998).
Newborn screening markers and second-tier tests by disorder
MS/MS and enzyme markers with second-tier and confirmatory tests.
| Disorder | Primary NBS marker | Second-tier or confirmatory test | Source |
|---|---|---|---|
| Phenylketonuria (PAH deficiency) and BH4 defects | Phenylalanine; phenylalanine/tyrosine ratio | Plasma amino acids; genetic testing | Trampuž 2025; Pieragostino 2020 |
| Tyrosinemia type I | Succinylacetone; or tyrosine | Second-tier succinylacetone after tyrosine | Kuypers 2024 |
| Maple syrup urine disease | Leucine plus isoleucine (isobaric sum with alloisoleucine and hydroxyproline) | Second-tier chromatographic separation of alloisoleucine on the same DBS; plasma amino acids | Servais 2026; Blackburn 2017 |
| Guanidinoacetate methyltransferase deficiency | Guanidinoacetate and guanidinoacetate/creatine ratio | Plasma guanidinoacetate high and creatine low | Ream 2023 |
| Cystathionine β-synthase deficiency | Methionine; methionine/phenylalanine ratio | Total homocysteine | Morris 2017 |
| Ornithine transcarbamylase deficiency | Low citrulline, high glutamine | DBS orotic acid combined with citrulline (one program) | Staretz-Chacham 2021 |
| Methylmalonic and propionic acidemias | C3 | DBS methylmalonic acid, methylcitric acid and total homocysteine; urine organic acids | Pajares 2021; Forny 2021 |
| Isovaleric acidemia | C5 | C5 isomer separation by UPLC-MS/MS | Murko 2023 |
| MCAD deficiency | C8 | ACADM analysis | Bentler 2016 |
| VLCAD deficiency | C14:1; C14:1/C2 | C14:1 ratios to C10, C8 and C6 | Tajima 2024 |
| Carnitine uptake deficiency | Low C0 | Maternal acylcarnitine profile; SLC22A5 | Turturo 2025 |
| Classic galactosemia | GALT activity | Red cell GALT activity and GALT analysis | Welling 2017 |
| Pompe disease | Acid α-glucosidase activity | GAA analysis | Sawada 2020 |
| Mucopolysaccharidosis type I | α-L-iduronidase activity | DBS dermatan sulfate and heparan sulfate | Peck 2020 |
| Infantile Krabbe disease | Galactocerebrosidase activity | DBS psychosine (≥10 nM for infantile disease) | Hall 2026; Ream 2025 |
| X-linked adrenoleukodystrophy | C26:0-lysophosphatidylcholine | ABCD1 analysis | Bonaventura 2022 |
| Cystic fibrosis | Immunoreactive trypsinogen (IRT) | Second IRT and/or CFTR variants; sweat chloride | Sinclair 2020; Farrell 2017a |
Amino acid disorders
- Phenylketonuria.
- Most programs use MS/MS, with a phenylalanine screening cutoff mostly at 120 µmol/L and a cutoff for starting dietary therapy at 360 µmol/L. Some programs add the phenylalanine/tyrosine ratio (Trampuž 2025).
- The 2023 ACMG guideline recommends lifelong treatment for untreated phenylalanine >360 µmol/L, lifelong phenylalanine ≤360 µmol/L in plasma or whole blood, phenylalanine ≤360 µmol/L before conception, and PAH genetic testing at birth (Smith 2025).
- Maple syrup urine disease (MSUD). Biallelic variants in BCKDHA, BCKDHB, DBT or PPM1K cause deficiency of branched-chain ketoacid dehydrogenase. Worldwide incidence is about 1 in 185,000 births (Servais 2026). Allo-isoleucine is the pathognomonic marker of all forms of MSUD and is almost undetectable normally (Servais 2026; Blackburn 2017). Flow-injection MS/MS cannot separate the isobaric leucine, isoleucine, allo-isoleucine and hydroxyproline, so a second-tier or plasma method is needed (Blackburn 2017). Mixed-mode LC-MS/MS plasma amino acid methods separate leucine, isoleucine and allo-isoleucine (DeArmond 2022). Milder variants can be missed with a normal newborn leucine (Blackburn 2017). Second-tier separation also distinguishes MSUD from benign hydroxyprolinemia (Blackburn 2017; Servais 2026).
- Tyrosinemia type I. Succinylacetone is the main screening marker. The pooled median succinylacetone cutoff was 1.50 µmol/L. Positive predictive values were 27.3% for succinylacetone, 1.2% for tyrosine alone and 90.1% for tyrosine with second-tier succinylacetone (Kuypers 2024). Nitisinone with a low-protein diet is the treatment, and hepatocellular carcinoma and neurocognitive deficits are long-term sequelae (Das 2025).
- Cystathionine β-synthase deficiency. Screening detects elevated methionine, the methionine-to-phenylalanine ratio or hyperhomocysteinemia. Total homocysteine has only exceptionally been used as a primary marker; it improves specificity as a second-tier test with the methionine/total homocysteine ratio. Methionine has limited sensitivity for pyridoxine-nonresponsive disease and probably very low sensitivity for pyridoxine-responsive disease (Morris 2017).
Urea cycle disorders and ammonia
- Frequency and onset. Urea cycle disorders have an estimated incidence of 1 in 35,000 and present with hyperammonemia in the neonatal period in about 50% of cases (Häberle 2019).
- Orotic acid in NBS. In over 1.1 million newborns screened with orotic acid and citrulline, orotate was elevated in 7 of 11 infants with OTC deficiency and normal in 4 males with early-onset or late-onset disease. All 7 historical OTC deficiency patients had elevated orotate on archived DBS, while only 3 had been detected by low citrulline and high glutamine. The algorithm also detected CPS1 deficiency (Staretz-Chacham 2021).
- Argininosuccinic acid. Plasma amino acid methods detect argininosuccinic acid qualitatively (DeArmond 2022).
- Ammonia handling. Ammonia specimen stability is taught in Liver, Kidney and Gastrointestinal Function Tests. A UK network guideline recommends analysis of samples not collected under ideal conditions, with an interpretive comment, so that hyperammonemia is not missed (Bowron 2024).
Organic acidemias
- Diagnosis of methylmalonic and propionic acidemia. Urine organic acids establish the diagnosis. Methylmalonic acid with 3-hydroxypropionate and 2-methylcitrate indicates methylmalonic acidemia (MMA). The same pattern without methylmalonic acid indicates propionic acidemia (PA). Tiglylglycine and propionylglycine are often present (Forny 2021).
- Exclusions for PA. Propionyl-CoA carboxylase requires biotin, so nutritional biotin deficiency and biotinidase and holocarboxylase synthetase deficiencies are excluded before PA is diagnosed (Forny 2021).
- Second-tier testing for elevated C3. Methylmalonic acid, methylcitric acid and total homocysteine on the first DBS were measured in 258,637 newborns. Screening identified 130 newborns with acquired vitamin B12 deficiency (1 in 1,989), 19 with genetic disorders (1 in 13,613) and 13 false positives (Pajares 2021). Biomarker concentrations overlapped between genetic and acquired disease, and maternal vitamin B12 status was incompletely ascertained (Held 2022).
- Isovaleric acidemia and pivaloylcarnitine. In Hamburg, 156,772 newborns yielded 1 genetically proven isovaleric acidemia and 99 false positives due to pivaloylcarnitine. A UPLC-MS/MS second-tier test separates pivaloyl-, 2-methylbutyryl-, isovaleryl- and valerylcarnitine (Murko 2023).
Fatty acid oxidation disorders
- MCAD deficiency. In 221 screened neonates, mean first-screen C8 was 11.2 µmol/L (median 8.6, range 0.36–43.91). C8 was higher in symptomatic newborns and in infants homozygous for c.985A>G or compound heterozygous for c.985A>G with a deletion or another severe variant (Bentler 2016). Asymptomatic individuals can have normal acylcarnitines and are then tested for urine acylglycines, with elevated hexanoylglycine, 3-phenylpropionylglycine, octanoylglycine and suberylglycine (Mason 2023).
- VLCAD deficiency. C14:1 is the primary marker, and ratios to C2 and other acylcarnitines are secondary markers. Ratios of C14:1 to C10, C8 and C6 best reduced false positives. Phenotypes are cardiomyopathy, hypoglycemia and myopathy (Tajima 2024).
- LCHAD deficiency and maternal liver disease. A mother with acute fatty liver in a previous pregnancy had a child with LCHAD deficiency and hypoketotic hypoglycemia. The proband was homozygous for c.1528G>C. The authors recommend screening for fatty acid oxidation disorders in newborns of mothers with acute fatty liver of pregnancy or severe or recurrent HELLP syndrome (Gutiérrez Junquera 2009). LCHAD and mitochondrial trifunctional protein deficiencies are screened by hydroxylated long-chain acylcarnitines, primarily C16-OH, C16:1-OH and C18-OH; programs also use C18:1-OH and the C16-OH/C16 ratio (Stinton 2021). Positive predictive values ranged from 0% to 100% across programs, and sensitivity and specificity could not be calculated because screen-negative infants were not followed (Stinton 2021).
- Carnitine uptake deficiency. SLC22A5 variants lower plasma and intracellular carnitine. Of 160,015 newborns, 46 recalled for low C0 included 3 with carnitine uptake deficiency, 16 with a maternal disorder, 5 heterozygous for one SLC22A5 variant and 19 false positives (Turturo 2025).
Galactosemia and hereditary fructose intolerance
- Classic galactosemia.
- Diagnosis is confirmed by red cell GALT activity (absent or markedly decreased) and/or GALT analysis. A galactose-restricted diet starts as soon as classic galactosemia is suspected (Welling 2017).
- Patients with red cell GALT activity below 10% and/or two pathogenic GALT variants, including p.S135L, are treated. Evidence is insufficient for 10–15% activity (Welling 2017).
- Red cell galactose-1-phosphate is measured at diagnosis, after 3 and 9 months of restriction and yearly after the first year of life until an individual baseline is established (Welling 2017).
- Urine reducing substances while the infant takes lactose suggest galactosemia, but the test lacks sensitivity and specificity. Fructosuria, lactosuria, severe liver disease and antimicrobial therapy give false positives, and intravenous nutrition can abolish galactosuria (Badiu Tișa 2022). On the newborn screen, a low-galactose formula or a blood transfusion before sampling can give a false-negative galactosemia result (Badiu Tișa 2022).
- Duarte galactosemia. The guideline recommends no treatment and no endocrine follow-up (Welling 2017). Among 206 children with Duarte galactosemia and 144 sibling controls aged 6–12 years, no developmental outcome was associated with Duarte galactosemia or with milk exposure in infancy (Carlock 2019).
- Hereditary fructose intolerance. Aldolase B deficiency causes fructose 1-phosphate accumulation. Excess fructose 1-phosphate causes postprandial hypoglycemia, lactic acidosis, hypophosphatemia, hyperuricemia and liver and kidney toxicity. Presentation is classically around 6 months of age, when fructose enters the diet. Prevalence is about 1 in 10,000 to 1 in 20,000. ALDOB testing is the usual confirmation. Liver aldolase B activity remains the only definitive test, because some variants are unknown or of uncertain significance (Úbeda 2024).
Glycogen storage diseases by laboratory pattern
Laboratory patterns of glycogen storage diseases types I, II, III, V and VI.
| Type | Enzyme | Laboratory pattern | Source |
|---|---|---|---|
| Ia | Glucose-6-phosphatase | Hypoglycemia, lactic acidemia, hyperlipidemia and hyperuricemia; symptoms when feeding intervals reach 3–4 hours | Kishnani 2014 |
| Ib | Glucose-6-phosphate transporter | Same as Ia, with neutropenia and impaired neutrophil function | Kishnani 2014 |
| II (Pompe) | Acid α-glucosidase (lysosomal) | Low DBS enzyme activity; CK, AST, ALT and urine Hex4 monitored in late-onset disease | Sawada 2020 |
| III | Glycogen debranching enzyme | Hepatomegaly, hypoglycemia and hyperlipidemia; type IIIa adds skeletal and cardiac myopathy | Kishnani 2010 |
| V (McArdle) | Myophosphorylase | CK at least 5 times the upper reference limit in all 33 patients tested; flat lactate and exaggerated ammonia rise on forearm exercise testing | Joshi 2020 |
| VI | Hepatic glycogen phosphorylase (PYGL) | Hepatomegaly, elevated transaminases, ketotic hypoglycemia and hyperlipidemia; not separable from GSD IX clinically | Kishnani 2019 |
- Forearm exercise test in McArdle disease. On the ischemic forearm test, mean lactate rise was 0.5 mmol/L in patients and 3.60 mmol/L in controls. Mean ammonia rise was 300.9 µmol/L in patients, about 7 times the control mean (Joshi 2020). Absolute lactate and ammonia rises on the non-ischemic test separated McArdle disease from other patients with 100% sensitivity and 99.7% specificity. Patients with GSD III can show a similar pattern (Hogrel 2015).
Lysosomal storage disorders
- Enzyme assays on DBS. Acid α-glucosidase is measured by fluorometry with 4-methylumbelliferyl substrates, by MS/MS with mass-differentiated internal standards that allow multiplexing, or by digital microfluidic fluorometry (Sawada 2020).
- Pseudodeficiency. A pseudodeficiency allele lowers enzyme activity without causing disease. GAA pseudodeficiency alleles interfere with Pompe screening and are distinguished from disease only by GAA analysis (Sawada 2020). Later-onset phenotypes and pseudodeficiency alleles were more frequent than expected in Pompe screening (Klug 2020). Pseudodeficiency alleles also give enzyme-based MPS I screening a high false-positive rate. Dermatan sulfate and heparan sulfate, the substrates of α-L-iduronidase, were elevated in DBS from all infants with confirmed MPS I and separated them from pseudodeficiency and heterozygosity (Peck 2020).
- Definitive Pompe diagnosis. Two known pathogenic GAA variants with decreased enzyme activity establish the diagnosis (Sawada 2020).
- Krabbe disease. Psychosine is measured on the DBS as a second tier when galactocerebrosidase activity is low. Psychosine ≥10 nM is the infantile disease-specific second-tier threshold; states used 1.5–2 nM in 2023 and also identify later-onset disease (Ream 2025). Two-tier screening gave a diagnosis 7 days sooner than psychosine measured at follow-up, allowed transplant by day 36 on average and virtually eliminated false positives (Hall 2026). State programs using psychosine could eliminate false positives with appropriate cutoffs without major loss of sensitivity (Matern 2024).
- Mucopolysaccharidoses. LC-MS/MS of urinary dermatan sulfate, heparan sulfate and keratan sulfate was more sensitive and reliable than the dimethylmethylene blue ratio. Heparan sulfate was higher in patients with intellectual disability (328.8 versus 3.2 µg/mL) (Lin 2018).
- Program experience. In 733,838 Japanese newborns screened for lysosomal diseases and ALD, Fabry disease was the most frequent diagnosis (75 of 101). Positive predictive values were low for Pompe disease, MPS II and ALD because of pseudodeficiency alleles and method differences (Onuki 2025).
- Fabry disease. Plasma globotriaosylsphingosine (lyso-Gb3) was ≥5 pmol/mL in 53 of 60 patients with classical variants and in 4 of 13 with late-onset variants. Five females with normal α-galactosidase A activity and confirmed Fabry disease had raised lyso-Gb3, so enzyme activity alone can miss heterozygous females (Talbot 2017).
- Gaucher disease. Diagnosis is by acid β-glucosidase activity in leukocytes or dried blood spots, confirmed by GBA1 variants. Chitotriosidase is a macrophage-activation marker but is absent in people homozygous for the CHIT1 24-bp duplication (about 6% worldwide). Glucosylsphingosine (lyso-Gb1) has high sensitivity and specificity and reflects disease burden and treatment response (Giuffrida 2023).
Peroxisomal disorders
- X-linked adrenoleukodystrophy (X-ALD).
- ABCD1 variants impair peroxisomal β-oxidation of very long-chain fatty acids (VLCFA). Addison disease has a lifetime prevalence of 80–90% in affected males, and cerebral ALD occurs in about 35%. Up to 88% of female carriers develop a milder, later adrenomyeloneuropathy, and adrenal insufficiency occurs in fewer than 1% (Bonaventura 2022).
- NBS measures C26:0-lysophosphatidylcholine (C26:0-LPC) on DBS. New York began screening in 2013. Screening panels also measure C20:0- to C24:0-LPC and C20:0- to C26:0-acylcarnitines (Bonaventura 2022).
- C26:0-LPC is also elevated in Zellweger spectrum disorders, ACOX1, HSD17B4 and ACBD5 deficiencies and contiguous ABCD1/DXS1357E/BCAP31 deletion syndrome, which produce positive X-ALD screens (Bonaventura 2022).
- Zellweger spectrum disorders. Elevated plasma VLCFA is the key biochemical feature of peroxisome biogenesis disorders. Some patients with PEX6 variants have normal plasma VLCFA (Ahangari 2026).
Mitochondrial disorders: laboratory evaluation
- First-line tests (Mitochondrial Medicine Society consensus). Complete blood count, CK, transaminases, albumin, postprandial lactate and pyruvate with the lactate/pyruvate ratio when lactate is elevated, uric acid, thymidine, plasma amino acids, acylcarnitines and urine organic acids, especially 3-methylglutaconic acid. CSF lactate, pyruvate, amino acids and 5-methyltetrahydrofolate are added with central nervous system disease (Morava 2023).
- Pyruvate specimen. Whole blood is deproteinized with 8% perchloric acid. Timing of deproteinization, storage temperature and hemolysis affect the enzymatic pyruvate result (Chuang 2006).
- Pyruvate dehydrogenase complex deficiency. Primary lactic acidosis is accompanied by elevated alanine and proline. DBS cutoffs of alanine/leucine ≥4.0 and proline/leucine ≥3.0 were used for early identification (Verma 2024).
- Rhabdomyolysis. Acylcarnitines and urine organic acids exclude fatty acid oxidation defects in new cases of recurrent rhabdomyolysis (Parikh 2017).
Laboratory evaluation of the acutely ill infant with a suspected inborn error
Laboratory patterns of inborn errors in the acutely ill infant.
| Disorder group | Pattern | Confirmatory tests | Source |
|---|---|---|---|
| Urea cycle disorders | Hyperammonemia; low citrulline and high glutamine in OTC deficiency; elevated orotic acid in OTC deficiency | Citrulline and orotic acid | Häberle 2019; Staretz-Chacham 2021 |
| Organic acidemias (MMA, PA) | Metabolic acidosis with or without hyperammonemia; hyperlactatemia; ketoacidosis; neutropenia or pancytopenia | Urine organic acids; acylcarnitines | Forny 2021 |
| Long-chain fatty acid oxidation disorders | Hypoketotic hypoglycemia | Acylcarnitines | Gutiérrez Junquera 2009 |
| Hereditary fructose intolerance | Postprandial hypoglycemia, lactic acidosis, hypophosphatemia, hyperuricemia after fructose | ALDOB analysis | Úbeda 2024 |
| Mitochondrial disorders | Elevated lactate with lactate/pyruvate ratio; alanine | Amino acids, acylcarnitines, urine organic acids | Morava 2023; Verma 2024 |
Cystic fibrosis newborn screening and sweat chloride testing
- Screening algorithms. CF NBS begins with IRT on the DBS. IRT alone has a positive predictive value below 1% and misses about 2–5% of cases. Algorithms combine IRT with CFTR variant panels as IRT-DNA, IRT-IRT, IRT-IRT-DNA or IRT-DNA-IRT (Sinclair 2020). In Colorado's IRT-IRT-DNA program, a 96th percentile floating IRT cutoff with a 50 ng/mL fixed cutoff would have detected 7 of 8 missed cases (Martiniano 2021). CF NBS has been offered in every US state since 2010 (Green 2024).
- Diagnosis requires CFTR dysfunction. Diagnoses are established with a sweat chloride test from newborn to adult. Infants with two CF-causing variants on NBS still need demonstration of CFTR dysfunction (Farrell 2017a; Farrell 2017b).
- Sweat test method. Pilocarpine is delivered by iontophoresis, sweat is collected on gauze, filter paper or a Macroduct coil, and chloride is measured as described by CLSI (Farrell 2008). The current standard is CLSI C34, Sweat Testing: Sample Collection and Quantitative Chloride Analysis, 5th edition, November 8, 2024 (CLSI 2024).
- Collection conditions (2008 guideline). Asymptomatic infants with a positive screen are tested at ≥2 weeks of age and >2 kg. Bilateral testing is performed in infants ≥2 kg and >36 weeks of gestation at birth. Symptomatic newborns can be tested from 48 hours. A sufficient specimen is ≥75 mg by the Gibson-Cooke method or ≥15 µL by Macroduct. Laboratories keep the insufficient-volume rate below 5% for infants over 3 months. Sweat conductivity and osmolality were not used for diagnosis (Farrell 2008).
- Insufficient specimens (QNS). The 2008 guideline states that two inadequate bilateral samples are never pooled (Farrell 2008). A 2023 study found negligible correlation of sweat rate with chloride. Reporting specimens ≥10 µL (rate ≥0.3 µL/min) may reduce QNS rates, and preliminary data suggest pooling may be feasible (Omosule 2023).
- False-positive sweat tests. Testing is deferred in acute dehydration, edema and corticosteroid or mineralocorticoid therapy to avoid false-positive results. Malnutrition, celiac disease and endocrine disease have caused elevated sweat chloride without CF. One regional CF center recorded false-positive results in 7% of about 10,000 tests over 20 years (Cimbalo 2021).
- Sweat chloride in healthy newborns. Mean sweat chloride was 23.3 mmol/L at 3–7 days, 17.6 mmol/L at 8–14 days and 13.1 mmol/L after 6 weeks (Farrell 2008).
Sweat chloride interpretation: CFF 2017 consensus with the 2008 rule (Sosnay 2017; Green 2024; Farrell 2008).
| Sweat chloride (mmol/L) | CFF 2017, all ages | CFF 2008, infants under 6 months | CFF 2008, age 6 months and older |
|---|---|---|---|
| ≤29 | CF unlikely | CF unlikely | CF unlikely |
| 30–39 | Intermediate | Intermediate | CF unlikely |
| 40–59 | Intermediate | Intermediate | Intermediate |
| ≥60 | Consistent with CF | Indicative of CF | Indicative of CF |
- What changed in 2017. Registries contained many patients with CF and sweat chloride of 30–40 mmol/L, so the lower limit of the intermediate range was lowered from 40 to 30 mmol/L for individuals outside the newborn period (Sosnay 2017). CF diagnoses use sweat chloride ≥60 mmol/L, or 30–59 mmol/L with two CF-causing variants (Baldwin 2019).
- CRMS/CFSPID. CFTR-related metabolic syndrome (CRMS) and CF screen positive, inconclusive diagnosis (CFSPID) are merged, equivalent terms (Farrell 2017a). The designation applies to an infant with a positive CF NBS and either sweat chloride <30 mmol/L with two CFTR variants, at least one of unclear consequence, or sweat chloride 30–59 mmol/L with one or no CF-causing variant (Green 2024).
- CRMS/CFSPID outcomes. Regions without gene sequencing identify 3–5 CF cases for each CRMS/CFSPID case. Most do not develop CF, while 10–20% of asymptomatic infants develop features concerning for CF (Ren 2017). The 2024 CFF guideline recommends sequencing with deletion/duplication analysis when NBS finds fewer than two disease-causing variants, and repeat sweat testing until at least age 8 years (Green 2024).
References
- Aarsand AK, To-Figueras J, Whatley S, et al. Practical recommendations for biochemical and genetic diagnosis of the porphyrias. Liver Int. 2025;45(3):e16012. doi:10.1111/liv.16012. PMID 38940544
- Abdenur JE, Chamoles NA, Guinle AE, et al. Diagnosis of isovaleric acidaemia by tandem mass spectrometry: false positive result due to pivaloylcarnitine in a newborn screening programme. J Inherit Metab Dis. 1998;21(6):624–630. doi:10.1023/a:1005424331822. PMID 9762597
- Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46(6):1127–1153. doi:10.1007/s00134-020-06050-1. PMID 32383061
- Adam S, Grama A, Mititelu A, et al. Lipid-adjusted vitamin E status in children with chronic liver disease: reclassification patterns and differences according to cholestasis and liver transplantation. Nutrients. 2026;18(19):3283. doi:10.3390/nu18193283. PMID 42884734
- Agarwal A, Garg D, Srivastava AK. Ataxia with vitamin E deficiency: a never to be missed treatable ataxia. Ann Indian Acad Neurol. 2023;26(6):1011–1012. doi:10.4103/aian.aian_666_23. PMID 38229626
- Ahangari N, Shirvan BB, Ashrafzadeh F, et al. Unraveling PEX6: insights into very-long-chain fatty acid levels and peroxisome biogenesis disorders in pediatric populations. Ann Pediatr Endocrinol Metab. 2026;31(1):3–10. doi:10.6065/apem.2550134.067. PMID 41787707
- Akerstrom M, Barregard L, Lundh T, et al. The relationship between cadmium in kidney and cadmium in urine and blood in an environmentally exposed population. Toxicol Appl Pharmacol. 2013;268(3):286–293. doi:10.1016/j.taap.2013.02.009. PMID 23454399
- Aksun S, Bağci B, Karalar O, et al. The Need to Include Pregabalin in Routine Substance Screening Panels to Detect Non Therapeutic Use and Abuse. Psychiatry Clin Psychopharmacol. 2025;36(1):21-9. doi:10.5152/pcp.2025.251202. PMID 41562628
- Albahrani AA, Rotarou V, Roche PJ, et al. Analyte stability during the total testing process: studies of vitamins A, D and E by LC-MS/MS. Clin Chem Lab Med. 2016;54(10):1609–1618. doi:10.1515/cclm-2015-1034. PMID 27071152
- Allen KR, Whatley SD, Degg TJ, et al. Hereditary coproporphyria: comparison of molecular and biochemical investigations in a large family. J Inherit Metab Dis. 2005;28(5):779–785. doi:10.1007/s10545-005-0092-z. PMID 16151909
- Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther. 2018;103(2):210–216. doi:10.1002/cpt.911. PMID 29152729
- Anderson GD, Pak C, Doane KW, et al. Revised Winter-Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia. Ann Pharmacother. 1997;31(3):279–284. doi:10.1177/106002809703100301. PMID 9066931
- Andrews P, Anseeuw K, Kotecha D, et al. Diagnosis and practical management of digoxin toxicity: a narrative review and consensus. Eur J Emerg Med. 2023;30(6):395–401. doi:10.1097/MEJ.0000000000001065. PMID 37650725
- Armstrong VW, Schuetz E, Zhang Q, et al. Modified pentamer formation assay for measurement of tacrolimus and its active metabolites: comparison with liquid chromatography-tandem mass spectrometry and microparticle enzyme-linked immunoassay (MEIA-II). Clin Chem. 1998;44(12):2516–2523. PMID 9836720
- Athbhaiya G, Tiwari A, Choudhary R, et al. Pharmacological and toxicological effects of paracetamol: current knowledge and a review. Drug Chem Toxicol. 2026;49(2):404-427. doi:10.1080/01480545.2025.2604674. PMID 41492720
- Aurbek N, Thiermann H, Eyer F, et al. Suitability of human butyrylcholinesterase as therapeutic marker and pseudo catalytic scavenger in organophosphate poisoning: a kinetic analysis. Toxicology. 2009;259(3):133-9. doi:10.1016/j.tox.2009.02.014. PMID 19428953
- Avendaño C, Alvarez JS, Sacristan JA, et al. Interference of digoxin-like immunoreactive substances with TDx digoxin II assay in different patients. Ther Drug Monit. 1991;13(6):523–527. doi:10.1097/00007691-199111000-00010. PMID 1771650
- Badiu Tișa I, Achim AC, Cozma-Petruț A. The importance of neonatal screening for galactosemia. Nutrients. 2022;15(1):10. doi:10.3390/nu15010010. PMID 36615667
- Bailey B, McGuigan M. Lithium poisoning from a poison control center perspective. Ther Drug Monit. 2000;22(6):650-5. doi:10.1097/00007691-200012000-00002. PMID 11128231
- Baird G. Preanalytical considerations in blood gas analysis. Biochem Med (Zagreb). 2013;23(1):19-27. doi:10.11613/bm.2013.005. PMID 23457763
- Baldwin C, Zerofsky M, Sathe M, et al. Acute recurrent and chronic pancreatitis as initial manifestations of cystic fibrosis and cystic fibrosis transmembrane conductance regulator-related disorders. Pancreas. 2019;48(7):888–893. doi:10.1097/MPA.0000000000001350. PMID 31268981
- Balwani M, Sardh E, Ventura P, et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N Engl J Med. 2020;382(24):2289–2301. doi:10.1056/NEJMoa1913147. PMID 32521132
- Balwani M, Wang B, Anderson KE, et al. Acute hepatic porphyrias: recommendations for evaluation and long-term management. Hepatology. 2017;66(4):1314–1322. doi:10.1002/hep.29313. PMID 28605040
- Bantle M, Stöth F, Weinmann W, et al. Interlaboratory comparison of phosphatidylethanol in dried blood spots using different sampling devices. Drug Test Anal. 2025;17(6):834-841. doi:10.1002/dta.3784. PMID 39148470
- Baron JM, Griggs DA, Nixon AL, et al. The trazodone metabolite meta-chlorophenylpiperazine can cause false-positive urine amphetamine immunoassay results. J Anal Toxicol. 2011;35(6):364-8. doi:10.1093/anatox/35.6.364. PMID 21740694
- Barr DB, Wilder LC, Caudill SP, et al. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ Health Perspect. 2005;113(2):192–200. doi:10.1289/ehp.7337. PMID 15687057
- Baud FJ, Barriot P, Toffis V, et al. Elevated blood cyanide concentrations in victims of smoke inhalation. N Engl J Med. 1991;325(25):1761-6. doi:10.1056/NEJM199112193252502. PMID 1944484
- Baud FJ, Borron SW, Mégarbane B, et al. Value of lactic acidosis in the assessment of the severity of acute cyanide poisoning. Crit Care Med. 2002;30(9):2044-50. doi:10.1097/00003246-200209000-00015. PMID 12352039
- Bazydlo LAL, Larkey NE. Testing Strategies and the Emergence of Designer Benzodiazepines. Clin Lab Med. 2025;45(2):305-314. doi:10.1016/j.cll.2025.01.013. PMID 40348441
- Bentler K, Zhai S, Elsbecker SA, et al. 221 newborn-screened neonates with medium-chain acyl-coenzyme A dehydrogenase deficiency: findings from the Inborn Errors of Metabolism Collaborative. Mol Genet Metab. 2016;119(1–2):75–82. doi:10.1016/j.ymgme.2016.07.002. PMID 27477829
- Beumer JH, Chu E, Allegra C, et al. Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology recommendations for 5-fluorouracil therapy. Clin Pharmacol Ther. 2019;105(3):598–613. doi:10.1002/cpt.1124. PMID 29923599
- Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015;98(1):19–24. doi:10.1002/cpt.113. PMID 25801146
- Bishop-Freeman SC, Bertholf RL, Powers RH, et al. False-Positive Enzymatic Alcohol Results in Perimortem Specimens. Lab Med. 2020;51(4):394-401. doi:10.1093/labmed/lmz082. PMID 31999346
- Bithi N, Merrigan SD, McMillin GA. Does Labetalol Trigger False Positive Drug Testing Results? J Addict Med. 2023;17(3):e209-e210. doi:10.1097/ADM.0000000000001117. PMID 37267192
- Bitzer AC, Jannetto PJ, Bornhorst JA. Evaluation of polypropylene CSF low-bind collection tubes for trace metal contamination. Lab Med. 2025;56(1):64–69. doi:10.1093/labmed/lmae067. PMID 39136221
- Blackburn PR, Gass JM, Vairo FPE, et al. Maple syrup urine disease: mechanisms and management. Appl Clin Genet. 2017;10:57–66. doi:10.2147/TACG.S125962. PMID 28919799
- Bodor GS. The Laboratory's Role in Opioid Pain Medication Monitoring. EJIFCC. 2012;23(2):55-62. PMID 27683413
- Boehnert MT, Lovejoy FH. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. N Engl J Med. 1985;313(8):474-9. doi:10.1056/NEJM198508223130804. PMID 4022081
- Bonaventura E, Alberti L, Lucchi S, et al. Newborn screening for X-linked adrenoleukodystrophy in Italy: diagnostic algorithm and disease monitoring. Front Neurol. 2022;13:1072256. doi:10.3389/fneur.2022.1072256. PMID 36698902
- Borra LCP, van der Hulst R, Elsinga PH, et al. 50 Years of postmortem redistribution research: What have we learned? Forensic Sci Int. 2026;378:112699. doi:10.1016/j.forsciint.2025.112699. PMID 41161033
- Bowron A, Osgood V. Acceptability of plasma ammonia results when samples are not transported and processed under ideal conditions. Ann Clin Biochem. 2024;61(3):230–232. doi:10.1177/00045632241232931. PMID 38298138
- Brunet M, van Gelder T, Åsberg A, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261–307. doi:10.1097/FTD.0000000000000640. PMID 31045868
- Cadeau-Comte N, Melendez-Oliva E, Cuenca-Zaldivar JN, et al. Contemporary scurvy in vulnerable populations in high-income countries: a systematic review and multilevel meta-analysis. Nutrients. 2026;18(14):2213. doi:10.3390/nu18142213. PMID 42514284
- Caravati EM, Juenke JM, Crouch BI, et al. Quetiapine cross-reactivity with plasma tricyclic antidepressant immunoassays. Ann Pharmacother. 2005;39(9):1446-9. doi:10.1345/aph.1G107. PMID 16046487
- Card DJ, Gorska R, Harrington DJ. Laboratory assessment of vitamin K status. J Clin Pathol. 2020;73(2):70–75. doi:10.1136/jclinpath-2019-205997. PMID 31862867
- Carlock G, Fischer ST, Lynch ME, et al. Developmental outcomes in Duarte galactosemia. Pediatrics. 2019;143(1):e20182516. doi:10.1542/peds.2018-2516. PMID 30593450
- Carlsson CJ, Hansen HE, Hilsted L, et al. An evaluation of the interference of hydroxycobalamin with chemistry and co-oximetry tests on nine commonly used instruments. Scand J Clin Lab Invest. 2011;71(5):378-86. doi:10.3109/00365513.2011.573573. PMID 21495916
- Carvalho Neto EG, Damiani Monteiro M, Rieder CRM. Teaching NeuroImage: Mees lines as a clinical clue to arsenic poisoning. Neurology. 2026;107(7):e218552. doi:10.1212/WNL.0000000000218552. PMID 42691428
- Caudle KE, Dunnenberger HM, Freimuth RR, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017;19(2):215–223. doi:10.1038/gim.2016.87. PMID 27441996
- Cavarzere P, Camilot M, Palma L, et al. Twenty years of neonatal screening for congenital adrenal hyperplasia in north-eastern Italy: role of liquid chromatography-tandem mass spectrometry as a second-tier test. Horm Res Paediatr. 2022;95(3):255–263. doi:10.1159/000524170. PMID 35350013
- Centers for Disease Control and Prevention. Recommended actions based on blood lead level. Childhood Lead Poisoning Prevention. Updated August 21, 2025. https://www.cdc.gov/lead-prevention/hcp/clinical-guidance/index.html (accessed 2026-11-17) (CDC 2025)
- Chace DH, De Jesús VR, Lim TH, et al. Detection of TPN contamination of dried blood spots used in newborn and metabolic screening and its impact on quantitative measurement of amino acids. Clin Chim Acta. 2011;412(15–16):1385–1390. doi:10.1016/j.cca.2011.04.009. PMID 21514290
- Chan BS, Buckley NA. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin Toxicol (Phila). 2014;52(8):824–836. doi:10.3109/15563650.2014.943907. PMID 25089630
- Chen C, Yuan Y, Tan W, et al. Acute thallium poisoning: clinical features, toxicokinetics and one-year neurological outcomes. Clin Toxicol (Phila). 2026;64(9):832–835. doi:10.1080/15563650.2026.2697048. PMID 42572989
- Chen F, Lu SZ, Chohan H, Lau A. The role of fomepizole in acetaminophen-related poisoning: a narrative review. Clin Exp Emerg Med. 2026;13(1):13-27. doi:10.15441/ceem.25.059. PMID 40803359
- Chen HH, Wu SH, Mu HW, et al. Parenteral iron overdose: a scoping review. Clin Toxicol (Phila). 2026;64(11):981-995. doi:10.1080/15563650.2026.2727916. PMID 42708798
- Chen MY, Ou SH, Chen NC, et al. Aluminum overload in the reverse osmosis dialysis era: does it exist? Ren Fail. 2022;44(1):1595–1603. doi:10.1080/0886022X.2022.2104165. PMID 36190833
- Chen S, Yudiono J, Vohra V, et al. Rapid Turnaround Time for Toxic Alcohol Testing Is Associated with Shorter Hospital Length of Stay. West J Emerg Med. 2026;27(4):1002-1010. doi:10.5811/westjem.56974. PMID 42550694
- Cheng W, Kiang TK, Bring P, Ensom MH. Predictive performance of the Winter-Tozer and derivative equations for estimating free phenytoin concentration. Can J Hosp Pharm. 2016;69(4):269–279. doi:10.4212/cjhp.v69i4.1573. PMID 27621486
- Chiew AL, James LP, Isbister GK, et al. Early acetaminophen-protein adducts predict hepatotoxicity following overdose (ATOM-5). J Hepatol. 2020;72(3):450-462. doi:10.1016/j.jhep.2019.10.030. PMID 31760072
- Choi JW, Song YC, Cheong NY, et al. Concentrations of blood and urinary arsenic species and their characteristics in general Korean population. Environ Res. 2022;214(Pt 2):113846. doi:10.1016/j.envres.2022.113846. PMID 35820651
- Chuang CK, Wang TJ, Yeung CY, et al. Interference and blood sample preparation for a pyruvate enzymatic assay. Clin Biochem. 2006;39(1):74–77. doi:10.1016/j.clinbiochem.2005.10.007. PMID 16309664
- Cimbalo C, Tosco A, Terlizzi V, et al. Elevated sweat chloride test: is it always cystic fibrosis? Ital J Pediatr. 2021;47(1):112. doi:10.1186/s13052-021-01060-1. PMID 33990208
- Clinical and Laboratory Standards Institute. CLSI C34: Sweat testing: sample collection and quantitative chloride analysis. 5th ed. November 8, 2024. Product page: https://clsi.org/shop/standards/c34/ (accessed 2026-11-17) (CLSI 2024)
- Colby JM. Comparison of umbilical cord tissue and meconium for the confirmation of in utero drug exposure. Clin Biochem. 2017;50(13-14):784-790. doi:10.1016/j.clinbiochem.2017.03.006. PMID 28288850
- Cooke BJ. Chirality of methamphetamine and amphetamine from workplace urine samples. J Anal Toxicol. 1994;18(1):49-51. doi:10.1093/jat/18.1.49. PMID 8127085
- Cotton J, Edwards J, Rahman MA, et al. Cholinesterase research outreach project (CROP): point of care cholinesterase measurement in an Australian agricultural community. Environ Health. 2018;17(1):31. doi:10.1186/s12940-018-0374-1. PMID 29606131
- Coulson JM, Hughes BW. Dose-response relationships in aluminium toxicity in humans. Clin Toxicol (Phila). 2022;60(4):415–428. doi:10.1080/15563650.2022.2029879. PMID 35179097
- Council of State and Territorial Epidemiologists. Public health reporting and national notification for lead in blood. Position statement 22-EH-01. 2022. https://cdn.ymaws.com/www.cste.org/resource/resmgr/ps/ps2022/22-EH-01_Lead_in_Blood.pdf (accessed 2026-11-17) (CSTE 2022)
- Creeke PI, Dibari F, Cheung E, et al. Whole blood NAD and NADP concentrations are not depressed in subjects with clinical pellagra. J Nutr. 2007;137(9):2013–2017. doi:10.1093/jn/137.9.2013. PMID 17709435
- Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin Pharmacol Ther. 2021;110(4):888–896. doi:10.1002/cpt.2149. PMID 33387367
- Crofton AK, Harris K, Wylie C, et al. Unintentional paediatric iron poisoning: A retrospective case series. Emerg Med Australas. 2021;33(6):1044-1048. doi:10.1111/1742-6723.13806. PMID 34121325
- Dart RC, Mullins ME, Matoushek T, et al. Management of Acetaminophen Poisoning in the US and Canada: A Consensus Statement. JAMA Netw Open. 2023;6(8):e2327739. doi:10.1001/jamanetworkopen.2023.27739. PMID 37552484
- Das AM, Ballhausen D, Haas D, et al. Diagnosis, treatment, management and monitoring of patients with tyrosinaemia type 1: consensus group recommendations from the German-speaking countries. J Inherit Metab Dis. 2025;48(1):e12824. doi:10.1002/jimd.12824. PMID 39676394
- Dasgupta A, Davis B, Slawson MH, et al. Effect of carbamazepine 10,11-epoxide on serum carbamazepine measurement using a new CMIA assay: comparison of values obtained by using PETINIA, CEDIA and liquid chromatography combined with tandem mass spectrometry. Ann Clin Lab Sci. 2016;46(3):242–246. PMID 27312546
- Dasgupta A, Johnson MJ. Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista digoxin assay. J Clin Lab Anal. 2010;24(6):413–417. doi:10.1002/jcla.20421. PMID 21089173
- Dasgupta A, Zaidi S, Johnson M, et al. Use of fluorescence polarization immunoassay for salicylate to avoid positive/negative interference by bilirubin in the Trinder salicylate assay. Ann Clin Biochem. 2003;40(Pt 6):684-8. doi:10.1258/000456303770367306. PMID 14629809
- Datar P, Sidhu JS, Virk J, et al. A Case of Hydroxocobalamin-Induced False Blood Leak Alarm on Dialysis Machine. J Investig Med High Impact Case Rep. 2019;7:2324709619883466. doi:10.1177/2324709619883466. PMID 31701774
- de Almeida Araújo S, Faria BCD, Vasconcelos JC, et al. Renal toxicity caused by diethylene glycol: an overview. Int Urol Nephrol. 2023;55(11):2867-2875. doi:10.1007/s11255-023-03604-2. PMID 37186212
- DeArmond PD, Bunch DR. Quantitation of non-derivatized free amino acids for detecting inborn errors of metabolism by incorporating mixed-mode chromatography with tandem mass spectrometry. J Mass Spectrom Adv Clin Lab. 2022;25:1–11. doi:10.1016/j.jmsacl.2022.05.002. PMID 35637738
- Debunne N, De Letter K, Delanghe J, et al. The effect of Sebia's CZE IFCC-converted results on carbohydrate-deficient transferrin (CDT) interpretation in driver's license assessments. Clin Chem Lab Med. 2026;64(11):2494-2502. doi:10.1515/cclm-2026-0346. PMID 42345124
- Decker BS, Goldfarb DS, Dargan PI, et al. Extracorporeal Treatment for Lithium Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. Clin J Am Soc Nephrol. 2015;10(5):875-87. doi:10.2215/CJN.10021014. PMID 25583292
- Department of Health and Human Services. Mandatory Guidelines for Federal Workplace Drug Testing Programs (using Urine). 88 FR 70768. FR Doc 2023-21734. October 12, 2023; effective February 1, 2024. https://www.federalregister.gov/d/2023-21734 (UrMG 2023)
- Department of Transportation. Procedures for Transportation Workplace Drug and Alcohol Testing Programs: Addition of Fentanyl to the Department of Transportation's Drug-Testing Panel; Harmonization With Certain Items in the HHS Mandatory Guidelines for Urine and Oral Fluid; and Technical Amendments (proposed rule). 90 FR 42363. FR Doc 2025-16720. September 2, 2025. https://www.federalregister.gov/d/2025-16720 (DOT NPRM 2025)
- Di Pierro E, De Canio M, Mercadante R, et al. Laboratory diagnosis of porphyria. Diagnostics (Basel). 2021;11(8):1343. doi:10.3390/diagnostics11081343. PMID 34441276
- Djebrani-Oussedik N, Desjardins C, Obadia MA, et al. Relative exchangeable copper: a highly specific and sensitive biomarker for Wilson disease diagnosis. JHEP Rep. 2025;7(10):101537. doi:10.1016/j.jhepr.2025.101537. PMID 40980162
- Doré M, San Juan AE, Frenette AJ, et al. Clinical importance of monitoring unbound valproic acid concentration in patients with hypoalbuminemia. Pharmacotherapy. 2017;37(8):900–907. doi:10.1002/phar.1965. PMID 28574586
- Dugandzic RM, Tierney MG, Dickinson GE, et al. Evaluation of the validity of the Done nomogram in the management of acute salicylate intoxication. Ann Emerg Med. 1989;18(11):1186-90. doi:10.1016/s0196-0644(89)80057-5. PMID 2817562
- Dutta S, Buciuc AG, Barry P, et al. A Narrative Review on Toxidromes in the Psychiatric Population: Implications for Overdose Prevention. J Clin Med. 2025;14(17):6160. doi:10.3390/jcm14176160. PMID 40943922
- Dwyer JB, Tamama K. Ketoacidosis and trace amounts of isopropanol in a chronic alcoholic patient. Clin Chim Acta. 2013;415:245-9. doi:10.1016/j.cca.2012.10.057. PMID 23159845
- ElSohly MA, deWit H, Wachtel SR, et al. Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study. J Anal Toxicol. 2001;25(7):565-71. doi:10.1093/jat/25.7.565. PMID 11599601
- Enriquez de Salamanca R, Sepulveda P, Moran MJ, et al. Clinical utility of fluorometric scanning of plasma porphyrins for the diagnosis and typing of porphyrias. Clin Exp Dermatol. 1993;18(2):128–130. doi:10.1111/j.1365-2230.1993.tb00992.x. PMID 8481987
- European Association for the Study of the Liver. EASL-ERN Clinical Practice Guidelines on Wilson's disease. J Hepatol. 2025;82(4):690–728. doi:10.1016/j.jhep.2024.11.007. PMID 40089450 (EASL 2025)
- Fallik N, Trakhtenbroit I, Fahoum F, et al. Therapeutic drug monitoring in pregnancy: levetiracetam. Epilepsia. 2024;65(5):1285–1293. doi:10.1111/epi.17925. PMID 38400747
- Farrell PM, Rosenstein BJ, White TB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008;153(2):S4–S14. doi:10.1016/j.jpeds.2008.05.005. PMID 18639722
- Farrell PM, White TB, Howenstine MS, et al. Diagnosis of cystic fibrosis in screened populations. J Pediatr. 2017;181S:S33–S44.e2. doi:10.1016/j.jpeds.2016.09.065. PMID 28129810 (Farrell 2017b)
- Farrell PM, White TB, Ren CL, et al. Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation. J Pediatr. 2017;181S:S4–S15.e1. doi:10.1016/j.jpeds.2016.09.064. PMID 28129811 (Farrell 2017a)
- Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int. 2003;23(3):139–142. doi:10.1034/j.1600-0676.2003.00824.x. PMID 12955875
- Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin Pharmacokinet. 1995;29(3):172–191. doi:10.2165/00003088-199529030-00004. PMID 8521679
- Fleischman A, Chiang VW. Carbamazepine overdose recognized by a tricyclic antidepressant assay. Pediatrics. 2001;107(1):176-7. doi:10.1542/peds.107.1.176. PMID 11134454
- Fleuren LM, Roggeveen LF, Guo T, et al. Clinically relevant pharmacokinetic knowledge on antibiotic dosing among intensive care professionals is insufficient: a cross-sectional study. Crit Care. 2019;23(1):185. doi:10.1186/s13054-019-2438-1. PMID 31118061
- Food and Drug Administration. Information about soft tissue imaging and metal ion testing (metal-on-metal hip implants). Content current as of March 15, 2019. https://www.fda.gov/medical-devices/metal-metal-hip-implants/information-about-soft-tissue-imaging-and-metal-ion-testing (accessed 2026-11-17) (FDA 2019)
- Forny P, Hörster F, Ballhausen D, et al. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: first revision. J Inherit Metab Dis. 2021;44(3):566–592. doi:10.1002/jimd.12370. PMID 33595124
- Frank J, Poblete-Gutiérrez P. Porphyria cutanea tarda – when skin meets liver. Best Pract Res Clin Gastroenterol. 2010;24(5):735–745. doi:10.1016/j.bpg.2010.07.002. PMID 20955974
- Gallagher CJ, Bentley LA, Challenger R, et al. Stability of porphyrins and porphyrin precursors in urine and plasma samples: implications for sample handling and storage. J Clin Pathol. 2024;77(8):574–578. doi:10.1136/jcp-2024-209443. PMID 38631910
- Gambacorta V, Orzan E, Molini E, et al. Critical issues in the management of newborn hearing screening in the time of COVID-19 in Umbria, Italy. Children (Basel). 2022;9(11):1736. doi:10.3390/children9111736. PMID 36421185
- Gammal RS, Court MH, Haidar CE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing. Clin Pharmacol Ther. 2016;99(4):363–369. doi:10.1002/cpt.269. PMID 26417955
- Ge M, Alabi A, Kelner MJ, et al. Evaluation of a Benzodiazepine Immunoassay for Urine Drug Testing in Clinical Specimens. J Appl Lab Med. 2024;9(6):964-976. doi:10.1093/jalm/jfae083. PMID 39163145
- Ghannoum M, Gosselin S, Hoffman RS, et al. Extracorporeal treatment for ethylene glycol poisoning: systematic review and recommendations from the EXTRIP workgroup. Crit Care. 2023;27(1):56. doi:10.1186/s13054-022-04227-2. PMID 36765419
- Ghashut RA, McMillan DC, Kinsella J, et al. The effect of the systemic inflammatory response on plasma zinc and selenium adjusted for albumin. Clin Nutr. 2016;35(2):381–387. doi:10.1016/j.clnu.2015.02.010. PMID 25753552
- Giuffrida G, Markovic U, Condorelli A, et al. Glucosylsphingosine (lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review. Orphanet J Rare Dis. 2023;18(1):27. doi:10.1186/s13023-023-02623-7. PMID 36782327
- Gkarmiri S, Zagalioti SC, Karagiannidis E, et al. Postmortem Redistribution of Drugs Commonly Used in Rapid Sequence Induction for Anesthesia: A Review. J Clin Med. 2026;15(4):1622. doi:10.3390/jcm15041622. PMID 41753309
- Glabonjat RA, Schilling K, Slavkovich VN, et al. Arsenic speciation analysis in human urine for long term epidemiological studies: the Multi-Ethnic Study of Atherosclerosis (MESA). Environ Res. 2024;262(Pt 1):119833. doi:10.1016/j.envres.2024.119833. PMID 39179143
- Gletsu-Miller N, Broderius M, Frediani JK, et al. Incidence and prevalence of copper deficiency following roux-en-y gastric bypass surgery. Int J Obes (Lond). 2012;36(3):328–335. doi:10.1038/ijo.2011.159. PMID 21876546
- Goo Y, der Nederlanden AM, Bleasel A, et al. Dose monitoring of lamotrigine monotherapy in pregnancy: are pregnant women with epilepsy currently optimally managed? A systematic review. Ther Drug Monit. 2024;46(2):181–194. doi:10.1097/FTD.0000000000001186. PMID 38366344
- Goseva Z, Gjorcev A, Kaeva BJ, et al. Analysis of plasma concentrations of theophylline in smoking and nonsmoking patients with asthma. Open Access Maced J Med Sci. 2015;3(4):672–675. doi:10.3889/oamjms.2015.117. PMID 27275306
- Gosselin S, Juurlink DN, Kielstein JT, et al. Extracorporeal treatment for acetaminophen poisoning: recommendations from the EXTRIP workgroup. Clin Toxicol (Phila). 2014;52(8):856-67. doi:10.3109/15563650.2014.946994. PMID 25133498
- Gou EW, Balwani M, Bissell DM, et al. Pitfalls in erythrocyte protoporphyrin measurement for diagnosis and monitoring of protoporphyrias. Clin Chem. 2015;61(12):1453–1456. doi:10.1373/clinchem.2015.245456. PMID 26482161
- Green DM, Lahiri T, Raraigh KS, et al. Cystic Fibrosis Foundation evidence-based guideline for the management of CRMS/CFSPID. Pediatrics. 2024;153(5). doi:10.1542/peds.2023-064657. PMID 38577740
- Güran T, Yürüker E, Anık A, et al. The first-year outcomes of the nationwide neonatal CAH screening in Türkiye: high rate of false positives for 21-hydroxylase deficiency and a higher detection rate of non-classical cases. J Clin Res Pediatr Endocrinol. 2025;17(4):488–493. doi:10.4274/jcrpe.galenos.2025.2024-9-11. PMID 40405612
- Gutiérrez Junquera C, Balmaseda E, Gil E, et al. Acute fatty liver of pregnancy and neonatal long-chain 3-hydroxyacyl-coenzyme A dehydrogenase (LCHAD) deficiency. Eur J Pediatr. 2009;168(1):103–106. doi:10.1007/s00431-008-0696-z. PMID 18408953
- Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision. J Inherit Metab Dis. 2019;42(6):1192–1230. doi:10.1002/jimd.12100. PMID 30982989
- Hall PL, White AL, Peck D, et al. Two-tiered newborn screening for infantile Krabbe disease allows timely treatment initiation and avoids false-positive results. Genet Med. 2026;28(4):101572. doi:10.1016/j.gim.2025.101572. PMID 40888240
- Haller C, Thai D, Jacob P, et al. GHB urine concentrations after single-dose administration in humans. J Anal Toxicol. 2006;30(6):360-4. doi:10.1093/jat/30.6.360. PMID 16872565
- Hart XM, Gründer G, Hiemke C, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2026. Pharmacopsychiatry. 2026;59(4):166–295. doi:10.1055/a-2860-7861. PMID 42392224
- Health Resources and Services Administration. Addition of Duchenne muscular dystrophy to the Recommended Uniform Screening Panel. Fed Regist. 2025;90:59840–59841. FR Doc 2025-23573. December 22, 2025 (HRSA 2025a)
- Health Resources and Services Administration. Addition of metachromatic leukodystrophy to the Recommended Uniform Screening Panel. Fed Regist. 2025;90:59847–59848. FR Doc 2025-23574. December 22, 2025 (HRSA 2025b)
- Health Resources and Services Administration. National Newborn Screening Stakeholder Workgroup. Fed Regist. 2026;91:52059–52060. FR Doc 2026-16396. August 12, 2026 (HRSA 2026)
- Hegstad S, Fuskevåg OM, Amundsen S, et al. Stability of direct oral anticoagulants and antiarrhythmic drugs in serum collected in standard (nongel) serum tubes versus tubes containing gel separators. Ther Drug Monit. 2022;44(2):328–334. doi:10.1097/FTD.0000000000000915. PMID 34310545
- Held PK, Singh E, Scott Schwoerer J. Screening for methylmalonic and propionic acidemia: clinical outcomes and follow-up recommendations. Int J Neonatal Screen. 2022;8(1):13. doi:10.3390/ijns8010013. PMID 35225935
- Herbst ED, Harris DS, Everhart ET, et al. Cocaethylene formation following ethanol and cocaine administration by different routes. Exp Clin Psychopharmacol. 2011;19(2):95-104. doi:10.1037/a0022950. PMID 21463066
- Hogrel JY, van den Bogaart F, Ledoux I, et al. Diagnostic power of the non-ischaemic forearm exercise test in detecting glycogenosis type V. Eur J Neurol. 2015;22(6):933–940. doi:10.1111/ene.12685. PMID 25740218
- Holford N, Ma G, Metz D. TDM is dead. Long live TCI! Br J Clin Pharmacol. 2022;88(4):1406–1413. doi:10.1111/bcp.14434. PMID 32543717
- Hostetler JS, Heykants J, Clemons KV, et al. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. Antimicrob Agents Chemother. 1993;37(10):2224–2227. doi:10.1128/AAC.37.10.2224. PMID 8257148
- Hsueh YM, Hsu MK, Chiou HY, et al. Urinary arsenic speciation in subjects with or without restriction from seafood dietary intake. Toxicol Lett. 2002;133(1):83–91. doi:10.1016/s0378-4274(02)00087-5. PMID 12076513
- Hughes L, Chamberlain K, Robinson H, et al. Follow-up of metal-on-metal hip replacements at a large district hospital and the implementation of Medicines and Healthcare Products Regulatory Agency guidelines: a review of 297 patients. Clin Orthop Surg. 2019;11(4):403–408. doi:10.4055/cios.2019.11.4.403. PMID 31788162
- Ialongo C, Jones AW. The enzymatic analysis of alcohol (ethanol) in serum and plasma with the alcohol dehydrogenase reagent: focus on intra-analytical and post-analytical aspects. Biochem Med (Zagreb). 2025;35(3):030501. doi:10.11613/BM.2025.030501. PMID 40822841
- Iolascon A, Bianchi P, Andolfo I, et al. Recommendations for diagnosis and treatment of methemoglobinemia. Am J Hematol. 2021;96(12):1666-1678. doi:10.1002/ajh.26340. PMID 34467556
- Ito H, Hirose T, Suzuki Y, et al. Sequential changes in urinary crystal morphology in ethylene glycol poisoning: first human LV-SEM characterization of recovery-phase crystals. CEN Case Rep. 2026;15(5):134. doi:10.1007/s13730-026-01173-8. PMID 42593571
- Jacob K, Doss MO. Excretion pattern of faecal coproporphyrin isomers I–IV in human porphyrias. Eur J Clin Chem Clin Biochem. 1995;33(12):893–901. doi:10.1515/cclm.1995.33.12.893. PMID 8845420
- Jacob K, Egeler E, Gross U, et al. Investigations on the formation of urinary coproporphyrin isomers I–IV in 5-aminolevulinic acid dehydratase deficiency porphyria, acute lead intoxication and after oral 5-aminolevulinic acid loading. Clin Biochem. 1999;32(2):119–123. doi:10.1016/s0009-9120(98)00104-0. PMID 10211628
- Jaiser SR, Winston GP. Copper deficiency myelopathy. J Neurol. 2010;257(6):869–881. doi:10.1007/s00415-010-5511-x. PMID 20232210
- Jalady AM, Dorandeu F. [Interest of the cholinesterase assay during organophosphate poisonings]. Ann Fr Anesth Reanim. 2013;32(12):856-62. doi:10.1016/j.annfar.2013.08.018. PMID 24209986
- Jarvie DR, Heyworth R, Simpson D. Plasma salicylate analysis: a comparison of colorimetric, HPLC and enzymatic techniques. Ann Clin Biochem. 1987;24 ( Pt 4):364-73. doi:10.1177/000456328702400405. PMID 3662387
- Jegen DA, Jannetto PJ. What's in your water? A well-known risk for arsenic toxicity. J Rural Med. 2023;18(2):149–153. doi:10.2185/jrm.2022-034. PMID 37032984
- Jin J, Saqui O, Allard JP. Effect of discontinuation of manganese supplementation from home parenteral nutrition solutions on whole-blood levels and magnetic resonance imaging of the brain: a 5-year cohort study. JPEN J Parenter Enteral Nutr. 2018;42(1):164–170. doi:10.1177/0148607117690519. PMID 29187042
- Jones AW, Tilson C. Distribution ratios of ethanol and water between whole blood, plasma, serum, and erythrocytes: Recommendations for interpreting clinical laboratory results in a legal context. J Forensic Sci. 2023;68(1):9-21. doi:10.1111/1556-4029.15164. PMID 36317846
- Joshi PR, Deschauer M, Zierz S. McArdle disease: clinical, biochemical, histological and molecular genetic analysis of 60 patients. Biomedicines. 2020;8(2):33. doi:10.3390/biomedicines8020033. PMID 32075227
- Jun H, Rong Y, Yih C, et al. Comparisons of four protein-binding models characterizing the pharmacokinetics of unbound phenytoin in adult patients using non-linear mixed-effects modeling. Drugs R D. 2020;20(4):343–358. doi:10.1007/s40268-020-00323-2. PMID 33026608
- Juurlink DN, Gosselin S, Kielstein JT, et al. Extracorporeal Treatment for Salicylate Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup. Ann Emerg Med. 2015;66(2):165-81. doi:10.1016/j.annemergmed.2015.03.031. PMID 25986310
- Kaehler A, Kuta P, Renné T, et al. Variance in intraindividual stability of vitreous humor for thanatochemistry. Int J Legal Med. 2025;139(5):2165-2175. doi:10.1007/s00414-025-03482-6. PMID 40198360
- Kalahasthi R, Nagaraju R, Balachandar R, et al. Association between occupational cadmium exposure and markers of kidney injury: a systematic review and meta-analysis. Chem Res Toxicol. 2025;38(10):1638–1651. doi:10.1021/acs.chemrestox.5c00099. PMID 40955464
- Kane SP, Bress AP, Tesoro EP. Characterization of unbound phenytoin concentrations in neurointensive care unit patients using a revised Winter-Tozer equation. Ann Pharmacother. 2013;47(5):628–636. doi:10.1345/aph.1R651. PMID 23606554
- Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24(1):1–10. doi:10.3904/kjim.2009.24.1.1. PMID 19270474
- Kariisa M, O'Donnell J, Kumar S, et al. Illicitly Manufactured Fentanyl-Involved Overdose Deaths with Detected Xylazine - United States, January 2019-June 2022. MMWR Morb Mortal Wkly Rep. 2023;72(26):721-727. doi:10.15585/mmwr.mm7226a4. PMID 37384558
- Karnes JH, Rettie AE, Somogyi AA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and HLA-B genotypes and phenytoin dosing: 2020 update. Clin Pharmacol Ther. 2021;109(2):302–309. doi:10.1002/cpt.2008. PMID 32779747
- Katzman BM, Kelley BR, Deobald GR, et al. Unintended consequence of high-dose vitamin C therapy for an oncology patient: evaluation of ascorbic acid interference with three hospital-use glucose meters. J Diabetes Sci Technol. 2021;15(4):897–900. doi:10.1177/1932296820932186. PMID 32506941
- Keibler MA, Sridharan GV, Sweetser MT, et al. Elevated homocysteine is negatively correlated with plasma cystathionine β-synthase activity in givosiran-treated patients. JIMD Rep. 2024;65(4):262–271. doi:10.1002/jmd2.12416. PMID 38974609
- Kiang TK, Ensom MH. A comprehensive review on the predictive performance of the Sheiner-Tozer and derivative equations for the correction of phenytoin concentrations. Ann Pharmacother. 2016;50(4):311–325. doi:10.1177/1060028016628166. PMID 26825643
- Kidwell DA, Smith FP. Susceptibility of PharmChek drugs of abuse patch to environmental contamination. Forensic Sci Int. 2001;116(2-3):89-106. doi:10.1016/s0379-0738(00)00353-4. PMID 11182260
- Kiran M, Armstrong C, Shivarathre D, et al. Blood metal ion levels have limited utility in the surveillance of asymptomatic large-head metal-on-metal total hip arthroplasties. J Arthroplasty. 2017;32(12):3685–3688. doi:10.1016/j.arth.2017.07.015. PMID 28781016
- Kishnani PS, Austin SL, Abdenur JE, et al. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genet Med. 2014;16(11):e1. doi:10.1038/gim.2014.128. PMID 25356975
- Kishnani PS, Austin SL, Arn P, et al. Glycogen storage disease type III diagnosis and management guidelines. Genet Med. 2010;12(7):446–463. doi:10.1097/GIM.0b013e3181e655b6. PMID 20631546
- Kishnani PS, Goldstein J, Austin SL, et al. Diagnosis and management of glycogen storage diseases type VI and IX: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2019;21(4):772–789. doi:10.1038/s41436-018-0364-2. PMID 30659246
- Klein CN, Suijker MH, Heitink-Pollé KMJ, et al. Acute hemolytic anemia and methemoglobinemia in a pediatric oncology patient with G6PD deficiency: a case report. Pharmacogenomics. 2026;27(3-4):71-75. doi:10.1080/14622416.2026.2658474. PMID 41972917
- Klug TL, Swartz LB, Washburn J, et al. Lessons learned from Pompe disease newborn screening and follow-up. Int J Neonatal Screen. 2020;6(1):11. doi:10.3390/ijns6010011. PMID 33073009
- Kocaoğlu S, Alatlı T. Instantaneous carboxyhemoglobin level change due to smoking and analysis of baseline SpCO in smokers. BMC Pharmacol Toxicol. 2025;26(1):141. doi:10.1186/s40360-025-00979-z. PMID 40760452
- Köhler-Forsberg O, Wiuff AC, Devantier TA, et al. Estimating the 12-hour serum lithium level (eLi12): development and two proof-of-concept studies. J Clin Psychiatry. 2025;86(1):24m15547. doi:10.4088/JCP.24m15547. PMID 40047546
- Köhrer S, Rusev A, Zimmer H, et al. Relative exchangeable and exchangeable copper: emerging new biomarkers for diagnosis and therapy monitoring in Wilson's disease. Liver Int. 2026;46(6):e70666. doi:10.1111/liv.70666. PMID 42083149
- Kosnett MJ, Wedeen RP, Rothenberg SJ, et al. Recommendations for medical management of adult lead exposure. Environ Health Perspect. 2007;115(3):463–471. doi:10.1289/ehp.9784. PMID 17431500
- Kraut JA. Approach to the Treatment of Methanol Intoxication. Am J Kidney Dis. 2016;68(1):161-7. doi:10.1053/j.ajkd.2016.02.058. PMID 27180631
- Kraut JA. Diagnosis of toxic alcohols: limitations of present methods. Clin Toxicol (Phila). 2015;53(7):589-95. doi:10.3109/15563650.2015.1056880. PMID 26114345
- Kuter DJ, Bonkovsky HL, Monroy S, et al. Efficacy and safety of givosiran for acute hepatic porphyria: final results of the randomized phase III ENVISION trial. J Hepatol. 2023;79(5):1150–1158. doi:10.1016/j.jhep.2023.06.013. PMID 37479139
- Kuypers AM, Bouva MJ, Loeber JG, et al. Evaluation of neonatal screening programs for tyrosinemia type 1 worldwide. Int J Neonatal Screen. 2024;10(4):82. doi:10.3390/ijns10040082. PMID 39728402
- Larson LM, Namaste SM, Williams AM, et al. Adjusting retinol-binding protein concentrations for inflammation: Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project. Am J Clin Nutr. 2017;106(Suppl 1):390S–401S. doi:10.3945/ajcn.116.142166. PMID 28615251
- Larson ME, Richards TM. Quantification of a methadone metabolite (EDDP) in urine: assessment of compliance. Clin Med Res. 2009;7(4):134-41. doi:10.3121/cmr.2009.859. PMID 19920164
- Laur N, Kinscherf R, Pomytkin K, et al. ICP-MS trace element analysis in serum and whole blood. PLoS One. 2020;15(5):e0233357. doi:10.1371/journal.pone.0233357. PMID 32433650
- Lea-Henry TN, Carland JE, Stocker SL, et al. Clinical pharmacokinetics in kidney disease: fundamental principles. Clin J Am Soc Nephrol. 2018;13(7):1085–1095. doi:10.2215/CJN.00340118. PMID 29934432
- Lee CG, Park SH. Case series: from ventilation failure to substitution success in occupational lead poisoning at a Korean indoor firing range. Ann Occup Environ Med. 2026;38:e5. doi:10.35371/aoem.2026.38.e5. PMID 41807263
- Lee CR, Luzum JA, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharmacol Ther. 2022;112(5):959–967. doi:10.1002/cpt.2526. PMID 35034351
- Leite Cruz R, Vieira CB, Silva P, et al. Primaquine-Induced Methemoglobinemia: A Case Report. Cureus. 2025;17(12):e99414. doi:10.7759/cureus.99414. PMID 41552137
- Levy RH, Schmidt D. Utility of free level monitoring of antiepileptic drugs. Epilepsia. 1985;26(3):199–205. doi:10.1111/j.1528-1157.1985.tb05406.x. PMID 3924585
- Li J, Zheng Y, Luo L. Analytical strategies for distinguishing endogenous and exogenous anabolic androgenic steroids in doping control. Anal Methods. 2026. doi:10.1039/d6ay01634k. PMID 43037151
- Lim AS, Foo SHW, Benjamin Seng JJ, et al. Area-under-curve-guided versus trough-guided monitoring of vancomycin and its impact on nephrotoxicity: a systematic review and meta-analysis. Ther Drug Monit. 2023;45(4):519–532. doi:10.1097/FTD.0000000000001075. PMID 36728329
- Lim TY, Poole RL, Pageler NM. Propylene glycol toxicity in children. J Pediatr Pharmacol Ther. 2014;19(4):277–282. doi:10.5863/1551-6776-19.4.277. PMID 25762872
- Lin HY, Lee CL, Lo YT, et al. The relationships between urinary glycosaminoglycan levels and phenotypes of mucopolysaccharidoses. Mol Genet Genomic Med. 2018;6(6):982–992. doi:10.1002/mgg3.471. PMID 30296009
- Long JY, Guo HL, He X, et al. Caffeine for the pharmacological treatment of apnea of prematurity in the NICU: dose selection conundrum, therapeutic drug monitoring and genetic factors. Front Pharmacol. 2021;12:681842. doi:10.3389/fphar.2021.681842. PMID 34381359
- Lorenzen C, Dons K, García-Solà C, et al. Relative exchangeable copper, exchangeable copper and total copper in the diagnosis of Wilson disease. Liver Int. 2025;45(5):e70089. doi:10.1111/liv.70089. PMID 40198317
- Lovell MA, Farmer JG. Arsenic speciation in urine from humans intoxicated by inorganic arsenic compounds. Hum Toxicol. 1985;4(2):203–214. doi:10.1177/096032718500400211. PMID 4007884
- Lowe RH, Abraham TT, Darwin WD, et al. Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend. 2009;105(1-2):24-32. doi:10.1016/j.drugalcdep.2009.05.027. PMID 19631478
- Ludden TM. Nonlinear pharmacokinetics: clinical implications. Clin Pharmacokinet. 1991;20(6):429–446. doi:10.2165/00003088-199120060-00001. PMID 2044328
- Luginbühl M, Wurst FM, Stöth F, et al. Consensus for the use of the alcohol biomarker phosphatidylethanol (PEth) for the assessment of abstinence and alcohol consumption in clinical and forensic practice (2022 Consensus of Basel). Drug Test Anal. 2022;14(10):1800-1802. doi:10.1002/dta.3340. PMID 35851997
- Magnusson MO, Dahl ML, Cederberg J, et al. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. Clin Pharmacol Ther. 2008;84(1):52–62. doi:10.1038/sj.clpt.6100431. PMID 17971810
- Mahmud M, Kales SN. Methylene chloride poisoning in a cabinet worker. Environ Health Perspect. 1999;107(9):769-72. doi:10.1289/ehp.99107769. PMID 10464079
- Maillard M, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2025 update. Clin Pharmacol Ther. 2026;119(4):916–927. doi:10.1002/cpt.70209. PMID 41618934
- Martínez-Morillo E, Bauça JM. Biochemical diagnosis of Wilson's disease: an update. Adv Lab Med. 2022;3(2):103–125. doi:10.1515/almed-2022-0020. PMID 37361868
- Martiniano SL, Croak K, Bonn G, et al. Improving outcomes for Colorado's IRT-IRT-DNA cystic fibrosis newborn screening algorithm by implementing floating cutoffs. Mol Genet Metab. 2021;134(1–2):65–67. doi:10.1016/j.ymgme.2021.08.005. PMID 34489170
- Mason E, Hindmarch CCT, Dunham-Snary KJ. Medium-chain acyl-CoA dehydrogenase deficiency: pathogenesis, diagnosis, and treatment. Endocrinol Diabetes Metab. 2023;6(1):e385. doi:10.1002/edm2.385. PMID 36300606
- Masuda S, Lemaitre F, Barten MJ, et al. Everolimus personalized therapy: second consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2025;47(1):4–31. doi:10.1097/FTD.0000000000001250. PMID 39331837
- Matern D, Basheeruddin K, Klug TL, et al. Newborn screening for Krabbe disease: status quo and recommendations for improvements. Int J Neonatal Screen. 2024;10(1):10. doi:10.3390/ijns10010010. PMID 38390974
- McCartney D, Irwin C, Arnold JC, et al. Urinary Δ9-tetrahydrocannabinol and metabolite concentrations following cannabis use: A systematic review. Pharmacol Res. 2026;225:108142. doi:10.1016/j.phrs.2026.108142. PMID 41707818
- McCune JS, Quinones CM, Ritchie J, et al. Harmonization of busulfan plasma exposure unit (BPEU): a community-initiated consensus statement. Biol Blood Marrow Transplant. 2019;25(9):1890–1897. doi:10.1016/j.bbmt.2019.05.021. PMID 31136799
- McDermott JH, Wolf J, Hoshitsuki K, et al. Clinical Pharmacogenetics Implementation Consortium guideline for the use of aminoglycosides based on MT-RNR1 genotype. Clin Pharmacol Ther. 2022;111(2):366–372. doi:10.1002/cpt.2309. PMID 34032273
- McDonald CM, Suchdev PS, Krebs NF, et al. Adjusting plasma or serum zinc concentrations for inflammation: Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project. Am J Clin Nutr. 2020;111(4):927–937. doi:10.1093/ajcn/nqz304. PMID 32266402
- McMillin GA, Marin SJ, Johnson-Davis KL, et al. A hybrid approach to urine drug testing using high-resolution mass spectrometry and select immunoassays. Am J Clin Pathol. 2015;143(2):234-40. doi:10.1309/AJCPMJKBC6VJA1SP. PMID 25596249
- Mégarbane B, Oberlin M, Alvarez JC, et al. Management of pharmaceutical and recreational drug poisoning. Ann Intensive Care. 2020;10(1):157. doi:10.1186/s13613-020-00762-9. PMID 33226502
- Merle U, Eisenbach C, Weiss KH, et al. Serum ceruloplasmin oxidase activity is a sensitive and highly specific diagnostic marker for Wilson's disease. J Hepatol. 2009;51(5):925–930. doi:10.1016/j.jhep.2009.06.022. PMID 19720421
- Millington DS, Ficicioglu C. Addition of MPS-II to the Recommended Uniform Screening Panel in the United States. Int J Neonatal Screen. 2022;8(4):55. doi:10.3390/ijns8040055. PMID 36278625
- Moffett BS, Price JF. Evaluation of sodium nitroprusside toxicity in pediatric cardiac surgical patients. Ann Pharmacother. 2008;42(11):1600-4. doi:10.1345/aph.1L192. PMID 18957627
- Mohr AL, Ofsa B, Keil AM, et al. Enzyme-linked immunosorbent assay (ELISA) for the detection of use of the synthetic cannabinoid agonists UR-144 and XLR-11 in human urine. J Anal Toxicol. 2014;38(7):427-31. doi:10.1093/jat/bku049. PMID 24908262
- Morava E, Oglesbee D. Laboratory and metabolic investigations. Handb Clin Neurol. 2023;194:167–172. doi:10.1016/B978-0-12-821751-1.00012-9. PMID 36813311
- Moriyama B, Obeng AO, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther. 2017;102(1):45–51. doi:10.1002/cpt.583. PMID 27981572
- Morris AA, Kožich V, Santra S, et al. Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. J Inherit Metab Dis. 2017;40(1):49–74. doi:10.1007/s10545-016-9979-0. PMID 27778219
- Moss MJ, Fisher JA, Kenny TA, et al. Salicylate toxicity after undetectable serum salicylate concentration: a retrospective cohort study. Clin Toxicol (Phila). 2019;57(2):137-140. doi:10.1080/15563650.2018.1502442. PMID 30306804
- Mowry JB, Burdmann EA, Anseeuw K, et al. Extracorporeal treatment for digoxin poisoning: systematic review and recommendations from the EXTRIP Workgroup. Clin Toxicol (Phila). 2016;54(2):103-14. doi:10.3109/15563650.2015.1118488. PMID 26795743
- Mudan A, Lebin JA, Wu AHB, et al. Serum iron concentrations in non-iron induced acute liver injury. Clin Chim Acta. 2022;525:12-14. doi:10.1016/j.cca.2021.12.008. PMID 34906557
- Murko S, Aseman AD, Reinhardt F, et al. Neonatal screening for isovaleric aciduria: reducing the increasingly high false-positive rate in Germany. JIMD Rep. 2023;64(1):114–120. doi:10.1002/jmd2.12345. PMID 36636590
- National Institute for Occupational Safety and Health. Blood lead level guidance (regulations and recommendations). Updated October 28, 2026. https://www.cdc.gov/niosh/lead/bll-reference/index.html (accessed 2026-11-17) (NIOSH BLL 2026)
- National Institute for Occupational Safety and Health. Workplace lead exposure trends (Adult Blood Lead Epidemiology and Surveillance). Updated October 28, 2026. https://www.cdc.gov/niosh/lead/data/index.html (accessed 2026-11-17) (NIOSH ABLES 2026)
- Nessim SJ, Richardson RM. Dialysis for thiocyanate intoxication: a case report and review of the literature. ASAIO J. 2006;52(4):479-81. doi:10.1097/01.mat.0000227670.39719.ec. PMID 16883131
- Nham A, Le JN, Thomas SA, et al. Overdoses Involving Medetomidine Mixed with Opioids - Chicago, Illinois, May 2024. MMWR Morb Mortal Wkly Rep. 2025;74(15):258-265. doi:10.15585/mmwr.mm7415a1. PMID 40310760
- Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39(3):650–655. doi:10.1128/AAC.39.3.650. PMID 7793867
- Nisar S, Gibson CD, Sokolovic M, et al. Pulse Oximetry Is Unreliable in Patients on Veno-Venous Extracorporeal Membrane Oxygenation Caused by Unrecognized Carboxyhemoglobinemia. ASAIO J. 2020;66(10):1105-1109. doi:10.1097/MAT.0000000000001144. PMID 33136597
- Nolen WA, Licht RW, Young AH, et al. What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium. Bipolar Disord. 2019;21(5):394–409. doi:10.1111/bdi.12805. PMID 31112628
- Norwegian Porphyria Centre (NAPOS). The Drug Database for Acute Porphyrias: drug search, risk classification of drugs and About the Database. https://www.drugs-porphyria.org/ and https://www.drugs-porphyria.org/riskclasses (accessed 2026-11-17) (NAPOS 2026)
- Occupational Safety and Health Administration. 29 CFR 1910.1025, Lead. Electronic Code of Federal Regulations, up to date as of 2026-11-13. https://www.ecfr.gov/current/title-29/subtitle-B/chapter-XVII/part-1910/subpart-Z/section-1910.1025 (accessed 2026-11-17) (OSHA)
- Occupational Safety and Health Administration. Advance notice of proposed rulemaking: blood lead level for medical removal. Federal Register. 87 FR 38343. FR Doc 2022-13696. June 28, 2022. https://www.federalregister.gov/documents/2022/06/28/2022-13696/advance-notice-of-proposed-rule-making-anprm-blood-lead-level-for-medical-removal (accessed 2026-11-17) (OSHA 2022)
- Occupational Safety and Health Administration. Lead; proposed rule, reopening of the rulemaking record. Federal Register. 91 FR 46027. FR Doc 2026-14851. July 22, 2026. https://www.federalregister.gov/d/2026-14851 (accessed 2026-11-17) (OSHA 2026)
- Occupational Safety and Health Administration. Lead; proposed rule. Federal Register. 90 FR 28277. FR Doc 2025-11641. July 1, 2025. https://www.federalregister.gov/d/2025-11641 (accessed 2026-11-17) (OSHA 2025)
- Olson A. Unit inconsistency in forensic blood and breath alcohol reporting. Forensic Sci Int Synerg. 2026;12:100674. doi:10.1016/j.fsisyn.2026.100674. PMID 41907578
- Omosule CL, Dietzen DJ, Roper SM. Reexamining the minimum sweat rate requirement for sweat chloride testing. J Appl Lab Med. 2023;8(6):1084–1091. doi:10.1093/jalm/jfad067. PMID 37757465
- Onuki T, Tajika M, Sugiyama Y, et al. Japanese experience of newborn screening for lysosomal storage diseases and adrenoleukodystrophy. Orphanet J Rare Dis. 2025;20(1):373. doi:10.1186/s13023-025-03848-4. PMID 40708026
- Pajares S, Arranz JA, Ormazabal A, et al. Implementation of second-tier tests in newborn screening for the detection of vitamin B12 related acquired and genetic disorders: results on 258,637 newborns. Orphanet J Rare Dis. 2021;16(1):195. doi:10.1186/s13023-021-01784-7. PMID 33931066
- Pandya V, Wilker C, McMillin GA. Can umbilical cord and meconium results be directly compared? Analytical approach matters. J Anal Toxicol. 2023;47(1):96-105. doi:10.1093/jat/bkac037. PMID 35707888
- Parikh S, Goldstein A, Karaa A, et al. Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med. 2017;19(12). doi:10.1038/gim.2017.107. PMID 28749475
- Parker MG, Fraser GL, Watson DM, et al. Removal of propylene glycol and correction of increased osmolal gap by hemodialysis in a patient on high dose lorazepam infusion therapy. Intensive Care Med. 2002;28(1):81-4. doi:10.1007/s00134-001-1125-1. PMID 11819005
- Parkington DA, Koulman A, Jones KS. Protocol for measuring erythrocyte glutathione reductase activity coefficient to assess riboflavin status. STAR Protoc. 2023;4(4):102726. doi:10.1016/j.xpro.2023.102726. PMID 37988268
- Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs: best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239–1276. doi:10.1111/j.1528-1167.2008.01561.x. PMID 18397299
- Peck DS, Lacey JM, White AL, et al. Incorporation of second-tier biomarker testing improves the specificity of newborn screening for mucopolysaccharidosis type I. Int J Neonatal Screen. 2020;6(1):10. doi:10.3390/ijns6010010. PMID 33073008
- Peterson BL, Midthun KM, Labay LM. Potential for postmortem formation of ethanol in vitreous humor. J Anal Toxicol. 2026;50(6):bkag044. doi:10.1093/jat/bkag044. PMID 42286417
- Pieragostino D, Cicalini I, Di Michele S, et al. A case of suspected hyperphenylalaninemia at newborn screening by tandem mass spectrometry during total parenteral nutrition. Metabolites. 2020;10(2):44. doi:10.3390/metabo10020044. PMID 31991569
- Poklis A, Edinboro LE, Lee JS, et al. Evaluation of a colloidal metal immunoassay device for the detection of tricyclic antidepressants in urine. J Toxicol Clin Toxicol. 1997;35(1):77-82. doi:10.3109/15563659709001169. PMID 9022656
- Pratt VM, Cavallari LH, Fulmer ML, et al. DPYD genotyping recommendations: a joint consensus recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics Knowledgebase, and Pharmacogene Variation Consortium. J Mol Diagn. 2024;26(10):851–863. doi:10.1016/j.jmoldx.2024.05.015. PMID 39032821
- Price HR, Collier AC, Wright TE. Screening pregnant women and their neonates for illicit drug use: consideration of the integrated technical, medical, ethical, legal, and social issues. Front Pharmacol. 2018;9:961. doi:10.3389/fphar.2018.00961. PMID 30210343
- Ralstin JO, Schneider PJ, Blackstone L, et al. Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979;3(3):179–181. doi:10.1177/014860717900300316. PMID 113585
- Ramirez Fernandez MDM, Cirimele V, Ruyssinckx E, et al. Challenges in the Interpretation of Isolated THC-COOH Detection in Hair: Forensic and Clinical Implications. Drug Test Anal. 2026;18(6):785-793. doi:10.1002/dta.70072. PMID 41978365
- Ramsey LB, Balis FM, O'Brien MM, et al. Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. Oncologist. 2018;23(1):52–61. doi:10.1634/theoncologist.2017-0243. PMID 29079637
- Ranjitkar P, Greene DN. Therapeutic concentrations of hydroxocobalamin interferes with several spectrophotometric assays on the Beckman Coulter DxC and AU680 chemistry analyzers. Clin Chim Acta. 2015;450:110-4. doi:10.1016/j.cca.2015.07.024. PMID 26232160
- Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289(7):871–878. doi:10.1001/jama.289.7.871. PMID 12588271
- Ratnaike RN. Acute and chronic arsenic toxicity. Postgrad Med J. 2003;79(933):391–396. doi:10.1136/pmj.79.933.391. PMID 12897217
- Ream MA, Lam WKK, Grosse SD, et al. Evidence and recommendation for guanidinoacetate methyltransferase deficiency newborn screening. Pediatrics. 2023;152(2):e2023062100. doi:10.1542/peds.2023-062100. PMID 37465909 (Ream 2023)
- Ream MA, Lam WKK, Grosse SD, et al. Evidence and recommendation for infantile Krabbe disease newborn screening. Pediatrics. 2025;155(4):e2024069152. doi:10.1542/peds.2024-069152. PMID 40074005 (Ream 2025)
- Redonnet-Vernhet I, Mercié P, Lebreton L, et al. Preventing hyperhomocysteinemia using vitamin B6 supplementation in givosiran-treated acute intermittent porphyria: highlights from a case report and brief literature review. Mol Genet Metab Rep. 2024;39:101076. doi:10.1016/j.ymgmr.2024.101076. PMID 38601120
- Reed W, Lane PA, Lorey F, et al. Sickle-cell disease not identified by newborn screening because of prior transfusion. J Pediatr. 2000;136(2):248–250. doi:10.1016/s0022-3476(00)70110-7. PMID 10657834
- Reidy L, Walls HC, Steele BW. Crossreactivity of bupropion metabolite with enzyme-linked immunosorbent assays designed to detect amphetamine in urine. Ther Drug Monit. 2011;33(3):366-8. doi:10.1097/FTD.0b013e3182126d08. PMID 21436763
- Reisfield GM, Teitelbaum SA, Mathias KT, et al. Extended urinary opiate detection following ad libitum ingestion of poppy seed pastry. J Anal Toxicol. 2026;50(2):bkaf086. doi:10.1093/jat/bkaf086. PMID 40929133
- Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther. 2019;105(5):1095–1105. doi:10.1002/cpt.1304. PMID 30447069
- Ren CL, Borowitz DS, Gonska T, et al. Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome and cystic fibrosis screen positive, inconclusive diagnosis. J Pediatr. 2017;181S:S45–S51.e1. doi:10.1016/j.jpeds.2016.09.066. PMID 28129812
- Roberts A, Korona-Bailey J, Mukhopadhyay S. Notes from the Field: Nitazene-Related Deaths - Tennessee, 2019-2021. MMWR Morb Mortal Wkly Rep. 2022;71(37):1196-1197. doi:10.15585/mmwr.mm7137a5. PMID 36107790
- Roberts DM, Yates C, Megarbane B, et al. Recommendations for the role of extracorporeal treatments in the management of acute methanol poisoning: a systematic review and consensus statement. Crit Care Med. 2015;43(2):461-72. doi:10.1097/CCM.0000000000000708. PMID 25493973
- Roberts WL, De BK, Coleman JP, et al. Falsely increased immunoassay measurements of total and unbound phenytoin in critically ill uremic patients receiving fosphenytoin. Clin Chem. 1999;45(6 Pt 1):829–837. PMID 10351992
- Roberts WL, Smith PT, Martin WJ, et al. Performance characteristics of three serum iron and total iron-binding capacity methods in acute iron overdose. Am J Clin Pathol. 1999;112(5):657-64. doi:10.1093/ajcp/112.5.657. PMID 10549253
- Ruan CJ, Olmos I, Ricciardi C, et al. Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients. Schizophr Res. 2024;268:293–301. doi:10.1016/j.schres.2023.07.002. PMID 37487869
- Ruckart PZ, Jones RL, Courtney JG, et al. Update of the blood lead reference value – United States, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(43):1509–1512. doi:10.15585/mmwr.mm7043a4. PMID 34710078
- Ruha AM. Recommendations for provoked challenge urine testing. J Med Toxicol. 2013;9(4):318–325. doi:10.1007/s13181-013-0350-7. PMID 24113861
- Ryan JB, Grant S, Walmsley T, et al. Falsely elevated plasma selenium due to gadolinium contrast interference: a novel solution to a preanalytical problem. Ann Clin Biochem. 2014;51(Pt 6):714–716. doi:10.1177/0004563214529262. PMID 24687164
- Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists (executive summary). Clin Infect Dis. 2020;71(6):1361–1364. doi:10.1093/cid/ciaa303. PMID 32658968. Full guideline: Am J Health Syst Pharm. 2020;77(11):835–864. doi:10.1093/ajhp/zxaa036. PMID 32191793
- Saitman A, Park HD, Fitzgerald RL. False-positive interferences of common urine drug screen immunoassays: a review. J Anal Toxicol. 2014;38(7):387-96. doi:10.1093/jat/bku075. PMID 24986836
- Salhi I, Karmi B. Therapeutic drug monitoring of antiepileptic drugs in the West Bank, Palestine: a 25-year retrospective cohort study from a multi-branch laboratory network. BMC Neurol. 2026;26(1):630. doi:10.1186/s12883-026-05103-0. PMID 42332619
- Sawada T, Kido J, Nakamura K. Newborn screening for Pompe disease. Int J Neonatal Screen. 2020;6(2):31. doi:10.3390/ijns6020031. PMID 33073027
- Schilsky ML, Roberts EA, Bronstein JM, et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases. Hepatology. 2023;77(4):1428–1455. doi:10.1002/hep.32805. PMID 36152019
- Schmolly K, Rudrapatna V, Beaven S. Recommendations for recognizing and diagnosing acute hepatic porphyria in atypical patient populations. Orphanet J Rare Dis. 2025;20(1):539. doi:10.1186/s13023-025-04067-7. PMID 41345676
- Schulenburg-Brand D, Maw K, Bentley LA, et al. Stability of plasma and erythrocyte porphyrins: implications for diagnosis and monitoring of erythropoietic protoporphyria. J Clin Pathol. 2026;79(3):206–211. doi:10.1136/jcp-2025-210393. PMID 41162157
- Schulze JJ, Lundmark J, Garle M, et al. Substantial advantage of a combined Bayesian and genotyping approach in testosterone doping tests. Steroids. 2009;74(3):365-8. doi:10.1016/j.steroids.2008.11.003. PMID 19056415
- Seidel S, Kreutzer R, Smith D, et al. Assessment of commercial laboratories performing hair mineral analysis. JAMA. 2001;285(1):67–72. doi:10.1001/jama.285.1.67. PMID 11150111
- Serrazina DC, Lopes De Andrade V, Cota M, et al. Biomarkers of exposure and effect in a working population exposed to lead, manganese and arsenic. J Toxicol Environ Health A. 2018;81(19):983–997. doi:10.1080/15287394.2018.1509408. PMID 30296394
- Servais A, Abi-Wardé MT, Arnoux JB, et al. Management of acute metabolic decompensation in maple syrup urine disease: guidance based on international clinical practice. Orphanet J Rare Dis. 2026;21(1). doi:10.1186/s13023-026-04418-y. PMID 42251408
- Shaikh S, Hull MJ, Bishop KA, et al. Effect of tramadol use on three point-of-care and one instrument-based immunoassays for urine buprenorphine. J Anal Toxicol. 2008;32(5):339-43. doi:10.1093/jat/32.5.339. PMID 18544218
- Shannon M. Life-threatening events after theophylline overdose: a 10-year prospective analysis. Arch Intern Med. 1999;159(9):989–994. doi:10.1001/archinte.159.9.989. PMID 10326941
- Shannon MW, Borron SW, Burns MJ. Emergency management of poisoning. In: Shannon MW, Borron SW, Burns MJ, eds. Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose. 4th ed. Philadelphia: Saunders Elsevier; 2007:13-61. doi:10.1016/B978-0-7216-0693-4.50007-4 (Shannon 2007)
- Shin I, Choi H, Kang S, et al. Detection of l-Methamphetamine and l-Amphetamine as Selegiline Metabolites. J Anal Toxicol. 2021;45(1):99-104. doi:10.1093/jat/bkaa058. PMID 32476010
- Shively RM, Hoffman RS, Manini AF. Acute salicylate poisoning: risk factors for severe outcome. Clin Toxicol (Phila). 2017;55(3):175-180. doi:10.1080/15563650.2016.1271127. PMID 28064509
- Sidi A, Paulus DA, Rush W, et al. Methylene blue and indocyanine green artifactually lower pulse oximetry readings of oxygen saturation. Studies in dogs. J Clin Monit. 1987;3(4):249–256. doi:10.1007/BF03337379. PMID 3681358
- Silva F, Keitt SA, Hobbs GA. Three cases of naloxone interference with an oxycodone immunoassay in oral fluid. Drug Test Anal. 2022;14(6):1166-1169. doi:10.1002/dta.3228. PMID 35146956
- Sinclair G, McMahon V, Schellenberg A, et al. Performance of a three-tier (IRT-DNA-IRT) cystic fibrosis screening algorithm in British Columbia. Int J Neonatal Screen. 2020;6(2):46. doi:10.3390/ijns6020046. PMID 33073036
- Singal AK. Porphyria cutanea tarda: recent update. Mol Genet Metab. 2019;128(3):271–281. doi:10.1016/j.ymgme.2019.01.004. PMID 30683557
- Singh S, Ojodu J, Kemper AR, et al. Implementation of newborn screening for conditions in the United States first recommended during 2010–2018. Int J Neonatal Screen. 2023;9(2):20. doi:10.3390/ijns9020020. PMID 37092514
- Sivilotti MLA, Yarema MC, Juurlink DN. Treating acetaminophen overdose. CMAJ. 2022;194(15):E554. doi:10.1503/cmaj.210703. PMID 35440504
- Smith ML, Barnes AJ, Huestis MA. Identifying new cannabis use with urine creatinine-normalized THCCOOH concentrations and time intervals between specimen collections. J Anal Toxicol. 2009;33(4):185-9. doi:10.1093/jat/33.4.185. PMID 19470219
- Smith ML, Nichols DC, Underwood P, et al. Methamphetamine and amphetamine isomer concentrations in human urine following controlled Vicks VapoInhaler administration. J Anal Toxicol. 2014;38(8):524-7. doi:10.1093/jat/bku077. PMID 25217541
- Smith WE, Berry SA, Bloom K, et al. Phenylalanine hydroxylase deficiency diagnosis and management: a 2023 evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2025;27(1):101289. doi:10.1016/j.gim.2024.101289. PMID 39630157
- Snozek CLH, Jannetto PJ, Langman LJ, et al. Limited added utility of urine ethyl glucuronide compared to blood phosphatidylethanol in a predominantly transplant population. J Anal Toxicol. 2026;50(1):bkaf084. doi:10.1093/jat/bkaf084. PMID 40910927
- Society of Hair Testing. 2021 SoHT consensus on drugs of abuse (DoA) testing in hair. Agreed November 16, 2021. https://www.soht.org/images/pdf/Consensus_DoA_2021.pdf (accessed 2026-11-17) (SoHT 2021)
- Society of Hair Testing. 2022 SoHT consensus on general recommendations for hair testing. Agreed September 27, 2022. https://www.soht.org/images/pdf/General_Consensus_Hair_Testing_2022.pdf (accessed 2026-11-17) (SoHT 2022)
- Song P, Adeloye D, Li S, et al. The prevalence of vitamin A deficiency and its public health significance in children in low- and middle-income countries: a systematic review and modelling analysis. J Glob Health. 2023;13:04084. doi:10.7189/jogh.13.04084. PMID 37565390
- Soriano VV, Tesoro EP, Kane SP. Characterization of free phenytoin concentrations in end-stage renal disease using the Winter-Tozer equation. Ann Pharmacother. 2017;51(8):669–674. doi:10.1177/1060028017707541. PMID 28470115
- Sosnay PR, White TB, Farrell PM, et al. Diagnosis of cystic fibrosis in nonscreened populations. J Pediatr. 2017;181S:S52–S57.e2. doi:10.1016/j.jpeds.2016.09.068. PMID 28129813
- Staretz-Chacham O, Daas S, Ulanovsky I, et al. The role of orotic acid measurement in routine newborn screening for urea cycle disorders. J Inherit Metab Dis. 2021;44(3):606–617. doi:10.1002/jimd.12331. PMID 33190319
- Steuerwald AJ, Parsons PJ, Arnason JG, et al. Trace element analysis of human urine collected after administration of Gd-based MRI contrast agents: characterizing spectral interferences using inorganic mass spectrometry. J Anal At Spectrom. 2013;28(6):821–830. doi:10.1039/C3JA30331D. PMID 27397951
- Stinton C, Fraser H, Geppert J, et al. Newborn screening for long-chain 3-hydroxyacyl-CoA dehydrogenase and mitochondrial trifunctional protein deficiencies using acylcarnitines measurement in dried blood spots: a systematic review of test accuracy. Front Pediatr. 2021;9:606194. doi:10.3389/fped.2021.606194. PMID 33816395
- Stout PR, Klette KL, Horn CK. Evaluation of ephedrine, pseudoephedrine and phenylpropanolamine concentrations in human urine samples and a comparison of the specificity of DRI amphetamines and Abuscreen online (KIMS) amphetamines screening immunoassays. J Forensic Sci. 2004;49(1):160-4. PMID 14979364
- Strahm E, Mullen JE, Gårevik N, et al. Dose-dependent testosterone sensitivity of the steroidal passport and GC-C-IRMS analysis in relation to the UGT2B17 deletion polymorphism. Drug Test Anal. 2015;7(11-12):1063-70. doi:10.1002/dta.1841. PMID 26198073
- Stroek K, Ruiter A, van der Linde A, et al. Second-tier testing for 21-hydroxylase deficiency in the Netherlands: a newborn screening pilot study. J Clin Endocrinol Metab. 2021;106(11):e4487–e4496. doi:10.1210/clinem/dgab464. PMID 34171085
- Strydom A, Jacob D, Pillay T, et al. The measurement of immunosuppressive drugs by mass spectrometry and immunoassay in a South African transplant setting. Pract Lab Med. 2024;42:e00440. doi:10.1016/j.plabm.2024.e00440. PMID 39582744
- Substance Abuse and Mental Health Services Administration, Department of Health and Human Services. Medical Review Officer Guidance Manual for Federal Workplace Drug Testing Programs. Effective July 7, 2025. Section 5.1.1, Amphetamine (AMP) and Methamphetamine (MAMP). https://www.samhsa.gov/sites/default/files/mro-guidance-manual-2025.pdf (accessed 2026-11-17) (MRO Manual 2025)
- Suzuki J, Zinser J, Issa M, et al. Quantitative testing of buprenorphine and norbuprenorphine to identify urine sample spiking during office-based opioid treatment. Subst Abus. 2017;38(4):504-507. doi:10.1080/08897077.2017.1356796. PMID 28723256
- Taboulet P, Baud FJ, Bismuth C. Clinical features and management of digitalis poisoning--rationale for immunotherapy. J Toxicol Clin Toxicol. 1993;31(2):247-60. doi:10.3109/15563659309000392. PMID 8492338
- Tajima G, Aisaki J, Hara K, et al. Using the C14:1/medium-chain acylcarnitine ratio instead of C14:1 to reduce false-positive results for very-long-chain acyl-CoA dehydrogenase deficiency in newborn screening in Japan. Int J Neonatal Screen. 2024;10(1):15. doi:10.3390/ijns10010015. PMID 38390979
- Talbot A, Nicholls K, Fletcher JM, et al. A simple method for quantification of plasma globotriaosylsphingosine: utility for Fabry disease. Mol Genet Metab. 2017;122(1–2):121–125. doi:10.1016/j.ymgme.2017.08.004. PMID 28847675
- Talwar D, Davidson H, Cooney J, et al. Vitamin B1 status assessed by direct measurement of thiamin pyrophosphate in erythrocytes or whole blood by HPLC: comparison with erythrocyte transketolase activation assay. Clin Chem. 2000;46(5):704–710. PMID 10794754
- Thiermann H, Kehe K, Steinritz D, et al. Red blood cell acetylcholinesterase and plasma butyrylcholinesterase status: important indicators for the treatment of patients poisoned by organophosphorus compounds. Arh Hig Rada Toksikol. 2007;58(3):359-66. doi:10.2478/v10004-007-0030-6. PMID 17913691
- Thomas MC, Edwards CJ, Dunlap A. Practice Patterns for N-acetylcysteine Dosing for Acetaminophen Toxicity in the United States. Innov Pharm. 2024;15(4). doi:10.24926/iip.v15i4.6459. PMID 40401298
- Trampuž D, Schielen PCJI, Zetterström RH, et al. International survey on phenylketonuria newborn screening. Int J Neonatal Screen. 2025;11(1):18. doi:10.3390/ijns11010018. PMID 40136633
- Turturo M, Rossi A, Barretta F, et al. Benefits and pitfalls in newborn screening for carnitine uptake deficiency: a 4-year single-center experience. Orphanet J Rare Dis. 2025;21(1). doi:10.1186/s13023-025-04133-0. PMID 41310792
- Twomey PJ. Effect of a different caeruloplasmin assay method on the relationship between serum copper and caeruloplasmin. Postgrad Med J. 2008;84(996):549–551. doi:10.1136/pgmj.2007.065805. PMID 19017841
- Úbeda F, Santander S, Luesma MJ. Clinical practice guidelines for the diagnosis and management of hereditary fructose intolerance. Diseases. 2024;12(3):44. doi:10.3390/diseases12030044. PMID 38534968
- Udomkarnjananun S, Sutharattanapong N, Larpparisuth N, et al. Thai Transplant Care Practice Guideline on immunosuppressive therapy for adult kidney transplantation. Nephrology (Carlton). 2026;31(Suppl 2):e70268. doi:10.1111/nep.70268. PMID 42813300
- Ueland PM, McCann A, Midttun Ø, et al. Inflammation, vitamin B6 and related pathways. Mol Aspects Med. 2017;53:10–27. doi:10.1016/j.mam.2016.08.001. PMID 27593095
- Ueland PM, Ulvik A, Rios-Avila L, et al. Direct and functional biomarkers of vitamin B6 status. Annu Rev Nutr. 2015;35:33–70. doi:10.1146/annurev-nutr-071714-034330. PMID 25974692
- United Porphyrias Association. Drug safety for acute porphyrias. https://www.porphyria.org/drug-safety-for-ahp (accessed 2026-11-17) (UPA 2026)
- van Trotsenburg P, Stoupa A, Léger J, et al. Congenital hypothyroidism: a 2020–2021 consensus guidelines update – an ENDO-European Reference Network initiative endorsed by the European Society for Pediatric Endocrinology and the European Society for Endocrinology. Thyroid. 2021;31(3):387–419. doi:10.1089/thy.2020.0333. PMID 33272083
- Verelst S, Vermeersch P, Desmet K. Ethylene glycol poisoning presenting with a falsely elevated lactate level. Clin Toxicol (Phila). 2009;47(3):236-8. doi:10.1080/15563650802432954. PMID 19016054
- Verma A, Lehman AN, Gokcan H, et al. Amino acid ratio combinations as biomarkers for discriminating patients with pyruvate dehydrogenase complex deficiency from other inborn errors of metabolism. Mol Genet Genomic Med. 2024;12(1):e2283. doi:10.1002/mgg3.2283. PMID 37688338
- Verstraete AG. Detection times of drugs of abuse in blood, urine, and oral fluid. Ther Drug Monit. 2004;26(2):200-5. doi:10.1097/00007691-200404000-00020. PMID 15228165
- Vu TN, Talasila S, Jeha GM, et al. Understanding the clinical spectrum of the cutaneous and acute hepatic porphyrias. Am J Clin Dermatol. 2026;27(4):745–764. doi:10.1007/s40257-026-01046-x. PMID 42213346
- Wahrenbrock T, Chambers A, Wheeler M, et al. Etiology of methemoglobinemia in the National Poison Data System®: an observational study. Clin Toxicol (Phila). 2026:1–7. doi:10.1080/15563650.2026.2722076. PMID 42684203
- Wang A, Rezania Z, Haugen KMB, et al. Screening for elevated blood lead levels: false-positive rates of tests on capillary samples, Minnesota, 2011–2017. J Public Health Manag Pract. 2019;25 Suppl 1:S44–S50. doi:10.1097/PHH.0000000000000879. PMID 30507769
- Wang B, Bonkovsky HL, Lim JK, et al. AGA clinical practice update on diagnosis and management of acute hepatic porphyrias: expert review. Gastroenterology. 2023;164(3):484–491. doi:10.1053/j.gastro.2022.11.034. PMID 36642627
- Wang C, Bensaber N, Rebeiz L, et al. Homozygous variegate porphyria: two cases misdiagnosed as erythropoietic protoporphyria. Mol Genet Metab Rep. 2026;47:101325. doi:10.1016/j.ymgmr.2026.101325. PMID 42293158
- Wang H, Torres CM, Giordano TP, et al. Attitudes and barriers toward antiretroviral therapeutic drug monitoring among infectious disease providers. Medicina (Kaunas). 2025;61(3):544. doi:10.3390/medicina61030544. PMID 40142355
- Watson CJ, Simpson MD, Saraiya N, et al. N-Acetylcysteine Dose and Treatment Duration in High-Risk Acetaminophen Ingestions Treated Within Eight Hours: A Retrospective Cohort Study. J Med Toxicol. 2026;22(2):253-262. doi:10.1007/s13181-026-01129-5. PMID 41857443
- Weiss ST, Campleman S, Wax P, et al. Failure of chelator-provoked urine testing results to predict heavy metal toxicity in a prospective cohort of patients referred for medical toxicology evaluation. Clin Toxicol (Phila). 2022;60(2):191–196. doi:10.1080/15563650.2021.1941626. PMID 34184587
- Welling L, Bernstein LE, Berry GT, et al. International clinical guideline for the management of classical galactosemia: diagnosis, treatment, and follow-up. J Inherit Metab Dis. 2017;40(2):171–176. doi:10.1007/s10545-016-9990-5. PMID 27858262
- West R, Pesce A, West C, et al. Comparison of clonazepam compliance by measurement of urinary concentration by immunoassay and LC-MS/MS in pain management population. Pain Physician. 2010;13(1):71-8. PMID 20119465
- Whitfield KC, Bourassa MW, Adamolekun B, et al. Thiamine deficiency disorders: diagnosis, prevalence, and a roadmap for global control programs. Ann N Y Acad Sci. 2018;1430(1):3–43. doi:10.1111/nyas.13919. PMID 30151974
- Willeman T, Laudet M, Revol B, et al. Underreporting of synthetic cathinone poisoning with clinical immunoassays: An experimental and observational study. Ann Clin Biochem. 2025;62(6):440-446. doi:10.1177/00045632251331404. PMID 40118811
- Williams AC, Hill LJ. The 4 D's of pellagra and progress. Int J Tryptophan Res. 2020;13:1178646920910159. doi:10.1177/1178646920910159. PMID 32327922
- Wills BK, Mycyk MB, Mazor S, et al. Factitious lithium toxicity secondary to lithium heparin-containing blood tubes. J Med Toxicol. 2006;2(2):61–63. doi:10.1007/BF03161172. PMID 18072115
- Wolf CE, Medrano FI, Poklis JL, et al. Determining the detection of 216 fentanyl analogs and synthetic opioids and predicting epitopes using four commercial immunoassays. Clin Biochem. 2025;140:111032. doi:10.1016/j.clinbiochem.2025.111032. PMID 42441761
- Wolf CE, Pokhai AA, Poklis JL, et al. The cross-reactivity of cannabinoid analogs (delta-8-THC, delta-10-THC and CBD), their metabolites and chiral carboxy HHC metabolites in urine of six commercially available homogeneous immunoassays. J Anal Toxicol. 2023;47(8):732-736. doi:10.1093/jat/bkad059. PMID 37602947
- Wortzman DJ, Grunfeld A. Delayed absorption following enteric-coated aspirin overdose. Ann Emerg Med. 1987;16(4):434-6. doi:10.1016/s0196-0644(87)80366-9. PMID 3826813
- Wu AH, McKay C, Broussard LA, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: recommendations for the use of laboratory tests to support poisoned patients who present to the emergency department. Clin Chem. 2003;49(3):357-79. doi:10.1373/49.3.357. PMID 12600948
- Wu PE, Austin E. Isopropanol toxicity. CMAJ. 2026;198(5):E175. doi:10.1503/cmaj.251228. PMID 41663142
- Ye BJ, Kim BG, Jeon MJ, et al. Evaluation of mercury exposure level, clinical diagnosis and treatment for mercury intoxication. Ann Occup Environ Med. 2016;28:5. doi:10.1186/s40557-015-0086-8. PMID 26807265
- Yoo DW, Kim HH. Endogenous vitamin C interference in routine clinical chemistry assays: evaluation of ascorbate oxidase pretreatment across 19 analytes. Lab Med. 2026;57(6). doi:10.1093/labmed/lmag058. PMID 42993860
- You K, Bittikofer JA. Quantification of salicylate in serum by use of salicylate hydroxylase. Clin Chem. 1984;30(9):1549-51. PMID 6467569
- Zavaliy LB, Petrikov SS, Simonova AY, et al. Diagnosis and treatment of persons with acute thallium poisoning. Toxicol Rep. 2021;8:277–281. doi:10.1016/j.toxrep.2021.01.013. PMID 33552926
- Zimmermann MB. Methods to assess iron and iodine status. Br J Nutr. 2008;99 Suppl 3:S2–S9. doi:10.1017/S000711450800679X. PMID 18598585